MONSANTO™




# A SINGLE FOCUS

**Company Profile:** Monsanto is a leading provider of agricultural products to farmers. We make *Roundup*, the world's best-selling herbicide, and other crop protection chemicals. We produce leading seed brands, including *DEKALB* and *Asgrow*, and we offer seeds improved through biotechnology with one or more traits. With our unique combination of products and our unparalleled resources in plant biotechnology, we create integrated solutions to improve farm productivity and to reduce the costs of farming.

A SINGLE FOCUS

# AGRICULTURE

ON THE COVER: John Howard grows corn and soybeans in northeastern Kansas. He is focused on producing food efficiently, and in ways that preserve the land for future generations. Monsanto is focused on continuing to earn Mr. Howard's business by providing him and other farmers around the world with solutions that match their needs.

## CONTENTS


2 **Letter to Shareowners**
Monsanto is focusing on fewer but better opportunities.

5 **A Single Focus: Agriculture**
Leadership, integrated capabilities, and innovation are our strengths.

6 **Maintain Leadership in the Agricultural Marketplace**
We will broaden commercialization of biotechnology products and will sustain strong growth for *Roundup* herbicide.

10 **Achieve the Benefits of Integrated Solutions and Operations**
We will create integrated solutions for farmers and will deliver strong financial performance from integrated operations.

14 **Advance Agriculture through Innovation**
We will use biotechnology capabilities to speed product development and will commercialize products in our pipeline.

18 **Financial Review**

62 **Board of Directors**

63 **Executive and Other Officers**

64 **Shareowner Information**


**MONSANTO | *At a Glance***

| | KEY PRODUCTS | MARKET POSITION |
|---|---|---|
| AGRICULTURAL PRODUCTIVITY | ■ *Roundup* herbicide and our other glyphosate products offer effective weed control at a competitive price.<br>■ Selective herbicides, such as *Harness Xtra, Machete* and *Maverick,* control specific weeds in corn, rice and wheat.<br>■ Products for animal agriculture focus on improving dairy cow productivity and swine genetics. | ■ Sales of *Roundup* herbicide exceed those of the next six leading herbicides combined.<br>■ Monsanto's acetanilide-based selective herbicides, which include *Harness Xtra,* hold the No. 2 U.S. position for control of grassy weeds in corn.<br>■ *Posilac* bovine somatotropin is the largest-selling dairy-related animal health product in the world. |
| SEEDS AND GENOMICS | ■ High-quality brand-name seeds, such as *DEKALB* and *Asgrow,* and germplasm serve growers of major crops in markets worldwide.<br>■ Biotechnology seed traits, such as herbicide tolerance and insect protection, are expressed in products such as *Roundup Ready* soybeans and *YieldGard* corn. | ■ Monsanto holds the No. 1 or No. 2 position in key corn and soybean markets, and a leading position in the European wheat market.<br>■ Monsanto is the world leader in biotechnology crops, and seeds containing our traits were planted on roughly 103 million acres in 2000. |

*Net Sales*[1]

DOLLARS IN BILLIONS




*Monsanto increased net sales by 5 percent in 2000, to $5.5 billion. Monsanto's goal is to increase sales by a similar percentage in 2001.*

*Pro Forma Earnings per Share Before Cumulative Effect of Accounting Change (EPS)*[1, 2, 3, 6]

IN DOLLARS




*Monsanto's pro forma EPS increased 28 percent in 2000, to $1.70. In 2001, our goal is to increase EPS by 9 percent to 13 percent.*

*Free Cash Flow*[4]

DOLLARS IN MILLIONS




*Free cash flow improved by 11 percent in 2000, to a negative $264 million. Monsanto's goal for 2001 is to achieve positive free cash flow before dividends.*

A RENEWED PURPOSE

*for Farmers* — **VALUE** — *for Shareowners*

The creation of Monsanto as a new, separate business devoted exclusively to agriculture focuses our entire company on creating value for farmers. By doing so, we also create value for shareowners.



## 2000 | *Financial Highlights*

| (DOLLARS IN MILLIONS, EXCEPT SHARE AND PER-SHARE AMOUNTS) | 2000 | 1999 | % CHANGE |
|---|---|---|---|
| **Operating Results** | | | |
| Net Sales[1] | $5,493 | $5,248 | 5 % |
| EBIT (excluding special items)[5,6] | $ 779 | $ 607 | 28 % |
| EBITDA (excluding special items)[5,6] | $1,325 | $1,154 | 15 % |
| Reported Net Income | $ 149 | $ 150 | (1)% |
| Reported Diluted Earnings per Share[3] | $ 0.58 | $ 0.58 | — |
| Pro Forma Income Before Cumulative Effect of Accounting Change (excluding special items)[1,2,6] | $ 440 | $ 344 | 28 % |
| Pro Forma Earnings per Share Before Cumulative Effect of Accounting Change (excluding special items)[1,2,3,6] | $ 1.70 | $ 1.33 | 28 % |
| **Other Selected Data** | | | |
| Free Cash Flow[4] | $ (264) | $ (295) | 11 % |
| Capital Expenditures | $ 582 | $ 632 | (8)% |
| Depreciation and Amortization | $ 546 | $ 547 | — |
| Shares Outstanding (year-end, in millions)[3] | 258 | N/A | N/A |

(1-6) See footnotes on page 65.

# Letter *to* SHAREOWNERS

**DEAR SHAREOWNERS:** Our year began with the merger of Monsanto Company and Pharmacia & Upjohn into Pharmacia Corporation, and closed with a partial (15 percent) initial public offering (IPO) of Monsanto. Today, our company is enjoying this new beginning, focused entirely on agriculture.

Agriculture offers a compelling opportunity for growth. A growing population, more nutritious diets, and increased spendable income are boosting demand for food and fiber worldwide. This demand creates an exciting opportunity for Monsanto to grow, as we develop and commercialize new products that are based on genomics and biotechnology. These technologies reduce farmers' costs, help increase food production in developing countries, improve nutrition, and better protect the environment.

HENDRIK VERFAILLIE
*President and Chief Executive Officer*

**Monsanto is uniquely positioned to take advantage of this opportunity.** This report focuses on how we're building on three key strengths:

- We have a strong core business based on the family of *Roundup* herbicides and other crop protection products, *DEKALB* and *Asgrow* seed brands, and *Posilac* bovine somatotropin. This provides the foundation for continued growth in net income and cash flow. We also have the global marketing structure in place to commercialize our new technologies and products.
- We are successfully integrating our experience in chemicals, seeds, genomics and biotechnology. This allows us to offer our customers customized solutions to their farming needs.
- Our leading position in the use of genomics and biotechnology — for the development of more productive seeds with enhanced traits — enables us to help move agriculture from the chemical era into the biological era. This change will let farmers produce crops more efficiently, and in ways that are more environmentally friendly.

Our capital structure following the IPO, combined with greater discipline and focus in research and operations, positions us for strong growth.

We have 14,700 people committed to delivering value for our customers and shareowners, and dedicated to delivering on our promises consistently.

In order to realize this opportunity and to deal with the challenges we are facing — such as the patent expiration of *Roundup* herbicide in the United States and the slower-than-desired public acceptance of biotechnology — we have laid out a three-step strategy.

**2001-2002** **In the near term, we will focus on three priorities:**

- **Maximize our existing businesses.**
- **Manage costs and cash by optimizing operations.**
- **Carry out our biotechnology acceptance strategy.**

Our most important near-term priority is managing the value of the *Roundup* brand so that we can limit potential price erosion. We plan to limit the effect of the U.S. patent expiration for *Roundup* by fueling its growth worldwide. We are working with our customers to expand their use of *Roundup* in conservation-tillage (con-till) systems. Con-till dramatically reduces the rate of soil erosion, thereby addressing a major issue in agricultural sustainability around the world. Con-till is our biggest growth opportunity for *Roundup* and one that relies on our unique approach of integrating our three product platforms — seeds, traits and chemistry.

We're managing costs and cash flow by exercising greater discipline and focusing on the priorities that make a difference. We started this process last year and are encouraged by the early results. Operating expenses

were reduced by more than $70 million in 2000, and year-end free cash flow improved by 11 percent.

We must work hard to earn public acceptance of biotechnology. A better climate for our products will set the stage for dramatic growth in the medium term. Specifically, we need to: (1) work with the Brazilian government and other stakeholders to obtain approval to plant *Roundup Ready* soybeans in Brazil; (2) accelerate the commercialization of *Roundup Ready* corn by obtaining a license to import grain grown from *Roundup Ready* seeds into Europe; and (3) continue to expand our markets in Asia with the approval of *Bollgard* insect-protected cotton in India. The opportunity for rapid growth is great, but we must earn public trust and confidence in order to harvest the fruits of our technology.

**2003-2005** **In the medium term, we must retain our near-term progress while realizing two more objectives:**

- **Re-accelerate the growth of biotechnology products.**
- **Accelerate the growth of the seed business.**

Next to defending the growth of *Roundup*, rejuvenating the growth of products improved through biotechnology is our highest priority. Global acceptance of biotechnology would give us the potential for unprecedented growth. Additional registrations of our *Roundup Ready* and insect-protected traits in more crops and in more countries — plus the commercialization of *MaxGard* corn, our new product candidate that protects itself from corn rootworm — would create a powerful portfolio for global expansion.

The application of genomics to seed breeding will begin to show results in enhanced germplasm and accelerated growth for our seed business. The integration of our premier germplasm position with genomic improvements and trait "stacking" (the inclusion of two or more beneficial traits in one plant) will further strengthen our competitive advantage and leadership.

**2006 AND BEYOND** **In the long term, we must keep doing what we did in the previous two stages. In addition, we expect to see significant returns as we:**

- **Expand and commercialize the products in our pipeline, especially those with traits that improve crop yield. These yield traits, when stacked with our other traits in enhanced germplasm through genomics, will create the next breakthrough in seed productivity.**
- **Create value from our downstream businesses, such as better animal feed products (through our Renessen joint venture with Cargill), products that improve animal productivity, and traits for nutritionally enhanced foods.**

**This is our strategy to make Monsanto a growth company.** We are focused on the strengths and assets we have built and acquired. Our care in putting these building blocks in place can pay off — for the farmers and food processors who are challenged to meet the world's growing food needs; for our shareowners who have invested their funds and faith in our promise; for developing countries that seek greater economic prosperity and the resources to feed their people; and for all who desire wholesome, plentiful food and a healthy environment.

We recognize and take seriously our responsibility to steward the technologies and products that we introduce. The most visible sign of our commitment to this responsibility is the New Monsanto Pledge. The pledge is a series of five principles: dialogue, transparency, respect, sharing and benefits. Together, they summarize our policies about our participation in the development of new solutions for agriculture. We encourage you to measure our progress on all of our commitments — our financial commitments as well as the commitments outlined in the pledge, which appears on the back of this report.

The year 2000 was an encouraging start for the new Monsanto. We had continued growth from *Roundup* and our other core businesses, resulting in revenue growth of 5 percent and income growth of 28 percent as measured by earnings before interest and taxes (EBIT) and excluding special items. Business growth, cost reductions and cash management should make us free cash positive in 2001. Our biotechnology acceptance strategy is already starting to provide encouraging results.

Monsanto is a company with a clear vision of abundant food and a healthy environment. We are FOCUSED on fewer but better opportunities; DEDICATED to delivering value to our shareowners, customers and consumers; and COMMITTED to consistently meeting our financial promises and social responsibilities.

HENDRIK A. VERFAILLIE
*President and Chief Executive Officer*
March 1, 2001

A SINGLE FOCUS

# AGRICULTURE

We will build on Monsanto's unique strengths:

- to maintain *leadership* in the agricultural marketplace
- to achieve the benefits of *integrated solutions* and *operations*
- to advance agriculture through *innovation*

A RENEWED PURPOSE

# VALUE

In each area, we will pursue goals that drive value creation for *farmers* and *shareowners*. The following pages describe Monsanto's progress and prospects.



LEFT: MA YUZHUO (FOREGROUND) AND HIS SON, YONGFENG, ARE AMONG THE MORE THAN 750,000 FARM HOUSEHOLDS IN CHINA WHO PLANTED COTTON SEED WITH MONSANTO'S INSECT-PROTECTED TECHNOLOGY IN 2000. THE INSECT-PROTECTED SEED ALLOWED THEM TO ELIMINATE MORE THAN 20 INSECTICIDE SPRAYINGS, WHICH SAVED $75 AN ACRE IN INSECTICIDE COSTS, AND INCREASED THEIR COTTON PRODUCTION AS MUCH AS 30 PERCENT.

VALUE [ 1 ] DRIVER

**Broaden commercialization of biotechnology products: Delivering benefits**

Biotechnology helps farmers reduce costs and protect the environment. Recognizing these benefits, farmers worldwide have expanded planting of crops improved through biotechnology, from 4 million acres in 1996 to more than 100 million acres in 2000. Insect-protected and herbicide-tolerant seeds developed through biotechnology have reduced the use of crop protection chemicals. A recent study projects that planting corn, cotton and soybeans improved through biotechnology will reduce annual pesticide use by 57 million pounds, or 19 percent, between 2000 and 2009. Grain farmer John Howard likes the fact that reduced pesticide use is healthier for him, his family, and the people who eat the food he produces.

TOP: THE HOWARD FAMILY OF HIAWATHA, KANSAS, GATHERS FOR A MEAL (CENTER, CLOCKWISE FROM LEFT: MOLLY, JOHN, EMILY, GRIFF AND BECKY). JOHN HOWARD LOOKS FORWARD TO CROPS BEING DEVELOPED THROUGH BIOTECHNOLOGY TO PROVIDE IMPROVED NUTRITION FOR HIS FAMILY AND PEOPLE EVERYWHERE.



VALUE [ 2 ] DRIVER

**Sustain strong growth for *Roundup* herbicide: Responding to customers**

New formulations of *Roundup* give farmers more value. U.S. farmers and retail suppliers such as Donnie Martinek asked for a product that was easier to use. In response, we developed *Roundup UltraMAX*. It's concentrated to treat 20 percent more acreage than the same amount of our previous product, so farmers have fewer containers to handle. With its patented *Transorb* technology, *Roundup UltraMAX* is absorbed into weeds more quickly. That gives farmers greater application flexibility and better weed control. *Roundup UltraMAX* is one of several improved formulations of glyphosate, the active ingredient in *Roundup*, that we're introducing to more than 20 markets worldwide during 2000 and 2001.

BOTTOM: DONNIE MARTINEK (IN HAT) OF MARTINEK GRAIN IN GUNTER, TEXAS, DISCUSSES THE LAUNCH OF *ROUNDUP ULTRAMAX* WITH MONSANTO ACCOUNT MANAGER LARRY STANBERRY. BECAUSE IT TREATS MORE ACRES PER CONTAINER THAN PREVIOUS OFFERINGS, *ROUNDUP ULTRAMAX* SIMPLIFIES HANDLING FOR RETAILERS AND FARMERS.

[ FOCUS ]

# Maintain LEADERSHIP *in the* Agricultural Marketplace

**Monsanto is a leading provider of agricultural products to farmers. Our continued leadership and our long-term growth depend upon our: [1] broadening commercialization of our products developed through biotechnology in key markets around the world, and [2] sustaining strong growth for *Roundup* herbicide, our best-selling product, and our entire portfolio of agricultural solutions.**

Monsanto offers the most advanced technology, the widest crop and geographic coverage, a global marketing network, and an unmatched portfolio of products. We're helping our customers manage the financial challenges of the current downturn in the farming economy. We continue to achieve growth and profitability that are unique in the industry.

VALUE [ 1 ] DRIVER

## Broaden commercialization of biotechnology products

Monsanto is the world leader in improving crop plants through biotechnology. Plant biotechnology is a safe, sustainable tool for farmers. In just five years of commercial application, it has already helped them meet the world's growing needs for food and fiber.

**Monsanto is well positioned to benefit from the growth potential of plant biotechnology.** (See GRAPH 1.) In 2000, seeds with Monsanto traits accounted for more than 90 percent of the acres planted with herbicide-tolerant or insect-protected traits. The company's products include *YieldGard* insect-protected corn; *Bollgard* insect-protected cotton; *Roundup Ready* crops — corn, soybeans, canola and cotton — developed to tolerate *Roundup* herbicide; and corn and cotton products that contain both herbicide-tolerant and insect-protected traits.

Realizing the full potential of this technology and the full value of Monsanto's investment requires broad commercialization of biotechnology products. We must earn a level of public acceptance and secure the regulatory approvals necessary to permit commercialization in countries around the world.

**To support further commercialization, we're focusing on the safety and benefits of plant biotechnology.** The New Monsanto Pledge, printed on the back of this report, outlines our commitment to addressing these issues.

Biotechnology offers benefits to farmers, consumers, and the environment. Current products of biotechnology include crops that reduce the use of pesticides. In the future, crops such as "golden rice" may be developed to provide important nutritional benefits. Through biotechnology, this rice — when commercialized — will be fortified with beta carotene, which is converted by the human body to vitamin A.

In keeping with our pledge, we'll continue to share these benefits where they are most needed. In 2000, for example, Monsanto pledged to provide royalty-free licenses for all of our technologies essential to completing the development of "golden rice." We're taking this step to help combat vitamin A deficiency, which claims the sight, or the lives, of more than a million people each year.



[ GRAPH 1 ]

*Biotechnology products offer global growth potential*

ACRES IN MILLIONS

*Total world acreage of herbicide-tolerant and insect-protected corn, soybeans and cotton grew from 4 million acres in 1996 to 102 million acres in 2000. This is just a small fraction of the hundreds of millions*




| | WHEAT | CORN | SOYBEANS | COTTON |
|---|---|---|---|---|
| ■ | 0 | 25 | 64 | 13 |
| ■□ | 300 | 250 | 175 | 150 |

*Current acres of herbicide-tolerant traits plus insect-protected traits by major crops as reported by International Service for the Acquisition of Agri-Biotech Applications (ISAAA).

**Acres suitable for herbicide-tolerant traits plus acres suitable for insect-protected traits estimated by Monsanto.

*of acres suitable for these technologies worldwide. These charts show the growth potential of herbicide-tolerant plus insect-protected biotechnology traits in four key crops.*

As we develop products through biotechnology, we continue rigorous testing of product safety for consumers and the environment. This testing is important both for our own product stewardship and for regulatory approval processes in countries around the world.

To protect people with allergies, for example, plants developed through biotechnology must be reviewed to ensure that known allergens have not been transferred to food sources not normally associated with them. This kind of review, as well as independent scientific research, continues to confirm the safety, effectiveness and environmental benefits of plant biotechnology.

We're working with the food industry and with other companies in the Council for Biotechnology Information to provide consumers with information about the benefits of food produced through plant biotechnology. Opinion surveys continue to show a strong positive correlation between knowledge of biotechnology and support for it.

**OUTLOOK** **Acres planted with Monsanto traits grew by more than 15 percent in 2000. To support growth, we'll continue to ensure the safety and efficacy of the technology, to seek regulatory approvals, and to provide farmers and consumers with helpful information.**

**In the near term, we're focusing on regulatory approvals in Brazil, India and Europe that would allow more farmers to choose products improved through biotechnology. We hope to gain Brazilian approval for our *Roundup Ready* soybeans, which would open up a $150 million sales opportunity in the medium term for our seeds, traits and herbicides.**

**As we gain public acceptance and regulatory approvals, we intend to expand commercialization of *Roundup Ready* crops, insect-protected corn and cotton, and multiple-trait products, and to spur growth by introducing new products.**



VALUE [ 2 ] DRIVER

## Sustain strong growth for *Roundup* herbicide

*Roundup* herbicide controls a broad spectrum of weeds, and it degrades biologically over time in the soil into natural products, such as carbon dioxide. In 2000, the family of *Roundup* herbicides grew in revenues and earnings, as we continued to build technology leadership and to reduce costs. Monsanto's success depends on our ability to sustain growth for a product that has been a market leader for three decades.

**Continued growth for *Roundup* is based on branded products and technology leadership.** Our U.S. patent for glyphosate — the active ingredient in *Roundup* — expired late in 2000. (See GRAPH 2.) Monsanto retains patents on product formulations and manufacturing processes for *Roundup*. Surveys indicate strong loyalty to *Roundup* brand herbicides. Farmers have demonstrated a willingness to pay a premium for trusted proprietary brands such as *Roundup UltraMAX*, which was introduced in late 2000. We're continuing to research new high-value formulations.

We're using proprietary technology to maintain our position as a low-cost, high-quality producer of glyphosate. Since 1992, we've expanded our glyphosate production capacity nearly fivefold and reduced costs by roughly 40 percent. We've successfully pursued a strategy based on price elasticity: Selective price reductions for *Roundup* have usually led to increased sales volumes around the world.

We announced price reductions for *Roundup* in the United States before the 1999 growing season, well ahead of U.S. patent expiration in September 2000. The volume growth in 1999 and 2000 more than offset the price decrease in the United States.

[ GRAPH 2 ]

*Postpatent strategy is working for* Roundup

*Before Monsanto's U.S. patent expired in September 2000, the United States was the last major country where* Roundup *was patent-protected. The five largest glyphosate markets outside the United States make up roughly 40 percent of the glyphosate market worldwide. In those countries, the patent for* Roundup *expired nine or more years ago.*


GLOBAL GLYPHOSATE SALES
MONSANTO BRANDED OR SUPPLIED GLYPHOSATE SHARE
TOP COUNTRIES WITH PATENT FOR *ROUNDUP* EXPIRING IN 1991 OR EARLIER

*Yet Monsanto's branded glyphosate products and the glyphosate we supply to other providers have maintained an average combined market share exceeding 80 percent in these countries during the past two years. Of course, there are differences between the United States and other markets, so U.S. results may not follow the same pattern.*

**FOCUS** | *Maintain Leadership in the Agricultural Marketplace*



**"We're the leader in proven technology that can drive outstanding long-term growth. But that future depends on what we do today — to build our market position, to deliver solid results, and to broaden acceptance for biotechnology."**

HUGH GRANT
*Executive Vice President and Chief Operating Officer*

**VALUE DRIVER: TARGETS**

**NEAR-TERM** (2001-2002)

- Broaden acceptance for biotechnology crops and gain key regulatory approvals in Brazil, India, and the European Union.
- Support con-till growth of more than 70 million acres per year with new product development, particularly in soybeans and corn, and with farmer programs.
- Continue growth of *Roundup* by developing new branded formulations and by increasing volumes with selective price reductions.
- Reduce manufacturing and overhead costs.

**MEDIUM-TERM** (2003-2005)

- Expand *Roundup Ready* crops, insect-protected corn and cotton, and stacked trait products as biotechnology crops gain public acceptance and regulatory approvals.

**LONG-TERM** (2006 AND BEYOND)

- Accelerate growth through rapid, effective commercialization of products in the pipeline.

Selectively lowering prices also helps promote conservation tillage (con-till) — a farming practice for which *Roundup* is the herbicide of choice. Con-till replaces plowing with the judicious use of herbicides to control weeds. Growers benefit from reduced soil erosion, and they save time and energy on plowing. Price reductions for *Roundup* have been associated with broader adoption of con-till around the world, and there is significant untapped potential, particularly in the United States. (See GRAPH 3.) We're also driving growth for *Roundup* with further expansion of *Roundup Ready* crops.

**Other strong products round out our portfolio.** Monsanto also offers farmers a variety of selective herbicides — designed to control specific weeds, primarily in corn, wheat and rice. Our *Harness Xtra* herbicide and related brands collectively hold the No. 2 position in U.S. sales of acetanilide-based products for weed control in corn.

Our *Posilac* bovine somatotropin is the largest-selling dairy-related animal health product in the world. To support the demand for *Posilac,* we have built the world's largest pharmaceutical-grade protein manufacturing facility in Augusta, Georgia.

**OUTLOOK** **Monsanto continues to develop new proprietary formulations of *Roundup* for high-value branded products. We'll encourage near-term con-till growth of more than 70 million acres per year through farmer education and equipment programs, and through new seeds and herbicide formulations designed specifically for con-till.**

**We'll also focus on maintaining our low-cost position. Monsanto's efficient glyphosate manufacturing facility in Camaçari, Brazil, is scheduled to go on line in 2001 to serve the growing Latin American market.**

**We continue to develop other new products. *Latitude* fungicide was recently launched in Europe to control take-all disease in wheat. Sales of *Latitude* are expected to grow as more regulatory approvals are received in the next two years.**

[ GRAPH 3 ]

Roundup *supports and benefits from growth of con-till*

*Conservation tillage (con-till) replaces plowing with the use of herbicides to control weeds. Price reductions for* Roundup *have been associated with con-till adoption around the world. An estimated 750 million acres of key crops are suitable for con-till worldwide. In 2000,*




*herbicides were used for con-till on 385 million acres — 51 percent of the potential acreage — and* Roundup *was used on roughly two-thirds of those acres. In the United States, con-till is practiced on only 25 percent of the major-crop acres, so there is ample opportunity for growth.*

VALUE [ 3 ] DRIVER

**Create integrated solutions for farmers: Discovering new opportunities in Indonesia**

Oil palm and rubber trees typically do not produce a commercial crop for at least four years. Monsanto representatives worked closely with agricultural research organizations in Indonesia to develop solutions that help farmers earn money in the meantime. Through the work of people like Samiah b. Jupri, farmers now use minimum-tillage techniques to grow corn between the rows of young trees. Farmers use our *Polaris* glyphosate herbicide to prepare the land, then plant Monsanto seed corn, which is well-suited for minimum-tillage systems. This saves valuable moisture and nutrients for the crops, and also contributes to Indonesia's goal of producing more food grains domestically.

TOP: SAMIAH B. JUPRI DISPLAYS CORN GROWN BETWEEN TREES AT THE SEMBAWA RESEARCH STATION OF THE INDONESIAN RUBBER RESEARCH INSTITUTE. MONSANTO IS HELPING DEVELOP AND DISSEMINATE NEW TECHNIQUES THAT CAN HELP INDONESIA'S FARMERS AND ECONOMY.



VALUE [ 4 ] DRIVER

**Deliver strong financial performance from integrated operations: Increasing value in soybeans**

Soybeans are planted on more than 175 million acres worldwide, and Monsanto's integrated capabilities are earning more business from soybean farmers. The combination of *Roundup* herbicide and *Roundup Ready* soybeans gives farmers better weed control. *Roundup Ready* soybeans account for approximately 60 percent of soybean acres in the United States and more than 90 percent in Argentina. Our new *Residue Proven Roundup Ready* soybeans offer farmers such as Bob Adcock the environmental benefits of conservation tillage, because these varieties are particularly well-suited for planting into the crop residue left on con-till fields. Now we're using our capabilities in breeding, biotechnology and genomics to develop soybeans with even higher yields.

BOTTOM: SOYBEAN FARMER BOB ADCOCK (HOLDING SEEDS) OF MOWEAQUA, ILLINOIS, AND MONSANTO SEED SYSTEMS MANAGER ERIC HUBNER DISCUSS THE BENEFITS OF PLANTING *ASGROW* BRAND *RESIDUE PROVEN ROUNDUP READY* SOYBEANS. THESE SEEDS WERE INTRODUCED IN TIME FOR THE 2001 U.S. GROWING SEASON.

FOCUS

# Achieve *the* Benefits *of* INTEGRATED SOLUTIONS *and* OPERATIONS

**With a combination of seeds, traits and chemicals, Monsanto can develop systems that work together to reduce the costs and risks of farming. The full potential of our integrated capabilities depends upon our: [3] creating integrated solutions for farmers, and [4] delivering strong financial performance from integrated operations.**

Our seed businesses have been fully integrated with our crop protection chemicals and biotechnology research to create a new business model. We're now focusing our efforts to develop new solutions and to maximize the value of our investment on key crops — corn, soybeans, cotton and wheat. (See GRAPH 4.)

VALUE [ 3 ] DRIVER

## Create integrated solutions for farmers

Monsanto has the ability to bring together seeds, traits and chemicals. We make the most of our capabilities by enhancing existing products and developing new ones. We're continually finding new ways to bring them together in higher-value, integrated solutions.

**Integrated solutions for farmers start with some of the world's strongest seed brands,** including *DEKALB* and *Asgrow*. Our seeds hold the No. 1 or No. 2 position in key corn and soybean markets globally and a leading position in the European wheat market.

Farmers can select from our conventional hybrids and varieties or choose seeds that were developed through biotechnology to have one or more traits for improved performance. These traits are the second element of our integrated solutions. Some traits give plants the ability to protect themselves against insects, such as our *Bollgard* insect-protected cotton and *YieldGard* insect-protected corn.

*Roundup* — a third element of our solutions — is the world's leading herbicide. Our *Roundup Ready* crops tolerate *Roundup* herbicide. Products such as *Roundup Ready* cotton offer farmers the convenience, cost savings, and environmental benefits of using *Roundup*.

These three elements allow us to provide complete solutions for crop protection and higher yields. For example, we currently offer corn farmers top-quality hybrid seeds that contain both *YieldGard* and *Roundup Ready* traits. We also provide them with *Roundup* and selective herbicides such as *Harness Xtra* for effective weed control. This integrated approach offers farmers more potential value from their corn crop. It also



[ GRAPH 4 ]

*Monsanto is focusing biotechnology research on new traits for key crops*

*To balance long-term growth opportunities with near-term financial performance, Monsanto is focusing its investment in research and development on key crops — corn, soybeans, cotton and wheat. Our biotechnology research focuses on three types of traits — yield traits, which increase crop yields or productivity; input traits, which provide weed, insect or disease control; and quality traits, which enhance the value of the food and fiber produced by the plant. At right are examples of two products in the pipeline.*

| | YIELD AND PRODUCTIVITY | INSECT, DISEASE AND WEED MANAGEMENT | FEED AND FOOD |
|---|---|---|---|
| Corn | ✓ | ✓ | ✓ |
| Cotton | ✓ | ✓ | |
| Soybeans | ✓ | ✓ | ✓ |
| Wheat | | ✓ | |

**Improved-Protein Soybeans**
*Meal from these genetically enhanced soybeans being developed by Renessen will have an improved amino acid profile for animal nutrition.*

**Cold-Tolerant Corn**
*This corn, modified through biotechnology, would allow farmers to plant their crop earlier and aid the adoption of conservation tillage practices.*

creates the opportunity for Monsanto to earn more of their business.

**Through Renessen, we're also developing solutions for downstream agricultural markets**. Renessen LLC, our joint venture with Cargill Incorporated, was created in 1999 to develop and market biotechnology products that will benefit the grain processing and animal feed industries. Renessen's medium-term pipeline includes two types of corn products improved through biotechnology — one to enhance energy content in animal feed, and another to reduce the need for synthetic feed supplements.

**OUTLOOK** **In the near term, we'll continue to enhance existing products and to create integrated solutions and product/price packages that offer farmers greater value.**

**We'll also continue to develop new products that complement existing products. For example, our new *Residue Proven Roundup Ready* soybeans are well-suited to conservation tillage, a farming practice for which *Roundup* is the herbicide of choice.**

**Medium- and long-term plans include commercialization of biotechnology products developed by Renessen for the grain processing and animal feed markets. We're working on integrated solutions for these downstream businesses.**



VALUE [ 4 ] DRIVER

**Deliver strong financial performance from integrated operations**

The successful integration of our seed, trait and chemical operations is the basis of Monsanto's ability to offer integrated solutions to farmers. We're now focused on achieving strong performance in these integrated operations. In 2000, we launched a restructuring designed to refocus research and development (R&D), to streamline manufacturing, and to reduce administrative overhead. The restructuring is expected to result in charges of $425 million to $475 million by the end of 2001 and to reduce annual costs by $100 million. We invested $261 million in restructuring in 2000. We expect to complete the process by the end of 2001.

**We're managing our costs, cash flow, and capital expenditures.** In 2000, we reduced selling, general and administrative (SG&A) costs as a percent of sales from 23.6 percent to 22.8 percent. We expect to achieve a similar reduction this year and to maintain this lower SG&A ratio in the years ahead. We've also reduced R&D spending as a percent of sales, while focusing our strong R&D effort on key crops.

In cash management, we're working to reverse the trend of recent years, when inventories and receivables grew as a percent of sales. We've already increased sales while reducing inventories, and we intend to maintain inventories at the current level of 23 percent to 24 percent of sales. In addition to managing inventories, we're also working to reduce receivables. We hope to pare six to eight days from our days' sales outstanding in 2001.

An aggressive capital spending program during the past two years was directed primarily at integrating our seed businesses (see GRAPH 5) and expanding our glyphosate manufacturing capacity. We see 2001 as a year of transition to lower capital spending levels, with the completion this year of our glyphosate manufacturing facility in Brazil.

[ GRAPH 5 ]

*Streamlined seed operations deliver results*

*A major component of our cost management efforts in 1999 and 2000 was the successful integration of our seed production facilities. For example, in the United States, we integrated 15 soybean facilities into 11 sites. By year-end 2000, we had integrated approximately one-fourth of the seed facilities we had worldwide in December 1998. The successful integration of our facilities and field sales forces allows us to implement best practices for safety and quality control at these locations worldwide.*



**FOCUS** | *Achieve the Benefits of Integrated Solutions and Operations*

**VALUE DRIVER: TARGETS**

**NEAR-TERM** (2001-2002)

- Introduce enhancements that increase the value of existing products to farmers.
- Achieve revenue growth of 5 percent in 2001 and increase net income in 2001 between 9 percent and 13 percent.
- Through a continued focus on business growth and cost and cash management, achieve positive free cash flow before dividends in 2001.

**MEDIUM-TERM** (2003-2005)

- Increase branded seed share and market penetration of Monsanto traits.
- Help develop biotechnology products for the grain processing and animal feed industries to be commercialized by Renessen.

**LONG-TERM** (2006 AND BEYOND)

- Introduce integrated solutions targeted at downstream businesses.

**"Our challenge is to maintain strong financial performance with a discipline in decision making that meets near-term objectives while supporting innovation to create long-term value for customers and shareowners."**

TERRY CREWS
*Executive Vice President and Chief Financial Officer*

**The integration of our businesses is also propelling top-line growth.** We use our seed assets and our extensive global production and distribution infrastructure to accelerate product development. Our assets include a broad, high-quality collection of genetic material — called germplasm — used to develop new seeds.

We can take advantage of integrated production facilities and field forces to expand sales of conventional seeds in markets such as Latin America, where advanced hybrids account for less than half of the crops planted. In addition, because we have access to superior germplasm, we can offer new biotechnology traits in the seed varieties that farmers prefer. Seeds containing Monsanto traits were planted on 89 million acres in 1999, and 103 million acres in 2000. (See GRAPH 6.) As more of our seeds carry valuable traits, we'll realize improved margins from our seed businesses.

**OUTLOOK** **Our 2001 goals are to achieve a 5 percent increase in revenue, and a 9 percent to 13 percent increase in net income. We expect positive free cash flow before dividends at the end of 2001. Having achieved the bulk of targeted savings in SG&A costs, R&D spending and inventories, we've turned our attention to managing receivables.**

**In the longer term, we plan to support higher earnings by developing high-value proprietary products and integrated solutions. In particular, we intend to sell more of our seeds under Monsanto brands, and to increase the overall percentage of seeds that carry our traits.**



[ GRAPH 6 ]

*Acreage planted in Monsanto biotechnology traits continues to grow*

ACRES IN MILLIONS

*Plantings of biotechnology crops containing Monsanto traits grew by more than 15 percent in 2000, to roughly 103 million acres. Global plantings are expected to increase in the near term.*




*We're actively pursuing regulatory approvals in three key markets — Brazil, India and Europe — for products already approved elsewhere. Approvals in these markets could set the stage for more rapid expansion.*

VALUE [ 5 ] DRIVER

**Use biotechnology capabilities to speed product development: Breeding improved plant varieties**

More than 90 researchers are at work at Monsanto's eight molecular breeding centers worldwide. With molecular breeding, researchers use genetic markers to reduce significantly the time necessary to develop new plant varieties. Marker-assisted breeding allows us to create a new variety containing a particular trait at least a year earlier than is possible with traditional methods. Through the work of researchers such as Becki Siefert, we can screen thousands of plants daily. That allows us to select hundreds of hybrids — those containing the most valuable genes — for advanced trials each year. From that group we can choose the dozens of top-performing hybrids that ultimately reach farmers' fields.

TOP: BECKI SIEFERT, A MONSANTO RESEARCHER, USES TRADITIONAL PLANT BREEDING TECHNIQUES TO CROSS-POLLINATE CORN IN OUR FACILITY IN JERSEYVILLE, ILLINOIS. HER WORK ALSO INVOLVES TAKING TISSUE SAMPLES OF NEWLY BRED CORN FOR ANALYSIS OF ITS GENETIC MAKEUP. THIS INFORMATION IS USED TO CORRELATE RESULTS FROM LAB AND FIELD, AND TO REFINE BREEDING.



VALUE [ 6 ] DRIVER

**Commercialize products in our pipeline: Bringing new solutions to livestock producers**

Satisfied customers are often the best customers for product innovations. Stuart Kemp is a grain farmer and livestock producer who plants *Roundup Ready* soybeans because they are user-friendly and help him reduce his production costs. Livestock producers also stand to benefit from corn being developed to improve the nutritional content of animal feed by Renessen, our joint venture with Cargill.

BOTTOM: STUART KEMP OF MCKINNEY, TEXAS, FEEDS SOME OF HIS 300 BLACK ANGUS BEEF COWS. HE IS ALWAYS LOOKING FOR NEW SOLUTIONS THAT CAN HELP MAKE HIS BREEDING, LIVESTOCK, AND GRAIN OPERATIONS MORE EFFICIENT.



FOCUS

# Advance Agriculture *through* INNOVATION

**Monsanto's unparalleled resources in genomics (a group of genetic research technologies) and plant biotechnology are complemented by our skills in chemistry and traditional plant breeding. Achieving the full benefit of these innovations depends upon our: [5] using biotechnology capabilities to speed product development, and [6] commercializing products in our pipeline.**

We're showing the value of plant biotechnology in commercial terms, and we're focusing on innovations that increase the value of farmers' crops. Small and large farmers around the world can share in the benefits of biotechnology: increased safety, reduced costs, and improved efficiencies.

VALUE [5] DRIVER

## Use biotechnology capabilities to speed product development

Monsanto was one of the first companies to apply biotechnology — the study of the structure and function of genes — to the improvement of plants. To date, we've earned more than 50 percent of all approvals of biotechnology products granted by the U.S. Department of Agriculture.

Monsanto has established a leading position in plant genomics. Our extensive network of genomics-related research includes Cereon Genomics LLC, a subsidiary we formed in collaboration with Millennium Pharmaceuticals. Monsanto scientists are also working in alliances with Paradigm Genetics, Rosetta Inpharmatics, and others in academic, public and private research.

Monsanto is a world leader in sequencing and characterizing plant genes. In 1999, Monsanto researchers determined a rough draft sequence of the first plant genome — the complete genetic structure of arabidopsis, a type of mustard plant. In 2000, Monsanto produced a working draft sequence of a rice genome and established a web site that gives researchers worldwide access to the company's rice genome data.

Early in 2001, our DEKALB Choice Genetics subsidiary announced the construction of a physical map covering the entire swine genome. This is the first time that this level of genetic information has been mapped for a livestock species. It's an important step in identifying genetic traits that can someday lead to improving animal health, performance, and meat quality.



**FOCUS** | *Advance Agriculture through Innovation*

**"We're committed to bringing the extraordinary benefits of biotechnology to growers and consumers. Our focus is to maintain the financial strength, technology leadership, and market position to realize the full value of this innovation."**

ROBB FRALEY, PH.D.
*Executive Vice President and Chief Technology Officer*

**VALUE DRIVER: TARGETS**

**NEAR-TERM** (2001-2002)

- Launch *MaxGard* insect-protected corn and second-generation *Bollgard* insect-protected cotton.
- Achieve plant breeding targets by refreshing current portfolio in key crops:

  **Corn:** Develop 130 new hybrids in 2001 and 2002.

  **Soybeans:** Develop 150 new varieties over two years.

  **Wheat:** Register 20 varieties and expand testing network in 2001 and 2002.

**MEDIUM-TERM** (2003-2005)

- Maintain technology leadership through Monsanto's network of biotechnology and genomics research capabilities.
- Advance 20 projects involving input, yield and quality traits.
- Develop new seeds for conservation tillage markets.

**LONG-TERM** (2006 AND BEYOND)

- Accelerate the next wave of biotechnology traits, including quality traits for downstream businesses.

**We're using our genomics capabilities to bring products to farmers sooner.** By helping us identify important genes in crop plants, genomics leads to improved varieties, both through genetic modification and through marker-assisted molecular breeding.

Here's an example: Using traditional breeding to develop soybeans resistant to cyst nematode — a devastating root disease — once required inspection of the roots of thousands of plants. Molecular breeding allows researchers to screen new plants quickly for a genetic marker that indicates resistance to the disease.

Plant genomics also expands the pool of genes available for cultivation. Genomics can help us identify useful genes in uncultivated varieties that can then be used to improve crop plants.

**OUTLOOK** **In the near term, we'll use breeding to help develop hybrids and varieties that provide improved yields and productivity for our key crops. In the longer term, we expect to improve plant yields further through both breeding and the introduction of biotechnology traits, particularly in corn and oilseeds. Medium- to long-term goals also include new quality traits for feed and food. To support all these efforts, we intend to maintain Monsanto's technology leadership in research and in intellectual property.**

VALUE [6] DRIVER

## Commercialize products in our pipeline

Our continued success depends on commercialization of products in our pipeline. Key near-term products include *MaxGard* corn, which is protected against corn rootworm. Corn rootworms cause $1 billion in U.S. crop losses annually and infest more than 40 million acres worldwide. The added value of self-protected corn lies in potential insecticide savings of approximately $12 per acre, based on current pesticide prices, in addition to labor savings, improved yields, and environmental benefits. Another near-term product, second-generation *Bollgard* cotton, will protect against additional insects.

The pipeline includes a number of products that offer higher yields. Higher yields achieved through traditional breeding have roughly tripled crop values since the 1930s. Genomics promises even more dramatic value advances by improving plant yields.

**OUTLOOK** **Monsanto's product pipeline comprises four types of innovative solutions for farmers. The chart below indicates potential launches of key products.**

**PRODUCT PIPELINE** | *Focus on Innovations that Create Value for Farmers*

| SOLUTION CATEGORY | NEAR-TERM (2001-2002)* | MEDIUM-TERM (2003-2005)* | LONG-TERM (2006 AND BEYOND)* |
|---|---|---|---|
| CROP YIELD AND PRODUCTIVITY *(includes products developed through breeding or through biotechnology)* | Refresh Current Seed Portfolio with:<br>■ 130 New Corn Hybrids<br>■ 150 New Soybean Varieties<br>■ 20 New Other Oilseed Varieties (sunflower, canola, and oilseed rape)<br>■ 20 New Wheat Varieties | ■ Higher-Yielding Soybeans<br>■ Higher-Yielding Canola<br>■ Additional New Hybrids and Varieties in Key Crops | ■ Higher-Yielding Corn<br>■ Higher-Yielding Cotton<br>■ Specialized Corn<br>■ Drought-Tolerant Corn<br>■ Cold-Tolerant Corn<br>■ Additional New Hybrids and Varieties in Key Crops |
| INSECT AND DISEASE MANAGEMENT** | ■ *MaxGard* Insect-Protected Corn<br>■ Second-Generation *Bollgard* Insect-Protected Cotton<br>■ *Latitude* Fungicide | ■ *Roundup Ready* and Insect-Protected Soybeans<br>■ Second-Generation *YieldGard* Insect-Protected Corn<br>■ Extended Control Seed Treatment | ■ Enhanced *Bollgard* Insect-Protected Cotton |
| WEED MANAGEMENT** | ■ *Roundup Ready* Corn<br>■ *Roundup Ready* Sugar Beets | ■ *Roundup Ready* Wheat<br>■ *Roundup Ready* Rice<br>■ *Roundup Ready* Alfalfa | ■ Enhanced *Roundup Ready* Cotton |
| FEED AND FOOD*** | | ■ Improved-Energy Corn<br>■ Corn Enhanced with Essential Amino Acids | ■ Corn Enhanced with Essential Amino Acids (two candidates)<br>■ Improved-Protein Soybeans<br>■ High-Oil Canola<br>■ High-Oil Soybeans<br>■ Improved-Oil Soybeans<br>■ Zero-Saturate Soybeans |

*Product launches are subject to technological success, regulatory approvals, and industry adoption.

**Multiple-trait product candidates are not listed, unless one of the traits is expected to be launched for the first time.

***Feed and processing products are in the Renessen pipeline. Renessen is a Monsanto/Cargill joint venture.

# PIPELINE PRODUCTS Designed To Provide Farmers *with* Innovations *that* Create Value

Products under development (as noted on page 16) include:

## CROP YIELD AND PRODUCTIVITY

**New Corn, Soybean, Sunflower, Canola, Oilseed Rape, and Wheat Hybrids and Varieties**
These products will include improved varieties and hybrids developed through traditional breeding, molecular breeding and/or biotechnology. They will be offered to farmers through our seed brands (including *Asgrow* and *DEKALB*) as well as through other seed companies that use our germplasm in their branded seeds.

**Higher-Yielding Soybeans, Canola, Corn and Cotton**
These products are being developed through traditional and molecular breeding, and with biotechnology approaches. They will provide farmers with greatly increased yields.

**Specialized Corn**
This product will dramatically lower the cost of seed corn production by making the labor-intensive detasseling process unnecessary.

**Drought-Tolerant Corn**
Through biotechnology, this corn will require less water, which will be beneficial on fields that receive limited rainfall during the growing season.

**Cold-Tolerant Corn**
This corn, modified through biotechnology, will allow farmers to plant their crop earlier and encourage them to adopt conservation tillage practices.

## INSECT AND DISEASE MANAGEMENT

***MaxGard* Insect-Protected Corn**
This corn, modified through biotechnology, will offer protection against the corn rootworm and related insects. In addition, *MaxGard* corn will have a coating that protects it against other insects, such as wireworms and flea beetles.

**Second-Generation *Bollgard* Insect-Protected Cotton**
This cotton will produce a novel protein that protects against specific insects in addition to the protein in currently marketed *Bollgard* cotton. It also will help farmers with a broader spectrum of insect control.

***Latitude* Fungicide**
This fungicide for control of take-all disease in wheat had a limited launch in 2000. It will be introduced in several key European markets following regulatory approvals.

***Roundup Ready* and Insect-Protected Soybeans**
Through biotechnology, these soybeans will offer farmers the advantages of both in-crop weed control with *Roundup* and protection from certain insects.

**Second-Generation *YieldGard* Insect-Protected Corn**
This corn will produce a protein that protects against specific insects by a mode of action different from that in the currently marketed *YieldGard* corn. It will provide farmers with a broader spectrum of insect control.

**Extended Control Seed Treatment**
This product will control certain diseases and insects in bagged corn, cotton, and wheat seed. It also will protect planted seedlings against insects and diseases longer into the season than treatments currently used.

**Enhanced *Bollgard* Insect-Protected Cotton**
Through biotechnology, this cotton will provide better control of beet and fall armyworms than earlier products.

## WEED MANAGEMENT

***Roundup Ready* Corn**
This *Roundup Ready* corn product, which uses Monsanto proprietary biotechnology, will offer farmers the advantages of in-crop weed control with *Roundup*.

***Roundup Ready* Sugar Beets, Wheat, Rice, and Alfalfa**
Through biotechnology, these crops will offer farmers the advantages of in-crop weed control with *Roundup*.

**Enhanced *Roundup Ready* Cotton**
This cotton will give farmers a longer period of time during which they can use *Roundup* for over-the-top weed control.

## FEED AND FOOD

**Improved-Energy Corn***
Through biotechnology, this corn is being developed to improve its energy density and increase its value as animal feed.

**Corn Enhanced with Essential Amino Acids***
Three product candidates are being developed through biotechnology to deliver increased levels of specific amino acids and to reduce the need for synthetic supplements.

**Improved-Protein Soybeans***
Meal from these genetically enhanced soybeans will have an improved amino acid profile for animal nutrition.

**High-Oil Canola and Soybeans***
Through biotechnology, these oilseeds will have higher levels of oil. This will improve processing efficiency.

**Improved-Oil Soybeans**
These soybeans, modified through biotechnology, are being developed as more nutritious food ingredients and as ingredients for other products.

**Zero-Saturate Soybeans**
Through biotechnology, these soybeans will produce oil that can help people maintain healthier cholesterol levels.

*These products are in the Renessen pipeline. Renessen is a Monsanto/Cargill joint venture.

# FINANCIAL REVIEW

## FINANCIAL CONTENTS


Selected Financial Data . . . . . 19
Management's Discussion and Analysis
of Financial Condition and Results of Operations . . . . . 20
Statement of Consolidated Income (Loss) . . . . . 35
Statement of Consolidated Financial Position . . . . . 36
Statement of Consolidated Cash Flows . . . . . 37
Statement of Consolidated Shareowners' Equity
and Statement of Consolidated Comprehensive Income (Loss) . . . . . 38
Notes to Consolidated Financial Statements . . . . . 39
Management Report . . . . . 60
Independent Auditors' Report . . . . . 61

# SELECTED FINANCIAL DATA *(unaudited)*

MONSANTO COMPANY

| (DOLLARS IN MILLIONS, EXCEPT PER PRO FORMA SHARE AMOUNTS) | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|
| **Operating Results:** | | | | | |
| Net sales[1] | $ 5,493 | $ 5,248 | $ 4,448 | $ 3,673 | $ 2,928 |
| Income from operations | 567 | 610 | 55 | 13 | 506 |
| Income (loss) before income taxes and cumulative effect of a change in accounting principle | 334 | 263 | (60) | 1 | 531 |
| Cumulative effect of a change in accounting principle[1] | (26) | — | — | — | — |
| Net income (loss)[2] | 149 | 150 | (125) | 31 | 319 |
| Pro forma net income (loss)[1] | 175 | 124 | (125) | N/A | N/A |
| **Diluted Earnings (Loss) Per Pro Forma Share:**[3] | | | | | |
| Net income (loss) | $ 0.58 | $ 0.58 | $ (0.48) | $ 0.12 | $ 1.24 |
| Pro forma net income (loss)[1] | 0.68 | 0.48 | (0.48) | N/A | N/A |
| **Year-End Financial Position:** | | | | | |
| Total assets | $ 11,726 | $11,101 | $ 10,891 | $ 5,123 | $ 3,650 |
| Working capital | 2,216 | 2,323 | 1,879 | 1,000 | 719 |
| Long-term debt | 962 | 4,278 | 4,388 | 1,000 | — |
| Debt-to-total capitalization[4] | 19.3% | 48.5% | 53.3% | 36.8% | N/A |
| Current ratio | 1.80:1 | 2.36:1 | 2.01:1 | 1.70:1 | 1.67:1 |
| **Other Data:** | | | | | |
| Dividends per share[5] | $ 0.09 | N/A | N/A | N/A | N/A |
| Stock price: | | | | | |
| High | 27.38 | N/A | N/A | N/A | N/A |
| Low | 19.75 | N/A | N/A | N/A | N/A |
| Year-end | 27.06 | N/A | N/A | N/A | N/A |
| Shares outstanding (year-end, in millions)[6] | 258.0 | N/A | N/A | N/A | N/A |
| Employees (year-end) | 14,700 | N/A | N/A | N/A | N/A |

The operating results data and earnings per pro forma share data, set forth above for the years ended Dec. 31, 2000, 1999, 1998, and 1997 and the financial position data as of Dec. 31, 2000, 1999, and 1998 are derived from our audited financial statements. The operating results data for the year ended Dec. 31, 1996 and the financial position information as of Dec. 31, 1997 and 1996 are derived from unaudited financial statements. In the opinion of management, this unaudited financial data has been prepared on a basis consistent with the audited financial statements and includes all adjustments, which are only normal recurring adjustments necessary for a fair presentation of the operating results and financial position.

(1) In 2000, Monsanto adopted Staff Accounting Bulletin No. 101, *Revenue Recognition in Financial Statements* (SAB 101), the Securities and Exchange Commission's interpretation of accounting guidelines on revenue recognition. The adoption of SAB 101 primarily affected the company's recognition of license revenues from biotechnology traits sold through third-party seed companies. Monsanto now recognizes this license revenue when a grower purchases seed as compared with the previous practice of recognizing the license revenue when the third-party seed company sold the seed into the distribution system. As a result, no license revenues from biotechnology traits sold by third-party seed companies were recognized in the fourth quarter of 2000, whereas the fourth quarter of 1999 included $42 million of such license revenues. SAB 101 requires companies to report any change in revenue recognition related to adopting its provisions as an accounting change in accordance with Accounting Principles Board Opinion No. 20, *Accounting Changes.* Monsanto recognized the cumulative effect of a change in accounting principle of a loss of $26 million, net of taxes of $16 million, effective Jan. 1, 2000. If Monsanto had recognized trait license revenue on a comparable basis, net income would have been $124 million or $0.48 per pro forma share in 1999 compared with $175 million or $0.68 per pro forma share in 2000.

(2) Pretax income for 2000 included $261 million in pretax costs associated with our restructuring plan to focus on key projects, resulting in the termination of certain research and development programs, net of the reversal of certain prior-year restructuring reserves; for the year ended 1999 it included a $101 million pretax charge associated with a failed merger and accelerated business integration costs, net of the reversal of restructuring reserves established in 1998; for the year ended 1998 it included $604 million pretax costs for restructuring charges and the write-off of acquired in-process research and development; for the year ended 1997 it included pretax charges of $633 million for the write-off of acquired in-process research and development; for 1996 it included restructuring and other special pretax charges of $95 million.

(3) For all periods prior to 2000, diluted earnings per pro forma share were calculated using 258 million weighted-average common shares, the number of common shares outstanding after the initial public offering on Oct. 23, 2000. Diluted earnings per pro forma share for 2000 were calculated using 258 million weighted-average common shares outstanding plus the effect of dilutive common share equivalents totaling 0.5 million, consisting of outstanding stock options.

(4) Debt-to-total capitalization is the sum of total short-term and long-term debt divided by the sum of total short-term and long-term debt and shareowners' equity.

(5) The dividend of $0.09 per share on the company's common stock declared in the fourth quarter of 2000 and paid in 2001 represents a prorated dividend based on a quarterly dividend of $0.12 per share.

(6) On Oct. 23, 2000, Monsanto sold 38 million shares of its common stock in an initial public offering, including 3 million shares of common stock with respect to which underwriters exercised their over-allotment option on Oct. 20, 2000. Subsequent to the offering, Pharmacia owned and continues to own 220 million shares of common stock.

## OVERVIEW

Monsanto Company and subsidiaries (Monsanto or the company) comprises the operations, assets and liabilities that were previously the agricultural business of Pharmacia Corporation (Pharmacia). Monsanto manages its business in two segments: Agricultural Productivity, and Seeds and Genomics. The Agricultural Productivity segment consists of the crop protection products, animal agriculture and environmental technologies business lines. The Seeds and Genomics segment consists of the global seeds and related traits business and genetic technology platforms.

We are a global provider of technology-based solutions and agricultural products for growers and downstream customers, such as grain processors, food companies and consumers, in agricultural markets. The combination of our herbicides, seeds and related genetic trait products provides growers with integrated solutions to more efficiently and cost effectively produce crops at higher yields, while controlling weeds, insects and diseases.

On Sept. 1, 2000, the assets and liabilities of the agricultural business were transferred from Pharmacia to Monsanto, pursuant to the terms of a Separation Agreement dated as of that date. The Statements of Consolidated Income (Loss), Consolidated Financial Position, and Consolidated Cash Flows for all periods prior to Sept. 1, 2000, were prepared on a carve-out basis to reflect the historical operating results, assets, and liabilities of the agricultural business operations.



Pharmacia provided and continues to provide certain general and administrative services to Monsanto, including finance, legal, treasury, information systems, public affairs, regulatory and human resources. Although prior to Sept. 1, 2000, it was not practicable to determine what the cost of certain services would have been on a stand-alone basis, these costs were allocated to Monsanto based on methodologies that management believes to be reasonable, but which do not necessarily reflect what the results of operations, financial position, or cash flows would have been had Monsanto been a separate, stand-alone public entity during all periods presented. Costs associated with finance, information systems, and human resources were allocated based on the number of people in those functions assigned to support Monsanto. Public affairs, legal, and regulatory cost allocations were based on work effort and projects specific to the business. Treasury cost allocations were based on Monsanto's sales as a percentage of total sales.

As described in Notes 11, 12, 13 and 14 to the consolidated financial statements, Monsanto employees and retirees participate in various pension, health care, savings and other benefit plans. The costs related to those plans and attributable to Monsanto are included in Monsanto's consolidated financial statements prior to Sept. 1, 2000, and generally are based on the percentage of Monsanto's payroll costs to total payroll costs. Following the separation of the agricultural business operations of Monsanto from Pharmacia on Sept. 1, 2000, Monsanto employees are covered by pension and stock-based compensation plans sponsored by either Monsanto or Pharmacia and participate in health care and other benefit plans sponsored by Monsanto.

Beginning Sept. 1, 2000, the consolidated financial statements reflect the results of operations, financial position, and cash flows of the company as a separate entity responsible for procuring or providing the services previously provided by Pharmacia. The consolidated financial statements also include the costs of services purchased from Pharmacia and the reimbursement for services provided to Pharmacia pursuant to a transition services agreement.

On Oct. 23, 2000, Monsanto sold 38,033,000 shares of its common stock at $20 per share in an initial public offering (IPO), including 3,033,000 shares of common stock with respect to which the underwriters exercised their over-allotment option. The total net proceeds to Monsanto were $723 million. Subsequent to the offering, Pharmacia owned and continues to own 220,000,000 shares of common stock, representing 85.3 percent ownership of Monsanto. Additionally, the company issued 10,000 restricted common stock shares at the date of the IPO. Basic earnings per pro forma share information was prepared using the number of common shares outstanding (258,043,000) after Monsanto's IPO. Diluted earnings per pro forma share for 2000 were calculated using the number of common shares outstanding at year-end plus the dilutive effect of common share equivalents totaling 0.5 million shares, consisting of outstanding stock options.

In 2000, Monsanto adopted Staff Accounting Bulletin No. 101, *Revenue Recognition in Financial Statements* (SAB 101), the Securities and Exchange Commission's interpretation of accounting guidelines on revenue recognition. The adoption of SAB 101 primarily affected the company's recognition of license revenues from biotechnology traits sold through third-party seed companies. Monsanto now recognizes this license revenue when a grower purchases seed as compared with the previous practice of recognizing the license revenue when the third-party seed company sold the seed into the distribution system. As a result, no license revenues from biotechnology traits sold by third-party seed companies were recognized in the fourth quarter of 2000, whereas the fourth quarter of 1999 included $42 million of such license revenues.

SAB 101 requires companies to report any change in revenue recognition related to adopting its provisions as an accounting change in accordance with Accounting Principles Board Opinion No. 20, *Accounting Changes*. Monsanto recognized the cumulative effect of a change in accounting principle of a loss of $26 million, net of taxes of $16 million, effective Jan. 1, 2000. If Monsanto had

recognized trait license revenues on a comparable basis, net income would have been $124 million or $0.48 per pro forma share in 1999 compared with $175 million or $0.68 per pro forma share in 2000.

The primary operating performance measure for our two segments is earnings before interest and taxes (EBIT). Total company EBIT for the year ended Dec. 31, 2000, increased slightly to $518 million from $506 million in the prior year. However, in 2000 and in prior years, special charges and other items significantly affected our results. Additionally, our seed company acquisitions in 1998 and 1997 resulted in a substantial increase in amortization expense associated with goodwill and other intangible assets. Accordingly, management believes that earnings before cumulative effect of accounting change, interest, taxes, depreciation, amortization, restructuring and special items (EBITDA (excluding special items)) is an appropriate measure for evaluating the operating performance of our business. EBITDA (excluding special items) eliminates, among other things, the effects of depreciation of tangible assets and amortization of intangible assets, most of which resulted from the seed company acquisitions accounted for under the purchase method of accounting. In particular, it also eliminates the effects of the special items. For further details see Note 5 — Restructuring and Other Special Items — to the consolidated financial statements. The presentation of EBITDA (excluding special items) is intended to supplement investors' understanding of our operating performance. EBITDA (excluding special items) may not be comparable to other companies' EBITDA performance measures. It is not intended to replace net income, cash flows, financial position or comprehensive income, as determined in accordance with accounting principles generally accepted in the United States.

Management's Discussion and Analysis should be read in conjunction with Monsanto's Consolidated Financial Statements, the accompanying footnotes and the Market Risk Management section. Unless otherwise indicated, "Monsanto" and "the company" are used interchangeably to refer to Monsanto Company or to Monsanto Company and consolidated subsidiaries, as appropriate to the context. With respect to time periods prior to the separation of Monsanto's businesses from those of Pharmacia on Sept. 1, 2000, references to "Monsanto" or "the company" also refer to the agricultural division of Pharmacia. In the tables, all dollars are in millions, except per-share amounts.

## RESULTS OF OPERATIONS



| YEAR ENDED DEC. 31, | 2000 | 1999 | 1998 |
|---|---|---|---|
| Net sales | $5,493 | $5,248 | $4,448 |
| Net income (loss) before cumulative effect of accounting change | 175 | 150 | (125) |
| Add: Interest expense — net | 184 | 243 | 94 |
| Income tax provision | 159 | 113 | 65 |
| EBIT[1] | 518 | 506 | 34 |
| Add: Restructuring and special items | 261 | 101 | 604 |
| EBIT (excluding special items) | 779 | 607 | 638 |
| Add: Depreciation | 270 | 238 | 205 |
| Amortization of goodwill and other intangible assets | 276 | 309 | 163 |
| EBITDA (excluding special items)[2] | $1,325 | $1,154 | $1,006 |
| Diluted earnings (loss) per pro forma share:[3] | | | |
| Income (loss) before cumulative effect of accounting change | $0.68 | $0.58 | $(0.48) |
| Pro forma financial information applying new accounting principle retroactively: | | | |
| Net income (loss) | $ 175 | $ 124 | $ (125) |
| Diluted earnings (loss) per pro forma share[3] | $0.68 | $0.48 | $(0.48) |

(1) Earnings before cumulative effect of accounting change, interest and taxes.

(2) Earnings before cumulative effect of accounting change, interest, taxes, depreciation, amortization, and restructuring and special items.

(3) For all periods prior to 2000, diluted earnings per pro forma share were calculated using 258 million weighted-average common shares, the number of common shares outstanding after the initial public offering. Diluted earnings per pro forma share for 2000 was calculated using 258 million weighted-average common shares outstanding plus the effect of dilutive common share equivalents totaling 0.5 million, consisting of outstanding stock options.

### Monsanto Achieves Sales of $5.5 Billion

Net sales increased to $5.5 billion in 2000, compared with $5.2 billion in 1999. This increase was due primarily to a 6 percent increase in *Roundup* herbicide and other glyphosate product sales, and to a lesser degree, increased sales of our selective chemistries business and of *Roundup* lawn and garden products, as well as an increase in technology royalty revenues. Offsetting these gains was the effect of weaker foreign currencies, primarily the euro, and a 3 percent decline in our seed business revenue, due primarily to the divestiture of the Stoneville Pedigreed Seed business (Stoneville) in December 1999 and lower sales of conventional seeds.

Cost of goods sold increased 8 percent to $2.8 billion in 2000 from $2.6 billion in the prior year. The primary reason for this increase was an 18 percent increase in glyphosate product sales volumes. Start-up expenses associated with our new manufacturing facility for *Posilac* bovine somatotropin in Augusta, Georgia, also contributed to increased cost of goods sold. Gross profit of $2.7 billion in 2000 remained relatively flat compared with 1999. Increased gross profit for the family of *Roundup* products and seed sales that included biotechnology traits was primarily offset by lower gross profit in our conventional seed and environmental technologies businesses, which reported lower net sales in 2000 than in 1999.

Selling, general and administrative expenses increased slightly to $1.3 billion for 2000, compared with $1.2 billion for 1999. This increase was attributable primarily to increased spending on biotechnology acceptance and education programs in 2000. Also contributing to the increase in selling, general and administrative expenses were increased agency fees payable to The Scotts Company (Scotts) in our *Roundup* lawn and garden business because of the increase in sales in 2000. See "Our Agreement with The Scotts Company" for further details.

Research and development expenses decreased 15 percent to $588 million in 2000 compared with $695 million in 1999. This decrease was due primarily to our decision to reduce our spending on non-core programs and to focus our research programs on certain key crops.

Amortization and adjustments of goodwill increased 66 percent to $212 million in 2000 compared with $128 million in the prior year as a result of an $88 million write-down of goodwill primarily associated with our decision to terminate the nutrition programs at Calgene. In 1999, we incurred an $8 million charge to amortization and adjustments of goodwill related to the termination of several research programs. Excluding these charges, amortization and adjustments of goodwill were relatively flat in 2000 compared with 1999.



Net interest expense in 2000 decreased 24 percent to $184 million from $243 million in the prior year, primarily reflecting the $2.9 billion reduction in debt resulting from our separation from Pharmacia and our initial public offering. Other expense — net decreased 53 percent to $49 million in 2000, compared with $104 million in 1999, primarily because of the inclusion in 1999 of $85 million in cost associated with the failed merger with Delta and Pine Land Company (Delta and Pine Land), partially offset by increased equity losses from affiliates ($16 million) and the write-down of our investment in a marketable equity security ($7 million) in 2000.

Pretax income increased approximately 27 percent or $71 million primarily because of an increase in net sales and a decrease in operating expenses in 2000, resulting in an increase in income tax expense of $46 million when compared with the prior year. The increase in the effective tax rate to 48 percent from 43 percent in the prior year was primarily because the $88 million write-down of goodwill in 2000 was not deductible. See "Restructuring and Special Items (before tax)" for further details.

Net income totaled $149 million, or $0.58 per pro forma share, for the year ended Dec. 31, 2000, compared with $150 million, or $0.58 per pro forma share, for 1999. However, net income for 2000 included a cumulative effect of accounting change of $26 million after tax, or $0.10 per pro forma share. In addition, both years' net income included special after tax charges of $197 million and $81 million, respectively. Excluding these special charges in both periods and the cumulative effect of an accounting change in 2000, net income for 2000 would have been $372 million, or $1.44 per pro forma share, a 61 percent increase over net income of $231 million, or $0.90 per pro forma share, for 1999. See "Restructuring and Special Items (before tax)" for further details.

Our business results are affected by changes in foreign economies and foreign currency exchange rates, as well as by climate conditions around the world. Our sales growth was adversely affected by weak economic conditions in certain world areas, which lessened the demand for herbicides, especially in Eastern Europe and the Commonwealth of Independent States in 2000 and 1999 and in Southeast Asia in 2000 and 1998. Unfavorable climate conditions in key areas of Latin America and Canada during late 1999 (the 2000 planting season) decreased demand for herbicides and limited sales volume growth of *Roundup* in the 2000 crop year. Although we have operations in virtually every region of the world, our business is principally conducted in the United States, Argentina, Brazil, Canada, Australia, France and Japan. Accordingly, changes in economic conditions, foreign exchange rates and climate conditions in those parts of the world generally have a more significant effect on our operations than similar changes in other places.

### Prior Year Review

Net sales increased 18 percent in 1999 to $5.2 billion from $4.4 billion in the prior year, primarily reflecting the inclusion of a full year of sales from seed companies acquired late in 1998. Excluding the 1998 seed company acquisitions and the divestiture of the tomato business, net sales would have increased 3 percent. The increase in net sales reflected increased sales of the family of *Roundup* herbicides and increased technology royalty revenues, partially offset by decreases in revenues in our environmental technologies business and our *Roundup* lawn and garden business.

Cost of goods sold for 1999 increased 19 percent to $2.6 billion from $2.1 billion in the prior year, primarily reflecting the inclusion of a full year of the results of seed companies acquired in 1998. Gross margin for 1999 was 51 percent of net sales, compared with 52 percent of net sales in 1998. This decline was the result of a slight decline in gross margin in our Agricultural Productivity segment, primarily in *Roundup* and other glyphosate products, partially offset by a modest gain in gross margin in our Seeds and Genomics segment, where an increase in seed trait revenues and improved seed gross margin drove up the gross margin.

Selling, general and administrative expenses increased to $1.2 billion in 1999 from $1.1 billion in 1998 primarily reflecting the full-year inclusion of seed companies acquired in 1998 and increased general and administrative services provided to our business, mainly in the area of information

technology, regulatory and biotechnology acceptance programs. In addition, our 1999 results were negatively affected by an increase in bad debt expense to $70 million compared with $29 million in 1998. Research and development expenses increased 30 percent, to $695 million in 1999, from $536 million in 1998, again because of the inclusion of a full year of the operating expenses of the acquired seed companies, and because of increased spending on genomics research and biotechnology. Amortization and adjustments of goodwill increased 66 percent to $128 million during the same period because of higher goodwill amortization from seed company acquisitions.

Other expenses increased $83 million to $104 million in 1999 compared with $21 million in 1998, primarily as a result of $85 million of costs associated with the failed merger with Delta and Pine Land combined with litigation costs. Net interest expense increased from $94 million in 1998 to $243 million in 1999 reflecting a full year of interest expense on approximately $4.3 billion of long-term acquisition-related debt. Our long-term debt increased significantly in late 1998 to $4.4 billion at Dec. 31, 1998; however our 1998 results included interest expense on this higher debt level for a shorter period of time compared with a full year in 1999.

Income tax expense for 1999 was $113 million, an increase from income tax expense for 1998 of $65 million, primarily because pretax income increased and because a portion of goodwill amortization and adjustments in 1999 was nondeductible.

Net income in 1999 improved to $150 million, or $0.58 cents per pro forma share, and included a full year of operating results, amortization and interest expense related to the acquired seed companies compared with a net loss of $125 million, or $0.48 cent loss per pro forma share in 1998.

## RESTRUCTURING AND SPECIAL ITEMS (BEFORE TAX)

For 2000 and each of the prior two years, our results have included restructuring and special items that significantly affected net income. The pretax income (expense) components of restructuring and special items were as follows:

| YEAR ENDED DEC. 31, | 2000 | 1999 | 1998 |
|---|---|---|---|
| Restructuring charges | $(107) | $ — | $(143) |
| Write-off of goodwill | (88) | (8) | (39) |
| Write-off of obsolete inventory | (60) | — | — |
| Reversal of restructuring reserves | 4 | 11 | — |
| In-process research and development write-offs | — | — | (402) |
| Accelerated integration costs | — | (53) | — |
| Failed merger costs | — | (85) | — |
| Gain on the sale of Stoneville | — | 35 | — |
| Other | (10) | (1) | (20) |
| Total restructuring and special items | $(261) | $(101) | $(604) |

### Restructuring and Special Items (before tax) for 2000

In 2000, we recorded a net pretax charge of $261 million ($197 million after tax) to operations, primarily associated with our plan to focus on key research and development projects, resulting in the elimination of certain programs, net of a $4 million reversal of restructuring reserves. The plan encompassed a decision to focus more stringently on our key crops and to eliminate certain food and biotechnology research programs, and the shutdown of certain administrative and manufacturing facilities. Of the $261 million of charges, $79 million was for the write-off of goodwill associated with the nutrition programs acquired from Calgene, $9 million was for the write-off of goodwill associated with a European seed business, $30 million was included in cost of goods sold for the write-off of laureate oil inventories and $30 million was included in cost of goods sold for the write-off of obsolete seed and other inventories. The restructuring charges of $107 million included $61 million of involuntary employee separation costs for 695 employees worldwide, including positions in administration, manufacturing and research and development. The remaining $46 million of restructuring charges consisted of equipment write-offs of $22 million, accounts receivable write-offs of $12 million, contract terminations of $5 million, $3 million of various license and germplasm write-offs associated with the eliminated research programs, dismantling costs of $2 million and other shut-down costs of $2 million. Also, included in the total charge were other special items of $10 million consisting of $3 million for costs associated with a failed joint venture and $7 million for the recognition of an impairment of a marketable equity security that was classified as available for sale. In addition, in the first half of 2000, we reversed restructuring liabilities of $4 million related to the 1998 restructuring plan, largely as a result of lower actual severance expenses than originally estimated. Our 1998 restructuring plan is complete.

Cash payments to complete the 2000 plan will be funded from operations and are not expected to significantly affect our liquidity. Additional charges are expected to be incurred as we plan to continue to stringently focus our research and development programs and streamline our operations. Total pretax charges from this plan are expected to be approximately $425 million to $475 million, including $261 million of net charges incurred in 2000. The remaining restructuring charges we expect to incur relate primarily to facility closures and employee severance. We expect to incur approximately $160 million to $215 million of these costs

during 2001 when plans are finalized, approved, and the appropriate communications with employees occur. We expect to implement these actions by the end of 2001 and we anticipate they will yield annual cash savings of approximately $100 million. See Note 5 — Restructuring and Other Special Items — to the consolidated financial statements for further details.

### Restructuring and Special Items (before tax) for 1999 and 1998

In 1999, we recorded a net pretax charge of $101 million ($81 million after tax) that included $61 million of costs associated with the accelerated integration of our agricultural chemical and seed operations and $85 million related to a failed merger with Delta and Pine Land. These costs were partially offset by a pretax gain of $35 million on the divestiture of Stoneville and an $11 million reversal of restructuring liabilities established in 1998.

Cash payments to complete the actions were funded from operations and did not significantly affect our liquidity. The accelerated integration actions were substantially completed by Dec. 31, 2000, and we expect our actions to result in annual pretax cash savings of $24 million.

Offsetting the restructuring and unusual charges in 1999 was a pretax gain of $11 million from the reversal of restructuring reserves established in 1998. These restructuring reversals were principally required as a result of actual severance and facility shutdown costs that were lower than originally estimated. In addition, we recognized a pretax gain of $35 million on the sale of Stoneville and miscellaneous other expense of $1 million which was recorded in "Other expense — net." See Note 5 — Restructuring and Other Special Items — to the consolidated financial statements for further details.

In 1998, we recorded pretax restructuring charges of $182 million as part of our overall strategy to cut costs and to integrate our acquired seed businesses via the closure of certain facilities, reductions in work force, and sale of our tomato business, the operations of which were no longer consistent with our strategic objectives. We also recorded a pretax charge of $20 million related to the cancellation of employee stock options in connection with the acquisition of DEKALB Genetics Corporation (DEKALB Genetics). In addition, we recognized $402 million of in-process research and development write-offs primarily arising from our purchases of DEKALB Genetics, Plant Breeding International Cambridge Limited (PBI) and certain international seed operations of Cargill Incorporated (Cargill).

Through Dec. 31, 2000, cash payments of $57 million were made to eliminate approximately 630 positions. Eighty positions contemplated in the plan were eliminated through attrition. In addition, $9 million in facility shutdown payments were incurred in connection with the 1998 restructuring plan. This restructuring plan has been completed. Cash payments to complete the 1998 plan were funded from operations and did not significantly impact our liquidity. The restructuring actions are expected to result in annual pretax savings of $60 million. See Note 5 — Restructuring and Other Special Items — to the consolidated financial statements for further details.



## AGRICULTURAL PRODUCTIVITY SEGMENT

**Our Agricultural Productivity segment consists of our crop protection products (*Roundup* and other glyphosate products and selective chemistries) and our animal agriculture, *Roundup* lawn and garden, and environmental technologies businesses.**

| YEAR ENDED DEC. 31, | 2000 | 1999 | 1998 |
|---|---|---|---|
| **Net sales** | | | |
| *Roundup* and other glyphosate products, excluding *Roundup* lawn and garden products | $2,625 | $2,482 | $2,289 |
| All other | 1,260 | 1,104 | 1,211 |
| Total net sales | $3,885 | $3,586 | $3,500 |

### Agricultural Productivity Net Sales for 2000

Net sales for our Agricultural Productivity segment increased 8 percent in 2000 to $3.9 billion compared with $3.6 billion in 1999 as lower prices for our family of *Roundup* herbicides, excluding *Roundup* lawn and garden products, were more than offset by higher sales volumes of these products. Sales were also affected by an increase in other Agricultural Productivity revenues because of increases in selective chemistry sales and *Roundup* lawn and garden product sales, partially offset by a slight decline in net sales in our animal agriculture and environmental technologies businesses.

Net sales for our *Roundup* herbicide and other glyphosate products (excluding *Roundup* lawn and garden products) in 2000 increased 6 percent to $2.6 billion, as compared with $2.5 billion in the prior year, primarily due to an 18 percent increase in *Roundup* herbicide and other glyphosate product volumes partly offset by lower selling prices. The increase in volumes was consistent with our strategy of selectively reducing prices to encourage new uses and increase sales volumes. *Roundup* herbicide and other glyphosate product sales increased primarily in the United States, Argentina, and Europe, because of an incremental number of acres planted with *Roundup Ready* traits and the

continued adoption of conservation tillage. On Sept. 20, 2000, the compound per se patent protection for the active ingredient in *Roundup* herbicide expired in the United States. Although we have not had patent protection on glyphosate outside the United States for several years, we anticipate increasing competition in the United States from lower-priced generic and other branded glyphosate products following the expiration of this patent.

Net sales of our other Agricultural Productivity products increased 14 percent in 2000 to $1.3 billion, from $1.1 billion in 1999, primarily because of increased net sales in our selective chemistries and *Roundup* lawn and garden businesses. Sales of selective chemistries increased 18 percent in 2000 over 1999 because of increased corn herbicide sales, primarily *Harness Xtra* in the United States, and our new wheat herbicide for control of brome grass. *Roundup* lawn and garden sales increased 47 percent over the prior year when sales had dropped, reflecting a change in distribution method which caused distribution channel inventories to decline for these products in 1999. Partially offsetting these increases in 2000 were slight declines in net sales in our animal agriculture and environmental technologies businesses.

### Prior Year Net Sales Review

Net sales of our Agricultural Productivity segment in 1999 increased to $3.6 billion compared with $3.5 billion in 1998 as lower prices for our family of *Roundup* herbicides, excluding *Roundup* lawn and garden products, were more than offset by higher sales volumes of these products. Sales were also affected by a decline in other Agricultural Productivity product revenues because of decreases in selective chemistry sales and *Roundup* lawn and garden product sales, and because of a decline in our environmental technologies business offset in part by higher sales of our animal agriculture products, primarily *Posilac.*

Net sales of *Roundup* and other glyphosate products (excluding *Roundup* lawn and garden products) grew 8 percent to $2.5 billion in 1999 compared with $2.3 billion in 1998. During 1999, volumes from *Roundup* and other glyphosate products, excluding *Roundup* lawn and garden products, grew at a rate slightly above the past decade's 20 percent average annual volume growth rate, principally because of strong volume growth in the United States, Argentina, Brazil, Australia and Canada. Higher sales volumes in the United States in 1999 were largely offset by lower selling prices announced in late 1998. We also reduced selling prices of *Roundup* over the past several years in most markets outside the United States in response to generic competition in those regions. Outside the United States, the effect of lower selling prices was more than offset by increased sales volumes. Sales volume growth during the period resulted from increased adoption of conservation tillage, use of *Roundup* in new applications and increased use of *Roundup* over the top of *Roundup Ready* crops.

Net sales of our other Agricultural Productivity products declined 9 percent to $1.1 billion in 1999 from $1.2 billion in 1998. The primary driver of this decline was a drop in net sales in our *Roundup* lawn and garden business and in our environmental technologies business, Enviro-Chem, and, to a lesser extent, a decrease in our selective chemistries sales. These declines were partially offset by increased net sales in our animal agriculture business. Net sales of our *Roundup* lawn and garden products were negatively affected in 1999 by a change in our distribution method. In connection with the change in distribution, distribution channel inventories declined during the year. As a result of a downward trend in metal and fertilizer prices that began in 1997, Enviro-Chem net sales declined by approximately 37 percent in 1999. Our worldwide selective chemistries sales declined 5 percent in 1999 from 1998, reflecting the downturn in the agricultural economy in the United States as well as the continued poor economic environment in the Commonwealth of Independent States. Net sales in our animal agriculture business grew because of a 14 percent increase in sales volumes of *Posilac* from 1998 to 1999.

Our sales growth was adversely affected by weak economic conditions in certain world areas in 1999, which lessened the demand for herbicides, especially in Eastern Europe and the Commonwealth of Independent States. Drought conditions in key areas of Brazil during the 1999 planting season decreased demand for herbicides and limited sales volume growth of *Roundup* in 1999.



### Agricultural Productivity EBIT and EBITDA (excluding special items)

| YEAR ENDED DEC. 31, | 2000 | 1999 | 1998 |
|---|---|---|---|
| EBIT[1] | $1,099 | $ 897 | $ 869 |
| Add: Restructuring and special items | 22 | 27 | 45 |
| EBIT (excluding special items) | 1,121 | 924 | 914 |
| Add: Depreciation | 205 | 178 | 169 |
| Amortization of goodwill and other intangible assets | 4 | 7 | 6 |
| EBITDA (excluding special items)[2] | $1,330 | $1,109 | $1,089 |

(1) Earnings before cumulative effect of accounting change, interest and taxes.
(2) Earnings before cumulative effect of accounting change, interest, taxes, depreciation, amortization, and restructuring and special items.

### EBIT for 2000

EBIT (excluding special items) for the Agricultural Productivity segment increased 21 percent to $1.1 billion in 2000, compared with $924 million in 1999. This increase was due primarily to increased sales and decreased operating expenses from the prior year.

Gross profit for the Agricultural Productivity segment increased 6 percent for 2000, as compared with 1999, driven by the increased sales of *Roundup*, selective chemistries, and *Roundup* lawn and garden products. However, gross margin for the segment declined one percentage point, primarily because of an overall decline in the net selling price of our *Roundup* and other glyphosate family of products as a result of our continued strategy to selectively reduce the prices of *Roundup* products to encourage increased uses.

Operating expenses for the Agricultural Productivity segment decreased approximately 6 percent in 2000 from 1999, despite the increase in net sales for the segment. This decrease in operating expenses was primarily because of cost reductions in research and development as we increased focus on core research and development programs. Other expense — net decreased $6 million in 2000 vs. 1999, primarily because of decreased losses from equity affiliates in 2000.

### EBIT for 1999

EBIT (excluding special items) for our Agricultural Productivity segment increased 1 percent in 1999 to $924 million compared with $914 million in 1998. Cost of goods sold for our Agricultural Productivity segment increased 3 percent during the period 1998 to 1999, while sales volumes for our family of *Roundup* herbicides and *Posilac* increased by 41 percent during the same period.

Agricultural Productivity segment gross profit improved slightly in 1999 on higher overall volume and lower unit cost in our family of *Roundup* herbicides. Gross margin declined one percentage point in this segment because of decreased glyphosate prices. The increase in gross profit, coupled with a slight decline in operating expenses, led to an overall increase in EBIT in 1999 for the Agricultural Productivity segment.

## SEEDS AND GENOMICS SEGMENT

**Our Seeds and Genomics segment consists of the global seeds and related trait business, and genetic technology platforms.**

Net sales for the Seeds and Genomics segment declined slightly to $1.6 billion in 2000 when compared with $1.7 billion in 1999. Seed net sales declined 3 percent in 2000 primarily because of lower sales of conventional seed varieties and the absence of sales from Stoneville which was sold in late 1999. This decrease was partially offset by a 14 percent increase in sales of seeds that included biotechnology traits, as the company continues to strategically shift more of its seed offerings to seeds with biotechnology traits. The number of acres planted with *Roundup Ready* traits increased 17 percent in 2000, with *Roundup Ready* soybean acres increasing 18 percent over 1999 planted acres.



### Prior Year Net Sales Review

The financial results of our Seeds and Genomics segment in 1999 were significantly affected by the seed company acquisitions made in 1998. In 1998, we acquired DEKALB Genetics, PBI and certain international seed operations of Cargill for a total cost of $4.1 billion. These acquisitions are part of our strategy to build a global seed infrastructure to provide breeding and distribution capabilities for our seed traits.

Net sales of the Seeds and Genomics segment were $1.7 billion in 1999, compared with $948 million in 1998. The $800 million increase in 1999 net sales primarily reflected the inclusion of our 1998 seed company acquisitions for a full year, and to a lesser extent an increase in seed sales which included biotechnology traits. The number of acres planted with *Roundup Ready* soybeans increased 46 percent in 1999, the product's fourth year in the marketplace. Revenues from seed sales which include biotechnology traits, both in connection with our seed sales and from licensing our technology to other seed companies, increased 68 percent in 1999 as the number of acres planted with crops possessing biotechnology traits increased. *Roundup Ready* soybeans, *Roundup Ready* cotton and *YieldGard* insect-protected corn showed the most significant increases.

### Seeds and Genomics EBIT and EBITDA (excluding special items)

| YEAR ENDED DEC. 31, | 2000 | 1999 | 1998 |
|---|---|---|---|
| EBIT[1] | $(581) | $(391) | $(835) |
| Add: Restructuring and special items | 239 | 74 | 559 |
| EBIT (excluding special items) | (342) | (317) | (276) |
| Add: Depreciation | 65 | 60 | 36 |
| Amortization of goodwill and other intangible assets | 272 | 302 | 157 |
| EBITDA (excluding special items)[2] | $ (5) | $ 45 | $ (83) |

(1) Earnings before cumulative effect of accounting change, interest and taxes.
(2) Earnings before cumulative effect of accounting change, interest, taxes, depreciation, amortization, and restructuring and special items.

### EBIT for 2000

EBIT for the Seeds and Genomics segment in 2000 was a loss of $581 million compared with a loss of $391 million in the prior year. The increased loss was largely because of one-time operating charges related to our plan to focus on specific key crops combined with lower gross profit. The decrease in gross profit was the result of lower sales volumes

combined with higher costs associated with inventory management initiatives. In addition, the company incurred increased spending on promotions and education associated with biotechnology acceptance and incurred higher legal fees. Partly offsetting these increased costs was a reduction in research and development expense as we focused our efforts on our key crops.

The one-time operating charges included the elimination of certain food and biotechnology research programs, and the shutdown of certain administrative and manufacturing facilities. We also wrote down $88 million of goodwill primarily associated with the decision to terminate the nutrition program at Calgene. Excluding this write-down, amortization and adjustments of goodwill decreased 10 percent in 2000 compared with 1999.

EBIT (excluding special items) was a loss of $342 million compared with a loss of $317 million in 1999. The increased loss was primarily attributable to a lower total gross profit from seed sales partly offset by a higher gross profit from trait licensing revenues. However, operating expenses were 8 percent lower compared with those in the previous year and, in addition to lower amortization expense, research and development spending decreased 7 percent.

### EBIT for 1999

EBIT for the Seeds and Genomics segment in 1999 was a loss of $391 million, compared with a loss of $835 million in 1998. The Seeds and Genomics segment's cost of goods sold as a percentage of sales improved from 53 percent to 51 percent from 1998 to 1999 because of trait licensing revenue growth and synergies from seed business integration. Operating expenses, excluding special items and amortization, increased primarily because of the inclusion of a full year of operating expenses in 1999 from the seed companies acquired in 1998. Additionally, we continued to expand our investment in genomics and biotechnology.

In 1998, EBIT was significantly negatively affected by costs related to our seed company acquisitions and restructuring actions. In 1998, unusual items included in-process research and development write-offs of $402 million and restructuring expense and other special charges of $157 million, which included $20 million related to the cancellation of DEKALB Genetics stock options in connection with the DEKALB Genetics acquisition. EBIT in 1999 and 1998 were also negatively affected by intangible asset amortization of $302 million and $157 million, respectively. The increase in intangible asset amortization was due primarily to increased goodwill from the seed company acquisitions.

### Acquired in-Process Research and Development

In-process research and development charges for the seed companies acquired in 1998 covered numerous seed breeding projects, no single one of which was significant, as is typical in the seed industry. These projects consisted of conventional breeding programs for corn, wheat and other hybrids; conventional breeding for soybean varieties; and the development of crops modified through biotechnology. The in-process research and development projects were valued by a discounted cash flow method with risk-adjusted discount rates, generally from 12 percent to 20 percent, which took into account the stage of development of each in-process research and development category. Successful commercialization of products developed through these projects is expected to occur five to nine years after program initiation. Although there are risks associated with the ultimate completion and commercialization of these research projects, the failure of any one project would not materially affect the total value of the research programs. The in-process projects were at various stages of completion at the dates of acquisition. In 2000, we had expenses of approximately $45 million for biotechnology-related activities and approximately $40 million for conventional breeding activities related to completing these in-process research and development projects. During the next six years, management expects to spend approximately $110 million on biotechnology-related activities and approximately $130 million on conventional breeding activities to complete these in-process research and development projects, as follows:



**Acquired In-Process Research and Development Expected Spending**

| (IN MILLIONS) | 2001 | 2002 | 2003 | 2004 | 2005 | THEREAFTER | TOTAL |
|---|---|---|---|---|---|---|---|
| **Acquired In-Process Research and Development** | | | | | | | |
| 1998 Acquisition-related conventional seed programs | $40 | $35 | $30 | $20 | $ 5 | $ — | $130 |
| 1998 Acquisition-related biotechnology programs | 35 | 25 | 20 | 15 | 10 | 5 | 110 |
| Total Expected In-Process R&D Spending | $75 | $60 | $50 | $35 | $15 | $ 5 | $240 |

We intend to fund these costs, consisting primarily of salary and benefit expenses for research and development employees, with cash generated from existing businesses. Revenues from the in-process research and development projects related to the 1998 acquisitions began in 1999.

## OUR AGREEMENT WITH THE SCOTTS COMPANY

In 1998, Monsanto entered into an agency and marketing agreement with The Scotts Company (Scotts) with respect to our *Roundup* lawn and garden business. Under the agreement, beginning in the fourth quarter of 1998, Scotts was obligated to pay us a $20 million fixed fee each year to defray costs associated with the *Roundup* lawn and garden business. Scotts' payment of a portion of this fee owed in each of the first three years of the agreement is deferred and required to be paid at later dates, together with interest. Monsanto is accruing the $20 million fixed fee per year owed by Scotts ratably over the periods during which it is being earned as a reduction of selling, general and administrative expenses. We are also accruing interest on the amounts owed by Scotts and including such amounts in interest income. The total amounts owed by Scotts, including accrued interest, were $42 million in 2000, and $26 million in 1999. Scotts is required to begin paying these deferred amounts at $5 million per year in monthly installments beginning Oct. 1, 2002.

## FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

| AS OF DEC. 31, | 2000 | 1999 |
|---|---|---|
| Working capital | $2,216 | $2,323 |
| Current ratio | 1.80:1 | 2.36:1 |
| Debt-to-total capitalization | 19.3% | 48.5% |

At the end of 2000, our working capital decreased $107 million from the prior year end primarily because of an increase in short-term borrowing requirements, partly offset by higher trade receivables. Receivables increased $487 million largely because of increased sales and more customer-favorable payment terms driven by competitive market conditions in the United States and Latin America, as well as unfavorable economic conditions in Latin America. Our operations generated $671 million of cash in 2000 compared with $120 million in 1999. The increase in cash from operations was because of increased sales, lower operating expenses, and the absence of a significant currency devaluation in Brazil.

Cash required for facility and equipment purchases decreased slightly in 2000. Although capacity expansions and improvements to manufacturing facilities in the United States and Latin America continued, expenditures were at a slightly lower rate in 2000. The increase in acquisitions and investments in 2000 over the prior year was primarily because of equity investments in biotechnology and the purchase of a controlling interest in an equity affiliate. We also deposited $205 million with Pharmacia Treasury Services AB (PTS), a wholly owned subsidiary of Pharmacia, as part of a cash management arrangement. During 1999 we invested $108 million in joint ventures and equity investments in manufacturing technology. Also during 1999, Monsanto received $335 million of cash from Cargill, as a refund of a portion of the original purchase price for certain international Cargill seed operations. Major investments in 1998 of $4.1 billion included the acquisitions of DEKALB Genetics, PBI and certain international seed operations of Cargill. See Note 4 — Principal Acquisitions, Mergers and Divestitures — to the consolidated financial statements for further details.

Related party transactions, excluding treasury cash management, during the last four months of 2000 resulted in a net receivable with Pharmacia of $99 million. Transition services, including payroll, pension, and information technology associated with the separation accounted for the outstanding receivable.

Long-term debt of the parent attributable to the Monsanto agriculture division of Pharmacia in 1999 decreased $4.3 billion as the result of a transfer of $2.2 billion of debt to Pharmacia as part of the separation, a reclassification of $1.1 billion of commercial paper borrowings to short-term debt, and a reclassification of the remaining $1.0 billion to long-term debt of Monsanto. These long-term obligations were primarily variable-rate, medium-term notes, debt of our subsidiaries, and debt associated with our employee stock ownership plan.

Since Sept. 1, 2000, Monsanto used proceeds of $723 million from the IPO which closed on Oct. 23, 2000, to repay a portion of the commercial paper debt that had been assumed from Pharmacia. As of Dec. 31, 2000, the company's short-term borrowings included a loan payable to PTS of $635 million. Monsanto has committed borrowing facilities amounting to $1.5 billion that were unused as of Dec. 31, 2000. The facilities largely exist to support commercial paper borrowings, and covenants under these credit facilities restrict maximum borrowings. See Note 9 — Debt and Other Credit Arrangements — to the consolidated financial statements for further details. These credit facilities give us the financial flexibility to satisfy future short- and medium-term funding requirements.

Our businesses are seasonal. Historically, the company has generated the majority of its sales during the first half of the year, consistent with the purchasing and growing patterns of growers in North America, our largest market. We historically have had net losses during the second half of the year. Sales and income may shift somewhat between quarters depending on growing conditions. Consistent with industry practice, we regularly extend credit to our customers to

enable them to acquire our products at the beginning of the growing season. The seasonality of our business and the need to extend credit to our customers results in short-term borrowings to finance working capital requirements. Cash provided by operations is a major source of working capital funds. To the extent the company's cash provided by operations was not sufficient to fund its cash needs, generally during the first half of the year, short-term borrowings were used to finance these requirements.

## SHAREOWNER MATTERS

On Dec. 7, 2000, Monsanto announced a prorated quarterly dividend on its common stock of $0.09 per share payable on Feb. 1, 2001, to shareowners of record on Jan. 8, 2001. This amount is based on a quarterly dividend of $0.12 per share, prorated from Oct. 23, 2000, the date of the closing of Monsanto's IPO of common stock. On Feb. 22, 2001, Monsanto declared a quarterly dividend on its common stock of $0.12 per share payable on May 1, 2001, to shareowners of record on April 10, 2001. The dividend rate reflects a policy adopted by the board of directors following the IPO. Monsanto's common stock is traded principally on the New York Stock Exchange. The number of shareowners of record as of March 2, 2001, was 154. The largest shareowner, Pharmacia Corporation, owns approximately 85 percent of Monsanto common stock outstanding. The high and low common stock price for the year were $27.38 and $19.75, respectively.

## EURO CONVERSION

On Jan. 1, 1999, 11 of the 15 member countries of the European Union established fixed conversion rates between their national currencies and the euro. During the transition period, from Jan. 1, 1999, until June 30, 2002, both the national currencies and the euro will be legal currencies. Beginning July 1, 2002, the euro will be the sole legal tender for transactions in these countries.

In September 1997, we formed a cross-functional team and hired a consultant to address issues associated with the euro conversion. As of Jan. 1, 1999, we began to engage in euro-denominated transactions and were legally compliant. We expect to have all affected information systems fully converted by April 2002. We do not expect the euro conversion to have a material effect on our competitive position, business operations, financial position or results of operations.



## NEW ACCOUNTING STANDARDS

In June 1998, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 133, *Accounting for Derivative Instruments and Hedging Activities*. This statement establishes accounting and reporting standards for derivative instruments, including certain derivative instruments imbedded in other contracts, and hedge accounting. It requires an entity recognize all derivatives as either assets or liabilities in the statement of financial position and measure those instruments at fair value. SFAS No. 133 requires changes in the fair value of derivatives should be recognized in either Net Income or Other Comprehensive Income, depending on the designated purpose of the derivative. Monsanto does not hold or issue such financial instruments for trading purposes. In June 2000, the FASB issued SFAS No. 138, *Accounting for Certain Derivative Instruments and Certain Hedging Activities*. This statement amends portions of SFAS No. 133, including the effective date. Monsanto adopted SFAS No. 133 and SFAS No. 138 on Jan. 1, 2001. In accordance with the transition provisions of SFAS No. 133, we recorded a cumulative-effect adjustment of $2 million, net of tax, in accumulated other comprehensive income to reflect the fair value of all derivatives that are designated as cash-flow hedges. No cumulative-effect adjustment was required to reflect the fair value of derivatives that are designated as fair-value hedges, nor for the difference between the carrying values and the fair values of related hedged assets and liabilities.

## MARKET RISK MANAGEMENT

Market risk represents the risk of a change in the value of a financial instrument, derivative or nonderivative, caused by fluctuations in interest rates, currency exchange rates, and commodity and equity prices. The company handles market risk in accordance with established policies and thereby enters into various derivative transactions. No such transactions are entered into for trading purposes.

Because the company's short and long-term debt exceeds cash and investments, the exposure to interest-rate risk relates primarily to the debt portfolio. To the extent the company has cash available for investment to ensure liquidity, the company will only invest that cash in short-term money market instruments. The majority of our debt consists of variable-rate, short-term obligations. Sensitivity analysis presents the hypothetical change in fair value of those financial instruments held by the company as of Dec. 31, 2000, which are sensitive to changes in interest rates. Market risk is estimated as the potential change in fair value resulting from an immediate hypothetical one-percentage point parallel shift in the yield curve. The fair values of the company's investments and loans are based on quoted market prices or discounted future cash flows. Except for the Employee Stock Ownership Plan (ESOP) guaranteed debt attributable to Monsanto from Pharmacia, which we plan to assume from Pharmacia, we currently only have debt and investments maturing in less than 180 days and variable-rate medium-term notes. As the carrying amounts on short-term loans and investments maturing in less than 180 days, and as the carrying amount of variable-rate medium-term notes approximate the fair value, a one-percentage point change in the interest rates would not change the fair value of our debt and investments portfolio.

The company's management of currency exposure is primarily focused on reducing the negative effect of currency fluctuations on consolidated cash flow and earnings. From time to time, the company uses forward contracts and currency options to actively manage the net exposure in accordance with established hedging policies. The company hedges recorded commercial transaction exposures, intercompany loans and anticipated transactions. The company's significant hedged positions included euros, Polish zlotys, Australian dollars, and Hungarian forint. Unfavorable currency movements of 10 percent would negatively affect the fair market values of the derivatives held to hedge commercial exposures by $49 million.

The company uses futures contracts to protect against commodity price increases mainly in the seeds and genomics business. The majority of these contracts hedge the purchases of soybean and corn inventories. A 10 percent decrease in soybean or corn prices would have a negative effect on the fair value of those futures by $10 million and $3 million, respectively.

The company also has investments in equity securities. All such investments are classified as long-term available for sale investments. The fair market value of these investments is $96 million. The majority of these investments are listed on a stock exchange or quoted in an over-the-counter market. If the market price of the traded securities would decrease by 10 percent, the fair value of the equities would decrease by $10 million. See Note 7 — Investments — to the consolidated financial statements for further details.



## OUTLOOK

At the close of 2000, agricultural commodity prices continued to be at multi-year low levels. Although our sales growth, like that of other agricultural companies, was adversely affected by the weakened farm economy, we have seen continued sales growth due to the cost-effectiveness of and value added to growers by our product portfolio. We expect sales growth to continue through increased sales of *Roundup* and other glyphosate products and expansion of our biotechnology seeds and traits.

We will continue to focus on managing costs in 2001. However, having achieved the majority of the planned savings in selling, general and administrative costs, research-and-development spending and inventories as reflected in 2000 results, the focus in 2001 also will be on receivables management. Increasing energy costs in late 2000 and early 2001 will slightly increase our cost of goods sold which we expect will be largely offset by manufacturing efficiencies in 2001.

*Roundup* and our other glyphosate products continue to face competition from generic producers in certain markets outside the United States, where patents protecting *Roundup* have expired. Compound per se patent protection for the active ingredient in *Roundup* herbicide expired in the United States on Sept. 20, 2000. Consistent with our global pricing strategy of selectively reducing prices to encourage new uses, we have reduced our prices on the family of *Roundup* products in the United States.

We expect to continue to selectively reduce prices, offer targeted discounts or rebates, and use other promotional strategies to encourage new uses and to increase our sales volumes. This strategy likely will result in a modest reduction in our gross margin, consistent with gross margin reduction in the last three years. We expect that increased *Roundup* and other glyphosate product sales volumes and growth in our other business lines will enable us to grow our total gross

profit in the future above 2000 levels. In addition, as other agricultural chemical suppliers have access to glyphosate in the United States, often through supply agreements with us, their pricing policies may cause downward pressure on prices. While there can be no assurance that any increases in volumes will offset price reductions, discounts, rebates and other incentives, this generally has been our experience in world areas outside of the United States where the glyphosate patents have expired.

Technological advances in manufacturing processes and formulations, as well as expanding production capacity, are expected to continue the improvement of our glyphosate manufacturing cost structure and to help maintain our leadership position. We aim to increase our sales and income from *Roundup* by encouraging expanded adoption of conservation tillage techniques by growers worldwide; introducing additional proprietary formulations of *Roundup*; increasing sales of *Roundup Ready* crops which tolerate *Roundup* herbicide for effective weed control; selectively reducing prices and other targeted promotional incentives to encourage new uses for *Roundup*; maintaining our position as a low-cost, high-quality glyphosate producer; and building on our relationships with our distribution partners.

We continue to address concerns of consumers, public interest groups and government regulators regarding agricultural and food products developed through biotechnology. We plan to invest significant amounts in 2001 to address these concerns, including participating in an integrated, industry-wide initiative involving major companies with an interest in agricultural biotechnology. This initiative includes using consumer media to provide consumers with improved information sources on biotechnology. We also have stated our commitments on issues related to public acceptance of biotechnology in the New Monsanto Pledge, which was announced in late 2000. As part of the New Monsanto Pledge, we have committed not to launch new biotechnology seed products in the United States until we have approvals in both the United States and Japan, for both food and feed. We also hope to extend this intention to Europe as soon as it has established a working regulatory system. We are committed to addressing concerns regarding food products developed through biotechnology, and to achieving more effective regulation and greater acceptance and commercialization of biotechnology products.

In the near term, we are focusing on regulatory approvals in Brazil, India, Europe and the United States that can bring biotechnology products to more farmers.

In December 2000, the federal government of Brazil issued a provisional measure, which clarifies the regulatory environment for approval of biotechnology products. While substantial legal and regulatory steps must be completed before Monsanto is granted approval to sell *Roundup Ready* soybeans in Brazil, we regard the provisional measure as a positive development.

In India, we have applied to the government for approvals so that cotton that incorporates our insect-protected technology can be grown there in the future.

We have filed for approval of two new corn products developed through the use of modern biotechnology in the United States as well as for import approval in Japan. The first is a variation of the *Roundup Ready* corn products already commercialized that will use Monsanto proprietary biotechnology exclusively. The second product, called *MaxGard* insect-protected corn, offers protection against the corn rootworm and other insects by replacing traditional insecticides. Although no prediction can be made with regard to timing of approvals, the agricultural biotechnology regulatory systems in both countries have been fully functioning.

In 2001, the European Union has voted to approve revisions to the 90/220 Council Directive, and officials are meeting to establish guidelines that should lead to a regulatory system that once again considers approving biotechnology products for importation. Such progress would be a positive step for many biotechnology products, including Monsanto's *Roundup Ready* corn and other products currently already approved or under evaluation by other regulatory bodies worldwide.

During 2001, all biotechnology crops that use the Bacillus thuringiensis *(Bt)* protein for insect protection will undergo a re-registration process conducted by the U.S. Environmental Protection Agency (EPA). Monsanto's *Bollgard* cotton and *YieldGard* corn will be part of this review, which was included as a condition of the original registration when the first *Bt* products were introduced five years ago. We expect all such regulatory actions to be subject to increased scrutiny.



In late 2000, certain processed foods were subject to a recall when found to contain biotechnology material from a competitor's biotechnology seed product. This product had been approved for animal feed uses but not for human food uses in the United States. All of our biotechnology seed products have both food and feed approval in the United States and all other countries in which they have been approved, but they have not been approved in all countries. In a number of countries, allegations have been made that unintended (adventitious) biotechnology materials, both approved and unapproved, have been detected in seed, crops or food. These allegations have been made with respect to materials developed by us, as well as those developed by other companies. Some of the allegations made against us have been determined to be unsubstantiated or the results of inconclusive testing, and some are still under investigation or pending. We expect that the issue of adventitious presence will be a continuing one. The detection of adventitious biotechnology material could negatively impact our business or results of operations, or result in governmental regulatory compliance actions such as crop

destruction or product recalls. We and others in the industry are seeking the establishment of explicit threshold levels for the adventitious presence of biotechnology traits. Although we believe that such thresholds are implicit in existing laws, the establishment of explicit thresholds would clearly render adventitious presence acceptable if it is below the established threshold amounts. However, even if explicit thresholds are adopted, our business could be adversely affected if adventitious biotechnology material is found in seed, crops or food in countries which have not approved such material or established explicit thresholds, or if the amounts of such material exceeds the established threshold.

As discussed in Note 16 — Commitments and Contingencies — to the consolidated financial statements, Monsanto is involved in a number of lawsuits and claims relating to a variety of issues. Many of these lawsuits relate to intellectual property disputes. We expect that such disputes will continue to occur as the agricultural biotechnology industry continues to evolve.

For additional information regarding the outlook for Monsanto, see "Cautionary Statements Regarding Forward-Looking Information."

## CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION

Under the Private Securities Litigation Reform Act of 1995, companies are provided with a "safe harbor" for making forward-looking statements about the potential risks and rewards of their strategies. We believe it is in the best interest of our shareowners to use these provisions in discussing future events. However, we are not required to, and you should not rely on us to, revise or update these statements or any factors that may affect actual results, whether as a result of new information, future events or otherwise. Forward-looking statements include our business plans; the potential for the development, regulatory approval, and public acceptance of new products; other factors that could affect our future operations or financial position; and other statements that are not matters of historical fact. Such statements often include the words "believes," "expects," "anticipates," "intends," "plans," "estimates," or similar expressions.



Our ability to achieve our goals depends on many known and unknown risks and uncertainties, including changes in general economic and business conditions. These factors could cause our actual performance and results to differ materially from those described or implied in forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below.

**Competition for *Roundup***

The family of *Roundup* herbicides is a major product line. Patents protecting *Roundup* in several countries expired in 1991, and compound per se patent protection for the active ingredient in *Roundup* herbicide expired in the United States in September 2000. These herbicides are likely to face increasing competition in the future. We believe that we can compensate for increased competition both within and outside the United States and continue to increase revenues and profits from *Roundup* through a combination of (1) marketing strategy, (2) pricing strategy, and (3) decreased production costs.

- ***Marketing Strategy*:** We expect to increase sales for *Roundup* by focusing on brand premiums, providing unique formulations and services, offering integrated seed and biotech solutions through cross selling and the growth and introduction of *Roundup Ready* crops, and continuing to encourage the practice of conservation tillage. The success of our *Roundup* marketing strategy will depend on the continued expansion of conservation tillage practices and our ability to realize and promote cost and production benefits of our product packages, and to introduce new *Roundup Ready* crops.

- ***Pricing Strategy:*** We have significantly reduced the sales price of *Roundup* in the United States and around the world. This price elasticity strategy is designed to increase demand for *Roundup* by making *Roundup* more economical, encouraging both new uses of the product and expansion of the number of acres treated. Our experience in numerous markets worldwide has been that price reductions have stimulated volume growth. However, such volume increases also may have been influenced by a variety of other factors, such as weather; launch of new products including *Roundup Ready* crops; competitive products and practices; and an increase in agricultural acres planted. Conditions, and therefore volume trends experienced to date, may or may not continue.

- ***Production Cost Decreases:*** We also believe that increased volumes and technological innovations will lead to efficiencies that will reduce the production cost of glyphosate. As part of this strategy, we have entered into agreements to supply glyphosate to other herbicide producers. Such cost reductions will depend on realizing such increased volumes and innovations, and securing the resources required to expand production of *Roundup*.

**Realization and Introduction of New Products**
Our ability to develop and introduce to market new products, particularly new agricultural biotechnology products, will be dependent, among other things, upon the availability of sufficient financial resources to fund research and development needs; the success of our research efforts; our ability to gain consumer acceptance and regulatory approvals; the demonstrated effectiveness of our products; our ability to produce new products on a large scale and to market them economically; our ability to develop, purchase or license required technology; and the existence of sufficient distribution channels.

**Governmental and Consumer Acceptance**
The commercial success of agricultural and food products developed through biotechnology will depend in part on government and public acceptance of their cultivation, distribution and consumption. We continue to work with consumers, customers and regulatory bodies to encourage understanding of agricultural biotechnology products. Biotechnology has enjoyed and continues to enjoy substantial support from the scientific community, regulatory agencies and many governmental officials around the world. However, public attitudes may be influenced by claims that genetically modified plant products are unsafe for consumption or pose unknown risks to the environment or to traditional social or economic practices, even if such claims have little or no scientific basis. Securing governmental approvals for, and consumer confidence in, such products poses numerous challenges, particularly outside the United States. Some countries also have labeling requirements. In some markets, because these crops are not yet approved for import, growers in other countries may be restricted from introducing or selling their grain. Because some markets have not approved these products, a few companies in the food industry have offered premiums for non-genetically-modified crops, or have refused to purchase crops grown from seeds developed through biotechnology. Concerns about marketability of these products may also deter farmers from planting them, even in countries where planting has been approved. These concerns have recently prompted agriculture officials in some states to propose prohibitions on planting genetically modified wheat, which is one of our pipeline products. The development and sales of our products have been, and may in the future be, delayed or impaired because of adverse public perception or regulatory concerns about the safety of our products and the potential effects of these products on other plants, animals, human health and the environment.

**Regulatory Approvals**
The field testing, production and marketing of our products are subject to extensive regulations and numerous government approvals, which vary widely among jurisdictions. Obtaining necessary regulatory approvals can be time-consuming and costly, and there is no guarantee of success. Regulatory authorities can block the sale or importation of our products, order recalls, or prohibit planting of seeds containing our technology. As agricultural biotechnology evolves, new unanticipated restrictions may be imposed. In addition, future international agreements such as the Cartagena Protocol on Biosafety, which is in the ratification process, may also affect the treatment of biotechnology products.

**Seed Quality**
The detection of unintended (adventitious) biotechnology material in pre-commercial seed, commercial seed varieties or the crops and products produced could negatively impact our business or results of operations, or result in governmental regulatory compliance actions such as crop destruction or product recalls. For instance, the presence of *Roundup* tolerance in conventional canola seed in the European Union resulted in government-mandated destruction of growing crops in some countries, and more recently, the reported presence of a competitor's *Bt* gene not approved for food use in taco shells in the United States has resulted in government scrutiny and a nationwide product recall. Concerns about seed quality related to biotechnology could also lead to additional regulations on our business, such as regulations related to testing procedures, mandatory governmental reviews of biotechnology advances, or the integrity of the food supply chain from the farm to the finished product. However, we and others in the industry are seeking the establishment of explicit threshold levels for the adventitious presence of biotechnology traits. Although we believe that such thresholds are implicit in existing laws, the establishment of explicit thresholds would clearly render adventitious presence acceptable if it is below the established threshold amounts.

**Intellectual Property**
We have devoted significant resources to obtaining and maintaining our intellectual property rights, which are material to our business. We rely on a combination of patents, copyrights, trademarks and trade secrets, confidentiality provisions, Plant Variety Protection Act registrations and licensing arrangements to establish and protect our intellectual property. We seek to preserve our intellectual property rights and to operate without infringing the proprietary rights of third parties. Intellectual property positions are becoming increasingly important within the agricultural biotechnology industry.

There is some uncertainty about the value of available patent protection in certain countries outside the United States. Moreover, the patent positions of biotechnology companies involve complex legal and factual questions. Rapid technological advances and the number of companies performing such research can create an uncertain environment. Patent applications in the United States are kept confidential, and outside the United States, patent applications are published 18 months after filing. Accordingly, competitors may be issued patents from time to time without any prior warning to us. That could decrease the value of similar technologies that we are developing. Because of this rapid pace of change, some of our products may unknowingly rely on key technologies already patent-protected by others. If that should occur, we must obtain licenses to such technologies in order to continue to use them.

Certain of our seed germplasm and other genetic material, patents, and licenses are currently the subject of litigation and additional future litigation is anticipated. Although the outcome of such litigation cannot be predicted with certainty, we will continue to defend and litigate our positions vigorously. We believe that we have meritorious defenses and claims in the pending suits.

**Technological Change and Competition**

Many companies are engaged in plant biotechnology research. Technological advances by others could render our products less competitive. In addition, the ability to be first to market a new product can result in a significant competitive advantage. We believe that competition will intensify, not only from agricultural biotechnology firms but from major agrichemical, seed and food companies with biotechnology laboratories. Some of our agricultural competitors have substantially greater financial, technical and marketing resources than we do.

**Planting Decisions and Weather**

Our business is highly seasonal. It is subject to weather conditions and natural disasters that affect commodity prices, seed yields, and grower decisions about purchases of seeds, traits and herbicides. As they have for the last three years, crop commodity prices continue to be at historically low levels. There can be no assurance that this trend will not continue. These lower commodity prices affect growers' decisions about the types and amounts of crops to plant and may negatively influence sales of our herbicide and seed products.

**Need for Short-Term Financing**

Like many other agricultural companies, we regularly extend credit to our customers to enable them to acquire agricultural chemicals and seeds at the beginning of the growing season. Our credit practices, combined with the seasonality of our sales, make us dependent on our ability to obtain substantial short-term financing to fund our cash flow requirements and on our ability to collect customer receivables. Our need for short-term financing typically peaks in the second quarter. Downgrades in our credit rating or other limitations on our ability to access short-term financing, including our ability to refinance our short-term debt as it becomes due, would increase our interest costs and adversely affect our sales and our profitability.

**Litigation**

We are involved in numerous major lawsuits regarding contract disputes, intellectual property issues, biotechnology, antitrust allegations and other matters. Adverse outcomes could subject us to substantial damages or limit our ability to sell our products.

**Markets Outside the United States**

Sales outside the United States make up a substantial portion of our revenues and we intend to continue to explore international sales opportunities actively. Challenges we may face in international markets include changes in foreign currency exchange rates, changes in a specific country's or region's political or economic conditions, climatic conditions, trade protection measures, import or export licensing requirements, and unexpected changes in regulatory requirements. Weakened economies may cause future sales to decrease because customers may purchase fewer goods in general, and also because imported products could become more expensive for customers to purchase in their local currency. Changes in exchange rates may affect our earnings, the book value of our assets outside the United States, and our equity.

# STATEMENT *of* CONSOLIDATED INCOME (LOSS)

MONSANTO COMPANY

| (DOLLARS IN MILLIONS, EXCEPT PER PRO FORMA SHARE AMOUNTS) YEAR ENDED DEC. 31, | 2000 | 1999 | 1998 |
|---|---|---|---|
| **Net Sales** | $ 5,493 | $ 5,248 | $ 4,448 |
| Cost of goods sold | 2,770 | 2,556 | 2,149 |
| **Gross Profit** | 2,723 | 2,692 | 2,299 |
| **Operating Expenses:** | | | |
| Selling, general and administrative expenses | 1,253 | 1,237 | 1,135 |
| Research and development expenses | 588 | 695 | 536 |
| Acquired in-process research and development | — | — | 402 |
| Amortization and adjustments of goodwill | 212 | 128 | 77 |
| Restructuring charges — net | 103 | 22 | 94 |
| Total operating expenses | 2,156 | 2,082 | 2,244 |
| **Income From Operations** | 567 | 610 | 55 |
| Interest expense (net of interest income of $30, $26 and $27 in 2000, 1999 and 1998, respectively) | (184) | (243) | (94) |
| Other expense — net | (49) | (104) | (21) |
| **Income (Loss) Before Income Taxes and Cumulative Effect of Accounting Change** | 334 | 263 | (60) |
| Income tax provision | (159) | (113) | (65) |
| **Income (Loss) Before Cumulative Effect of Accounting Change** | 175 | 150 | (125) |
| Cumulative effect of a change in accounting principle, net of tax benefit of $16 million | (26) | — | — |
| **Net Income (Loss)** | $ 149 | $ 150 | $ (125) |
| **Basic and Diluted Earnings (Loss) per Pro Forma Share:** | | | |
| Income (loss) before cumulative effect of accounting change | $ 0.68 | $ 0.58 | $ (0.48) |
| Cumulative effect of accounting change | (0.10) | — | — |
| **Net Income (Loss)** | $ 0.58 | $ 0.58 | $ (0.48) |
| **Pro Forma Amounts Assuming New Accounting Principle Is Applied Retroactively:** | | | |
| Net income (loss) | $ 175 | $ 124 | $ (125) |
| Basic and diluted earnings (loss) per pro forma share | $ 0.68 | $ 0.48 | $ (0.48) |

The accompanying notes are an integral part of these financial statements.

# STATEMENT *of* CONSOLIDATED FINANCIAL POSITION

MONSANTO COMPANY

| (DOLLARS IN MILLIONS, EXCEPT PER-SHARE AMOUNTS) AS OF DEC. 31, | 2000 | 1999 |
|---|---|---|
| **Assets** | | |
| Current Assets: | | |
| Cash and cash equivalents | $ 131 | $ 26 |
| Trade receivables (net of allowances of $171 in 2000 and $151 in 1999) | 2,515 | 2,028 |
| Miscellaneous receivables | 283 | 350 |
| Related party loan receivable | 205 | — |
| Related party receivable | 261 | — |
| Deferred tax assets | 225 | 130 |
| Inventories | 1,253 | 1,440 |
| Other current assets | 100 | 53 |
| **Total Current Assets** | 4,973 | 4,027 |
| Property, Plant and Equipment: | | |
| Land | 69 | 82 |
| Buildings | 766 | 708 |
| Machinery and equipment | 2,688 | 2,187 |
| Computer software | 190 | 155 |
| Construction in progress | 746 | 726 |
| Total Property, Plant and Equipment | 4,459 | 3,858 |
| Less Accumulated Depreciation | 1,800 | 1,639 |
| Net Property, Plant and Equipment | 2,659 | 2,219 |
| Goodwill (net of accumulated amortization of $290 in 2000 and $183 in 1999) | 2,827 | 3,081 |
| Other Intangible Assets (net of accumulated amortization of $506 in 2000 and $362 in 1999) | 779 | 935 |
| Other Assets | 488 | 839 |
| **Total Assets** | $11,726 | $11,101 |
| **Liabilities and Shareowners' Equity** | | |
| Current Liabilities: | | |
| Short-term debt | $ 158 | $ — |
| Related party short-term loan payable | 635 | — |
| Short-term debt of parent attributable to Monsanto | — | 89 |
| Accounts payable | 525 | 466 |
| Related party payable | 162 | — |
| Accrued compensation and benefits | 172 | 147 |
| Restructuring reserves | 38 | 26 |
| Accrued marketing programs | 181 | 256 |
| Miscellaneous short-term accruals | 886 | 720 |
| **Total Current Liabilities** | 2,757 | 1,704 |
| Long-Term Debt | 962 | — |
| Long-Term Debt of Parent Attributable to Monsanto | — | 4,278 |
| Postretirement Liabilities | 367 | — |
| Other Liabilities | 299 | 474 |
| Commitments and Contingencies (see Note 16) | | |
| Shareowners' Equity: | | |
| Common stock (authorized: 1,500,000,00 shares, par value $0.01) | | |
| Issued: 258,043,000 shares in 2000 | 3 | — |
| Additional contributed capital | 7,853 | — |
| Parent company's net investment | — | 4,926 |
| Retained earnings | 2 | — |
| Accumulated other comprehensive loss | (479) | (281) |
| Reserve for ESOP debt retirement — attributable to Monsanto | (38) | — |
| **Total Equity** | 7,341 | 4,645 |
| **Total Liabilities and Shareowners' Equity** | $11,726 | $11,101 |

The accompanying notes are an integral part of these financial statements.

# STATEMENT *of* CONSOLIDATED CASH FLOWS

MONSANTO COMPANY

| (DOLLARS IN MILLIONS) YEAR ENDED DEC. 31, | 2000 | 1999 | 1998 |
|---|---|---|---|
| **Operating Activities:** | | | |
| Income (loss) before income taxes | $ 334 | $ 263 | $ (60) |
| Adjustments to reconcile to cash provided (required) by operations: | | | |
| Items that did not require cash: | | | |
| Depreciation and amortization | 546 | 547 | 368 |
| Acquired in-process research and development expense | — | — | 402 |
| Restructuring and other special items | 261 | 50 | 202 |
| Working capital changes that provided (required) cash: | | | |
| Trade receivables | (560) | (370) | (578) |
| Inventories | 118 | (35) | (139) |
| Accounts payable and accrued liabilities | 14 | (108) | (779) |
| Related party transactions | (35) | — | — |
| Other | (54) | (29) | 27 |
| Brazil currency devaluation | — | (223) | — |
| Other items | 47 | 25 | 29 |
| **Net Cash Provided (Required) by Operations** | 671 | 120 | (528) |
| **Investing Activities:** | | | |
| Property, plant and equipment purchases | (582) | (632) | (432) |
| Acquisitions and investments | (148) | (108) | (4,112) |
| Loans with related party | (205) | — | — |
| Investment and property disposal proceeds | — | 325 | — |
| **Net Cash Required by Investing Activities** | (935) | (415) | (4,544) |
| **Financing Activities:** | | | |
| Net change in short-term financing | (993) | (233) | (69) |
| Loans from related party | 635 | — | — |
| Long-term debt proceeds | — | — | 3,276 |
| Long-term debt reductions | (58) | (110) | — |
| Issuance of stock | 723 | — | — |
| Net transactions with parent | 62 | 627 | 1,866 |
| **Net Cash Provided by Financing Activities** | 369 | 284 | 5,073 |
| **Net Increase (Decrease) In Cash And Cash Equivalents** | 105 | (11) | 1 |
| **Cash And Cash Equivalents:** | | | |
| Beginning of year | 26 | 37 | 36 |
| End of year | $ 131 | $ 26 | $ 37 |

The effect of exchange rate changes on cash and cash equivalents was not material. All interest expense on debt specifically attributable to Monsanto is included in the Statement of Consolidated Income (Loss). However, no cash payments for interest or taxes were made by Monsanto during 1998 and 1999 and the eight months ended Aug. 31, 2000, because all interest and tax payments during these periods were made by Pharmacia. Cash payments for interest and taxes for the fourth quarter of 2000 were $21 million and $8 million, respectively.

Non-cash transactions for 2000 include a reclassification of $1.1 billion of long-term debt to short-term debt. In addition, $2.2 billion of debt transferred to Pharmacia in exchange for additional equity in Monsanto was partially offset by net obligations of approximately $500 million assumed by Monsanto. Net transactions with parent include approximately $200 million of non-cash transactions.

The accompanying notes are an integral part of these financial statements.

## STATEMENT *of* CONSOLIDATED SHAREOWNERS' EQUITY

MONSANTO COMPANY

| (DOLLARS IN MILLIONS) | COMMON STOCK | ADDITIONAL CAPITAL | PARENT COMPANY NET INVESTMENT | RETAINED EARNING | ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) | RESERVE FOR ESOP DEBT | TOTAL |
|---|---|---|---|---|---|---|---|
| **Balance as of Jan. 1, 1998** | **$ —** | **$ —** | **$ 2,408** | **$ —** | **$ (22)** | **$ —** | **$ 2,386** |
| Net income (loss) | — | — | (125) | — | — | — | (125) |
| Net transactions with parent | — | — | 1,866 | — | — | — | 1,866 |
| Foreign currency translation | — | — | — | — | (8) | — | (8) |
| Net unrealized gain on investments | — | — | — | — | 6 | — | 6 |
| **Balance as of Dec. 31, 1998** | **$ —** | **$ —** | **$ 4,149** | **$ —** | **$ (24)** | **$ —** | **$ 4,125** |
| Net income | — | — | 150 | — | — | — | 150 |
| Net transactions with parent | — | — | 627 | — | — | — | 627 |
| Foreign currency translation | — | — | — | — | (250) | — | (250) |
| Net unrealized loss on investments | — | — | — | — | (7) | — | (7) |
| **Balance as of Dec. 31, 1999** | **$ —** | **$ —** | **$ 4,926** | **$ —** | **$ (281)** | **$ —** | **$ 4,645** |
| Net income through Aug. 31, 2000 | — | — | 124 | — | — | — | 124 |
| Net transactions with parent[1] | — | — | 318 | — | (104) | — | 214 |
| Capitalization of Monsanto from Pharmacia (1,000 shares)[2] | 2 | 5,366 | (5,368) | — | — | — | — |
| Debt exchanged for additional Pharmacia capital contribution | — | 1,765 | — | — | (15) | (38) | 1,712 |
| Common stock issued on Oct. 23, 2000 (38,033,000 shares) | 1 | 722 | — | — | — | — | 723 |
| Grant of restricted stock (10,000 shares) | — | — | — | — | — | — | — |
| Net income from Sept. 1, 2000, through Dec. 31, 2000 | — | — | — | 25 | — | — | 25 |
| Cash dividend of $0.09 per common share | — | — | — | (23) | — | — | (23) |
| Foreign currency translation | — | — | — | — | (107) | — | (107) |
| Net unrealized gain on investments | — | — | — | — | 27 | — | 27 |
| Minimum pension liability | — | — | — | — | 1 | — | 1 |
| **Balance as of Dec. 31, 2000** | **$ 3** | **$ 7,853** | **$ —** | **$ 2** | **$ (479)** | **$ (38)** | **$ 7,341** |

(1) Includes adjustments to reflect final determination of the historical amounts of net assets related to accumulated foreign currency translation adjustments.

(2) In September 2000, Monsanto shares were split with Pharmacia receiving 219,999 shares for each share held. After the separation, Pharmacia held 220,000,000 shares.

The components of accumulated other comprehensive income (loss) included: accumulated foreign currency translation of $(504) million, $(293) million and $(43) million for 2000, 1999 and 1998, respectively; net unrealized gain on investments, net of taxes, of $39 million, $12 million and $19 million for 2000, 1999 and 1998, respectively; and minimum pension liability, net of taxes, of $(14) million in 2000. There was no minimum pension liability directly attributable to Monsanto in 1999 and 1998.

## STATEMENT *of* CONSOLIDATED COMPREHENSIVE INCOME (LOSS)

| (DOLLARS IN MILLIONS) YEAR ENDED DEC. 31, | 2000 | 1999 | 1998 |
|---|---|---|---|
| Net income (loss) | $ 149 | $ 150 | $ (125) |
| Other comprehensive (loss) income: | | | |
| Foreign currency translation adjustments | (107) | (250) | (8) |
| Unrealized net holding gains (losses) (net of tax of $15 in 2000, $(4) in 1999, $4 in 1998) | 23 | (7) | 6 |
| Reclassification adjustment for losses included in income (net of tax of $3 in 2000) | 4 | — | — |
| Additional minimum pension liability adjustment (net of tax of $1 in 2000) | 1 | — | — |
| Total other comprehensive loss | (79) | (257) | (2) |
| **Total Comprehensive Income (Loss)** | $ 70 | $ (107) | $ (127) |

The accompanying notes are an integral part of these financial statements.

## NOTE 1
## Background and Basis of Presentation

Monsanto Company and subsidiaries (Monsanto or the company) is comprised of the operations, assets and liabilities that were previously the agricultural business of Pharmacia Corporation (Pharmacia). Monsanto manages its business in two segments: Agricultural Productivity, and Seeds and Genomics. The Agricultural Productivity segment consists of the crop protection products, animal agriculture and environmental technologies business lines. The Seeds and Genomics segment consists of the global seeds and related traits business and genetic technology platforms.

On Sept. 1, 2000, the assets and liabilities of the agricultural business were transferred from Pharmacia to Monsanto, pursuant to the terms of a Separation Agreement dated as of that date (the "Separation Agreement"). The consolidated financial statements for all periods prior to Sept. 1, 2000, have been prepared on a carve-out basis, which reflects the historical operating results, assets, and liabilities of the agricultural business operations.

Pharmacia provides certain general and administrative services to Monsanto, including finance, legal, treasury, information systems, public affairs, regulatory and human resources. Although prior to Sept. 1, 2000, it was not practicable to determine what the cost of certain services would have been on a stand-alone basis, these costs were allocated to Monsanto based on methodologies that management believes to be reasonable, but which do not necessarily reflect what the results of operations, financial position, or cash flows would have been had Monsanto been a separate, stand-alone public entity during all periods presented. Costs associated with finance, information systems, and human resources were allocated based on the number of people in those functions assigned to support Monsanto while public affairs, legal, and regulatory costs were driven by work effort and projects specific to the business. Treasury costs were allocated based on Monsanto's sales as a percentage of total sales.

As described in Notes 11, 12, 13 and 14 to the consolidated financial statements, Monsanto employees and retirees participate in various pension, health care, savings and other benefit plans. The costs related to those plans and attributable to Monsanto included in Monsanto's consolidated financial statements prior to Sept. 1, 2000, generally are based upon the percentage of Monsanto's payroll costs to total payroll costs. Subsequent to Sept. 1, 2000, Monsanto employees are covered by pension and stock-based compensation plans either sponsored by Monsanto or Pharmacia and participate in health care and other benefit plans sponsored by Monsanto.

Beginning Sept. 1, 2000, the consolidated financial statements reflect the results of operations, financial position, and cash flows of the company as a separate entity responsible for procuring or providing the services previously provided by Pharmacia, and include the costs of services purchased from Pharmacia pursuant to a transition services agreement.

On Oct. 23, 2000, Monsanto sold 38,033,000 shares of its common stock at $20 per share in an IPO, including 3,033,000 shares of common stock with respect to which the underwriters exercised their over-allotment option. The total net proceeds to Monsanto were $723 million. Subsequent to the offering, Pharmacia owned and continues to own 220,000,000 shares of common stock, representing 85.3 percent ownership of Monsanto.

Unless otherwise indicated, "Monsanto" and "the company" are used interchangeably to refer to Monsanto Company or to Monsanto Company and consolidated subsidiaries, as appropriate to the context. With respect to periods prior to the separation of Monsanto's businesses from those of Pharmacia on Sept. 1, 2000, references to "Monsanto" or "the company" also refer to the agricultural division of Pharmacia. In the tables, all dollar amounts are in millions, unless otherwise indicated.

## NOTE 2
## Significant Accounting Policies

**Basis of Consolidation**

The consolidated financial statements are presented in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements pertain to the company and its majority-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. Investments in other companies over which Monsanto has the ability to exercise significant influence (generally through an ownership interest greater than 20 percent) are included in "Other Assets" in the Statement of Consolidated Financial Position. Monsanto's share of these companies' net earnings or losses is included in "Other expense — net" in Monsanto's Statement of Consolidated Income (Loss).

**Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and that affect revenues and expenses during the period reported. Estimates are adjusted to reflect actual experience when necessary. Significant estimates and assumptions are used to account for allowances for doubtful accounts, restructuring reserves, environmental reserves, self-insurance reserves, employee benefit plans, asset impairments, in-process research and development, the allocation of corporate costs and contingencies. Actual results may differ from those estimates and assumptions.

**Revenue Recognition**
Revenues are recognized when title to finished goods inventories is transferred and goods are delivered to customers. Where the right of return exists, sales revenues are reduced at the time of sale to reflect expected returns which are estimated based on historical experience. License revenues and revenues from the sale of product rights are recognized when the rights have been contractually conferred to the licensee or purchaser. Additional conditions for recognition of revenue are that the collection of sales proceeds is reasonably assured and that there are no further performance obligations under the sale or license agreement. Interest income from providing customers extended financing terms is included in revenues as earned, generally based upon the passage of time, with appropriate reductions for amounts whose collection is considered doubtful.

**Income Taxes**
Monsanto's operating results historically have been included in the consolidated federal and state income tax returns filed by Pharmacia and its subsidiaries in various U.S. and ex-U.S. jurisdictions. Following completion of the initial public offering described in Note 1 — Background and Basis of Presentation — to the consolidated financial statements, Monsanto will continue to be included in the Pharmacia consolidated group for all taxable periods during which Pharmacia beneficially owns at least 80 percent of the total voting power and value of Monsanto's common stock. The tax provisions reflected in Monsanto's Statement of Consolidated Income (Loss) have been computed as if Monsanto were a separate tax payer. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts.



**Marketing and Advertising Costs**
Marketing and advertising costs are expensed as incurred. Marketing program liabilities are accrued based upon specific performance criteria achieved by distributors, dealers and/or farmers, such as purchase volumes, promptness of payment and/or market share increases. The associated cost of marketing programs is recognized as a reduction of gross sales in the Statement of Consolidated Income (Loss).

**Cash and Cash Equivalents**
All highly liquid investments with a maturity of three months or less at date of purchase are considered to be cash equivalents.

**Investments**
Investments in debt securities are classified in the Statement of Consolidated Financial Position as either short-term (with maturities of greater than three months but less than one year) or long-term (with maturities beyond one year). Monsanto also has investments in equity securities, all of which are considered to be available for sale and are classified as other non-current assets.

**Fair Values of Financial Instruments**
The recorded amounts of cash, trade receivables, investments in securities, miscellaneous receivables, third-party guarantees, commodity futures contracts, accounts payable, related party receivables and payables, related party loans/advances, and short-term debt approximate their fair values. Fair values are estimated by the use of quoted market prices, estimates obtained from brokers, and other appropriate valuation techniques based on information available at year end. The fair value estimates do not necessarily reflect the values that could be realized in the current market. See Note 10 — Financial Instruments Fair Values — to the consolidated financial statements for further details.

**Inventory Valuation**
Inventories are stated at the lower of cost or market. Actual cost is used to value raw materials and supplies. Standard cost, which approximates actual cost, is used to value finished goods and goods in process. Standard cost includes direct labor and raw materials, and manufacturing overhead based on practical capacity. The cost of certain inventories (approximately 37 percent as of Dec. 31, 2000) is determined by using the last-in, first-out (LIFO) method, which generally reflects the effects of inflation or deflation on cost of goods sold sooner than other inventory cost methods. The cost of other inventories generally is determined by the first-in, first-out (FIFO) method. Inventories at FIFO approximate current cost.

**Goodwill and Other Intangible Assets**
Goodwill, the excess of cost over the fair value of net assets acquired, is amortized using the straight-line method over various periods not exceeding 40 years. Monsanto periodically reviews goodwill to evaluate whether changes have occurred that would suggest that goodwill may be impaired based on the estimated undiscounted cash flows of the assets acquired over the remaining amortization period. If this review indicates that the remaining estimated useful life of goodwill requires revision or that the goodwill is not

recoverable, the carrying amount of the goodwill is reduced by the estimated shortfall of cash flows on a discounted basis. Trademarks that are included in other intangible assets are assessed for impairment whenever events indicate a possible loss. Such assessment involves a review of undiscounted cash flows over the remaining useful life of the trademark. If this review indicates that the remaining estimated useful life of the trademark requires revision, the carrying amount of the trademark is reduced by the estimated shortfall of cash flows on a discounted basis. Patents obtained in a business acquisition are recorded at the present value of estimated future cash flows resulting from patent ownership. The cost of patents is amortized over their remaining legal lives and the cost of other intangible assets (principally seed germplasm and product rights) is amortized over their estimated useful lives.

**Property, Plant and Equipment**
Property, plant and equipment is recorded at cost. Additions and improvements are capitalized and include all material, labor, and engineering costs to design, install or improve the asset. Interest costs are also capitalized on significant construction projects. These costs are carried in construction in progress until the asset is ready for its intended use, at which time the costs are transferred to land, buildings or machinery and equipment. Routine repairs and maintenance are expensed as incurred. The cost of plant and equipment is depreciated over weighted-average periods of 18 years for buildings and 10 years for machinery and equipment using the straight-line method. Long-lived assets are reviewed for impairment whenever conditions indicate a possible loss. Such impairment tests are based on a comparison of undiscounted cash flows to the recorded value of the asset. If an impairment is indicated, the asset is written down to its fair market value or using discounted cash flows, if fair market value is not readily determinable.

**Environmental Remediation Liabilities**
Monsanto follows Statement of Position 96-1, *Environmental Remediation Liabilities*, which provides guidance for recognizing, measuring and disclosing environmental remediation liabilities. Monsanto accrues for these costs in the period in which responsibility is established and when costs are probable and reasonably estimable based on current law and existing technology. Post-closure and remediation costs for hazardous and other waste facilities at operating locations are accrued over the estimated life of the facility as part of its anticipated closure cost.

**Foreign Currency Translation**
The financial statements for most of Monsanto's ex-U.S. operations are translated into U.S. dollars at current exchange rates, the year-end rate for assets and liabilities and the average rate for the period for revenues, expenses, gains and losses. Unrealized currency adjustments in the Statement of Consolidated Financial Position are accumulated in equity as a component of Accumulated Other Comprehensive Income (Loss). The financial statements of ex-U.S. operations in highly inflationary economies are translated at either current or historical exchange rates, as appropriate. These currency adjustments are included in net income.

Significant translation exposures are the euro (which, as of Jan. 1, 1999, replaced the Belgian franc, German mark, Italian lira, and eight other European currencies), Brazilian real, Argentine peso, and U.K. pound sterling. Other translation exposures include the Japanese yen, Australian dollar and Canadian dollar. Currency restrictions are not expected to have a significant effect on Monsanto's cash flow, liquidity, or capital resources.

Monsanto identified Ecuador, Turkey, Russia, Romania, and Venezuela as hyperinflationary countries as of Jan. 1, 1999, and added Ukraine on Jan. 1, 2000. Monsanto identified the Brazilian economy as non-hyperinflationary as of Jan. 1, 1998, and established the Brazilian real as a functional currency.



**Derivatives and Other Financial Instruments**
Monsanto uses derivative financial instruments to limit its exposure arising from changes in commodity prices and participates in a foreign currency risk management program sponsored by Pharmacia. Monsanto does not use derivative financial instruments for trading purposes, nor does it engage in commodity or interest rate speculation. Monsanto monitors its underlying market risk exposures on an ongoing basis and believes that it can modify or adapt its hedging strategies as needed. Gains and losses on contracts that are designated and effective as hedges are deferred and are included in the recorded value of the transaction being hedged. Gains and losses on contracts that are not designated as or effective as hedges are included in net income immediately. From time to time, interest rate swap agreements are used to reduce interest rate risks and to manage interest exposure. By entering into these agreements, the company changes the interest rate mix (fixed/variable) of its debt portfolio.

## NOTE 3
### New Accounting Standards

In June 1998, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 133, *Accounting for Derivative Instruments and Hedging Activities*. This statement establishes accounting and reporting standards for derivative instruments, including certain derivative instruments imbedded in other contracts, and hedge accounting. It requires an entity to recognize all derivatives as either assets or liabilities in the Statement of Financial Position and measure those instruments at fair value. SFAS No. 133 requires that changes in the fair value of derivatives be recognized in either the Statement of Consolidated Income (Loss) or the Statement of Consolidated Comprehensive Income (Loss), depending on the designated purpose of the derivative. Monsanto does not hold or issue such financial instruments for trading purposes. In June 2000, the FASB issued SFAS No. 138, *Accounting for Certain Derivative Instruments and Certain Hedging Activities*. This statement amends portions of SFAS No. 133 including the effective date. Monsanto adopted SFAS No. 133 and SFAS No. 138 on Jan. 1, 2001. In accordance with the transition provisions of SFAS No. 133, the company recorded a cumulative-effect adjustment of $2 million, net of tax, in accumulated other comprehensive income to reflect the fair value of all derivatives that are designated as cash-flow hedges. No cumulative-effect adjustment was required to reflect the fair value of derivatives that are designated as fair-value hedges, nor for the difference between the carrying values and the values of related hedged assets and liabilities.

In 2000, Monsanto adopted Staff Accounting Bulletin No. 101, *Revenue Recognition in Financial Statements* (SAB 101), the Securities and Exchange Commission's interpretation of accounting guidelines on revenue recognition. The adoption of SAB 101 primarily affected the company's recognition of license revenues from biotechnology traits sold through competitor seed companies. Monsanto now recognizes this license revenue when a grower purchases seed as compared with the previous practice of recognizing the license revenue when the third-party seed company sold the seed into the distribution system. As a result, no license revenues from biotechnology traits sold by third-party seed companies were recognized in the fourth quarter of 2000, whereas the fourth quarter of 1999 included $42 million of such license revenues.

SAB 101 requires companies to report any change in revenue recognition related to adopting its provisions as an accounting change in accordance with Accounting Principles Board Opinion No. 20, *Accounting Changes.* Monsanto recognized the cumulative effect of a change in accounting principle of a loss of $26 million, net of taxes of $16 million, effective Jan. 1, 2000. If Monsanto had recognized trait license revenue on a comparable basis, net income would have been $124 million or $0.48 per pro forma share in 1999 compared with $175 million or $0.68 per pro forma share in 2000.

## NOTE 4
### Principal Acquisitions, Mergers and Divestitures

On Dec. 29, 1999, Monsanto completed the sale of Stoneville Pedigreed Seed Company. Proceeds were $92 million, resulting in a pretax gain of $35 million.

On Dec. 20, 1999, Monsanto withdrew its filing for U.S. antitrust clearance of its proposed merger with Delta and Pine Land Company (Delta and Pine Land) in light of the U.S. Department of Justice's unwillingness to approve the transaction on commercially reasonable terms. On Jan. 3, 2000, Monsanto paid Delta and Pine Land $80 million in cash, equal to the amount of a termination fee set forth in the merger agreement, plus reimbursement of $1 million in expenses. In addition, Monsanto incurred $4 million of other expenses in 1999 related to the failed merger with Delta and Pine Land, resulting in a total charge of $85 million.

On Oct. 20, 1999, Monsanto and Cargill Incorporated (Cargill) announced that they had reached an agreement that resolved outstanding issues related to Monsanto's purchase of certain international seed operations of Cargill. Under terms of the agreement, Cargill made a cash payment of $335 million, including $28 million for reimbursement of expenses incurred, to Monsanto for the lost use of certain germplasm, for damages caused by the delay in integrating the acquired seed operations and for legal expenses. Additionally, Monsanto and Pioneer Hi-Bred International, Inc. (Pioneer) announced a resolution of the litigation between them stemming from Monsanto's purchase of these Cargill international seed operations. Under terms of this agreement, Monsanto was required to destroy genetic

material derived from Pioneer's seed lines and pay damages of $42 million to Pioneer. As a result, the purchase price for certain international seed operations of Cargill was reduced by $307 million and a liability of $42 million was recorded, which has subsequently been paid. Monsanto also recorded $28 million in the 1999 Statement of Consolidated Income (Loss) as a reduction of incremental costs incurred.

In 1998, Monsanto made strategic acquisitions of several seed companies. In July 1998, Monsanto acquired Plant Breeding International Cambridge Limited (PBI) for approximately $525 million. In October 1998, Monsanto announced the acquisition of certain international seed operations of Cargill in Asia, Africa, Central and South America, and Europe, excluding certain operations in the United Kingdom, for approximately $1.4 billion. In December 1998, Monsanto completed its acquisition of DEKALB Genetics Corporation (DEKALB Genetics) for approximately $2.3 billion. Monsanto accounted for these acquisitions as purchases. Monsanto's final purchase price allocations for the principal acquisitions made during 1998 were to goodwill, $2,648 million; germplasm and core technology, $324 million; trademarks, $222 million; in-process research and development, $402 million; exit costs and employee termination liabilities, $(54) million; inventories and other individually insignificant tangible assets and liabilities, $421 million. The final purchase price allocations were based on final valuation studies. The following pretax charges were recorded in 1998 for the write-off of acquired in-process research and development (R&D) related to these acquisitions: approximately $60 million for PBI, approximately $150 million for DEKALB Genetics and approximately $190 million for certain Cargill international seed operations. Management believed that the technological feasibility of the acquired in-process R&D had not been established and that it had no alternative future uses. Accordingly, the amounts allocated to in-process R&D were required to be expensed immediately under accounting principles generally accepted in the United States.

At the time of and in connection with the 1998 seed company acquisitions, Monsanto established a plan to integrate the acquired businesses. This plan involved closing or rationalizing (consolidating, shutting down or moving facilities to achieve more efficient operations) certain assets or facilities and eliminating approximately 1,400 jobs, primarily in manufacturing and administrative functions, as part of this integration plan. Approximately 300 of these positions related to Monsanto's existing seed operations and were therefore included in the December 1998 restructuring plan discussed in Note 5 — Restructuring and Other Special Items. The costs related to approximately 1,000 positions and the other actions were originally estimated to be $78 million, and were recognized as liabilities in 1998. As of Dec. 31, 1999, more than 900 positions had been eliminated at a cost of approximately $50 million and the original liability was reduced during 1999 by $14 million as a result of lower actual severance costs resulting in an adjustment to the final purchase price allocations to goodwill. The remaining 200 positions (including an estimated 100 additional positions identified in 1999) were eliminated during 2000 at a cost of approximately $4 million and the original liability was reduced by an additional $10 million to zero.

The in-process R&D charges for the 1998 seed company acquisitions covered numerous seed breeding projects, no single one of which was significant, as is typical in the seed industry. These projects consisted of conventional breeding programs for corn, wheat and other hybrids; conventional breeding for soybean varieties; and the development of transgenic crops. Successful commercialization of products developed through these projects is expected to occur five to nine years after program initiation. The in-process R&D projects were valued using a discounted cash flow method with risk-adjusted discount rates generally ranging from 12 percent to 20 percent, which took into account the stage of completion and the appropriate development cycle of each in-process R&D category. The in-process projects were at various stages of completion at the dates of acquisition. Revenues from the in-process R&D projects related to the 1998 acquisitions began in 1999. On average, a new seed technology is in the research process or developmental stage for approximately eight years before it is launched in a commercial product. Additionally, based on historical experience, Monsanto assumed that approximately one eighth of the products in the in-process pipeline would be released or launched each year for the next eight years. From this information, a weighted-average percent complete was computed. The present value of future cash flows was then multiplied by the estimated percentage complete as of the valuation date to determine the value of the acquired in-process R&D.

The following unaudited pro forma condensed combined financial information combines the consolidated results of operations of Monsanto with those of PBI, DEKALB Genetics, and certain Cargill operations as if these acquisitions had occurred at the beginning of 1998:

| | 1998 |
|---|---|
| Sales | $5,146 |
| Income (loss) from operations | 181 |

The pro forma results give effect to certain purchase accounting adjustments, including additional amortization expense from goodwill and other identified intangible assets, and to increased interest expense and additional shares outstanding related to debt and common stock issued to finance the acquisitions. Pro forma income from operations for 1998 excludes unusual after tax charges of $371 million, primarily for the write-offs of in-process R&D related to these acquisitions of $351 million, and $20 million for the cancellation of stock options in exchange for cash related to the DEKALB Genetics acquisition. These charges were excluded because of their nonrecurring nature.

This pro forma financial information is presented for comparative purposes only. It is not necessarily indicative of the operating results that actually would have occurred had the acquisitions occurred at the beginning of 1998. In addition, these results are not intended to be a projection of future results. Pro forma income from operations for 1998 includes after tax restructuring and special charges of $239 million.



## NOTE 5
## Restructuring and Other Special Items

In 2000, Monsanto recorded a net pretax charge of $261 million ($197 million after tax) to operations, primarily associated with a plan to more stringently focus on key programs within research and development, net of a $4 million reversal of prior restructuring reserves. The plan encompassed a decision to focus more stringently on key crops and included the elimination of certain food and biotechnology research programs, including laureate oil and certain wheat programs. The plan also includes the realignment of our commercial and administrative operations in Western Europe and the Commonwealth of Independent States.

The net pretax charge of $261 included asset impairments of $185 million, work force reduction costs of $61 million, contract terminations of $5 million, dismantling costs of $2 million, other shutdown costs of $2 million and other special items of $10 million. This charge was partially offset by the reversal of $4 million of the 1998 restructuring liability, largely as a result of lower actual severance expense than originally estimated. The net charge was recorded in the Statement of Consolidated Income (Loss) in the following categories:

| | UNUSUAL ITEMS | RESTRUCTURING REVERSALS | TOTAL |
|---|---|---|---|
| Cost of goods sold | $ (60) | $ — | $ (60) |
| Amortization and adjustments of goodwill | (88) | — | (88) |
| Restructuring charges — net | (107) | 4 | (103) |
| Other expense — net | (10) | — | (10) |
| Income (loss) before income taxes | (265) | 4 | (261) |
| Income tax benefit (provision) | 65 | (1) | 64 |
| **Net Income (Loss)** | $ (200) | $ 3 | $ (197) |

The asset impairments consisted of $30 million for laureate oil inventories, $30 million for seed and other inventories, $91 million for intangible assets, $12 million for trade receivables and $22 million for equipment write-offs. The work force reduction charge reflected involuntary employee separation costs for 695 employees worldwide and included charges of $31 million for positions in administration, and $27 million for positions in research and development and $3 million for positions in manufacturing. The affected employees are entitled to receive severance benefits pursuant to established severance policies or by governmentally mandated labor regulations. As of Dec. 31, 2000, 460 of the planned employee terminations were completed; 358 of these employees received cash severance payments totaling $28 million during 2000 and 102 employees elected deferred payments of $9 million which will be paid during the first quarter of 2001. The remaining employee reductions are expected to be completed by the end of 2001. The other exit costs included expenses associated with contract terminations, equipment dismantling and other shutdown costs, of which $3 million were paid in 2000. Also included in the charges were other special items of $10 million, consisting of $3 million for costs associated with a failed joint venture and $7 million for the recognition of an impairment of a marketable equity security that was classified as available for sale. Payments to complete the remaining restructuring actions will be funded from operations and are not expected to significantly impact Monsanto's liquidity. These actions are expected to be completed by December 2001. During 2000, costs charged against prior established reserves were $21 million primarily related to work force reductions. Our prior restructuring plans are substantially complete.

Activities related to restructuring and other special items for 2000 were as follows:

| | WORK FORCE REDUCTIONS | FACILITY CLOSURES | ASSET IMPAIR-MENTS | OTHER | TOTAL |
|---|---|---|---|---|---|
| **Restructuring and Other Special Items** | | | | | |
| Jan. 1, 2000, reserve balance | $ — | $ — | $ — | $ — | $ — |
| Additions | 61 | 9 | 185 | 10 | 265 |
| Costs charged against reserves | (28) | (3) | — | — | (31) |
| Reclassification of reserves to other balance sheet accounts: | | | | | |
| Inventories | — | — | (60) | — | (60) |
| Property, plant and equipment | — | — | (22) | — | (22) |
| Accumulated other comprehensive loss | — | — | — | (7) | (7) |
| Trade receivables | — | | (12) | — | (12) |
| Goodwill | — | — | (88) | — | (88) |
| Other intangible assets | — | — | (3) | — | (3) |
| Other assets | — | — | | (1) | (1) |
| Miscellaneous accruals | (3) | — | — | — | (3) |
| Dec. 31, 2000, reserve balance | $ 30 | $ 6 | $ — | $ 2 | $ 38 |

In 1999, Monsanto recorded a net pretax charge associated with restructuring and other unusual items of $101 million ($81 million after tax) resulting from the failed merger between Monsanto and Delta and Pine Land, combined with costs associated with the accelerated integration of agricultural chemical and seed operations. These charges were net of the reversal of restructuring liabilities established in 1998 and the gain on the sale of Stoneville Pedigreed Seed Company. The 1999 net unusual items were recorded in the Statement of Consolidated Income (Loss) in the following categories:

| | UNUSUAL ITEMS | RESTRUCTURING REVERSALS | TOTAL |
|---|---|---|---|
| Cost of goods sold | $ (20) | $ — | $ (20) |
| Amortization and adjustments of goodwill | (8) | — | (8) |
| Restructuring charges — net | (33) | 11 | (22) |
| Other expense — net | (51) | — | (51) |
| Income (loss) before income taxes | (112) | 11 | (101) |
| Income tax (provision) benefit | 24 | (4) | 20 |
| **Net Income (Loss)** | $ (88) | $ 7 | $ (81) |

During 1999, Monsanto recorded in "Other expense — net" a one-time pretax charge of $85 million equal to the amount of a termination fee and other expenses associated with the failed merger between Monsanto and Delta and Pine Land. Monsanto also recorded a pretax charge of $61 million principally associated with the continued focus on improving operating efficiency through accelerated integration of its agricultural and seed operations ("the accelerated integration plan"). The charge of $61 million was comprised of facility shutdown charges of $39 million, work force reduction costs of $12 million, and asset impairments of $10 million, and was recorded in the Statement of Consolidated Income (Loss) as cost of goods sold of $20 million, amortization of intangible assets of $8 million, and restructuring expense of $33 million. The affected employees are entitled to receive severance benefits pursuant to established severance policies or by governmentally mandated labor regulations.

The facility shutdown charges included $14 million for contractual research and other commitments, $9 million for intangible assets, $8 million for inventories, $6 million for leasehold termination costs, and $2 million for property, plant and equipment write-offs. During 1999, these actions resulted in cash payments of $2 million for contractual obligations and asset write-offs of $19 million. Commitments of $18 million resulting from these actions were reclassified to other liabilities. These remaining actions were completed during 2000.

The work force reduction charge reflected involuntary employee separation costs for 305 employees worldwide and included charges for positions in administration of $8 million and research and development of $4 million. As of Dec. 31, 1999, 125 of the planned employee eliminations were completed; approximately 55 of these employees received cash severance payments totaling $2 million during 1999, and 70 employees elected deferred payments of $4 million which were paid in January 2000. As of Dec. 31, 1999, these deferred payments were classified in the Statement of Consolidated Financial Position as other liabilities. The remaining balance for employee severance related to 180 positions was $6 million as of Dec. 31, 1999. These employee reductions were completed by June 2000.

Offsetting the restructuring and unusual items in 1999 was a pretax gain of $11 million from the reversal of restructuring reserves established in 1998. These restructuring reversals were principally required as a result of lower actual severance and facility shutdown costs than were originally estimated. In addition, Monsanto recognized a pretax gain of $35 million for the sale of Stoneville Pedigreed Seed Company and miscellaneous other expense of $1 million which was recorded in "Other expense — net."

In 1998, Monsanto recorded in-process research and development charges, net restructuring and other special items of $604 million ($504 million after tax). The 1998 net restructuring and special items were recorded in the Statement of Consolidated Income (Loss) in the following categories:

| | WORK FORCE REDUCTIONS | FACILITY CLOSURES | ASSET IMPAIR-MENTS | OTHER | TOTAL |
|---|---|---|---|---|---|
| Cost of goods sold | $ — | $ (5) | $(43) | $ — | $ (48) |
| Acquired in-process research and development | — | — | — | (402) | (402) |
| Amortization and adjustments of goodwill | — | (1) | (38) | — | (39) |
| Restructuring charges — net | (63) | (31) | — | — | (94) |
| Other expense — net | — | — | (1) | (20) | (21) |
| (Loss) before income taxes | (63) | (37) | (82) | (422) | (604) |
| Income tax benefit | 21 | 12 | 17 | 50 | 100 |
| Net Loss | $(42) | $(25) | $(65) | $(372) | $(504) |

In December 1998, the Pharmacia board of directors approved a plan relating to Monsanto to reduce costs and to integrate its acquired seed businesses. The plan included the closure of certain facilities, reductions in the current work force and the sale of its tomato business. The plan provided for the elimination of approximately 710 jobs, primarily in manufacturing and administrative functions, by the end of 1999, at a total cost of $69 million. This amount included work force reduction costs of $6 million related to 60 positions originally accrued as part of a restructuring plan approved in 1996. Those work force reductions had been delayed principally as a result of a failed merger in 1998 between Monsanto's parent with American Home Products Corporation; Monsanto remained committed to accomplishing these work force reductions and transferred the remaining accrual to the 1998 plan. The employees affected by the 1998 restructuring plan were entitled to receive severance benefits pursuant to established severance policies or by governmentally mandated labor regulations.

The plan also included pretax amounts for asset impairments, primarily for property, plant and equipment, intangible assets and inventories, totaling $82 million. These asset impairments were recorded because of the decision to sell the tomato business. As a result, the net assets of this business were classified as assets held for sale and were carried at their net realizable value as of Dec. 31, 1998, based on estimated sale proceeds of approximately $33 million. This business was sold during the second quarter of 1999. It produced net income of $11 million in 1998. The after tax effect of suspending depreciation on assets held for sale was not material in 1999 and 1998.

The December 1998, restructuring amounts also included pretax charges of $37 million for the shutdown or rationalization of certain production and administrative facilities. Rationalization entails the consolidation, shutdown or movement of facilities to achieve more efficient operations. Approximately 40 facilities, located primarily in the United States, Europe and Latin America, were affected by these actions. Charges for these shutdowns included $17 million for property, plant and equipment, $1 million for intangible assets, and $4 million for inventories. Leasehold termination costs of $8 million and various facility closure costs of $7 million, principally for facilities shutdown costs and equipment dismantling are also included in the shutdown charges. The closure or rationalization of these facilities was completed by Dec. 31, 1999. In addition, $9 million in facility shutdown payments were incurred in connection with the 1998 restructuring plan.

Through Dec. 31, 2000, cash payments of $57 million were made to eliminate approximately 630 positions. An additional 80 positions originally contemplated in the plan were eliminated through attrition. Cash payments to complete the 1998 plan were funded from operations and did not significantly affect Monsanto's liquidity.

Activity related to the 1999 accelerated integration plan, and the 1998 restructuring plan and other special items were as follows:

| | WORK FORCE REDUCTIONS | FACILITY CLOSURES | ASSET IMPAIRMENTS | TOTAL |
|---|---|---|---|---|
| **Restructuring and Other Special Items:** | | | | |
| **Jan. 1, 1998 reserve balance** | **$ 18** | **$ —** | **$ —** | **$ 18** |
| 1998 restructuring and special charges[1] | 63 | 37 | 82 | 182 |
| Reclassification of reserves to other balance sheet accounts: | | | | |
| Property | — | (17) | (44) | (61) |
| Intangible assets | — | (1) | (38) | (39) |
| Inventories | — | (4) | — | (4) |
| Costs charged against reserves | (12) | — | — | (12) |
| **Reserve balance as of Dec. 31, 1998** | **69** | **15** | **—** | **84** |
| Addition for accelerated integration costs | 12 | 39 | 10 | 61 |
| Costs charged against reserves: | | | | |
| 1998 plan | (39) | (9) | — | (48) |
| Accelerated integration | (2) | (2) | — | (4) |
| Reversal of reserves related to 1998 plan | (12) | (4) | 5 | (11) |
| Reclassification of reserves to other balance sheet accounts: | | | | |
| 1998 plan — property | — | — | (5) | (5) |
| Accelerated integration: | | | | |
| Property | — | (2) | (10) | (12) |
| Inventories | — | (8) | — | (8) |
| Intangible assets | — | (9) | — | (9) |
| Other liabilities | (4) | (18) | — | (22) |
| **Reserve balance as of Dec. 31, 1999** | **$ 24** | **$ 2** | **$ —** | **$ 26** |
| Costs charged against reserves | (20) | (1) | — | (21) |
| Reversal of reserves related to pre-2000 plans | (4) | — | — | (4) |
| **Reserve balance as of Dec. 31, 2000** | **$ —** | **$ 1** | **$ —** | **$ 1** |

(1) Restructuring reserves recorded in 1998 did not include the charges for the cancellation of the DEKALB Genetics stock options and the write-off of acquired in-process research and development.



Monsanto also recorded pretax charges of $422 million relating to its 1998 seed company acquisitions, of which $402 million related to the write-off of in-process research and development and $20 million related to the cancellation of DEKALB Genetics stock options associated with that acquisition.

## NOTE 6
## Inventories

Components of inventories were:

| | 2000 | 1999 |
|---|---|---|
| Finished goods | $ 753 | $ 705 |
| Goods in process | 267 | 412 |
| Raw materials and supplies | 259 | 346 |
| Inventories, at FIFO cost | 1,279 | 1,463 |
| Excess of FIFO over LIFO cost | (26) | (23) |
| **Total** | $1,253 | $1,440 |

Commodity futures and options contracts are used to hedge the price volatility of certain commodities, primarily soybeans and corn. This hedging activity is intended to manage the price paid to production growers for corn and soybean seeds. Gains and losses on contracts that are designated as or effective as hedges are deferred in inventory and are included in cost of goods sold when the underlying seed products are sold. See Note 10 — Financial Instruments Fair Value — for further details. As of Dec. 31, 2000, Monsanto had futures contracts to purchase $126 million of corn and soybeans. The excess of FIFO over LIFO cost increased $7 million primarily due to an acquisition of a former equity affiliate offset by reduced inventory levels and lower costs favorably affecting 2000 net income by $4 million.

## NOTE 7
## Investments

| | COST | GROSS GAINS | UNREALIZED (LOSSES) | FAIR VALUE |
|---|---|---|---|---|
| **Long-term investments:** | | | | |
| Dec. 31, 2000, Equity securities available for sale | 33 | 67 | (4) | 96 |
| Dec. 31, 1999, Equity securities available for sale | 34 | 27 | (7) | 54 |

The total of unrealized gains and losses (net of deferred taxes) included in shareholders' equity amounted to $39 million as of Dec. 31, 2000, and $12 million as of Dec. 31, 1999. A realized loss of $4 million, net of a $3 million tax benefit, was determined using the specific identification method, and was included in net income in 2000.

## NOTE 8
## Income Taxes

The components of income (loss) before income taxes were:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| United States | $333 | $198 | $ 44 |
| Outside United States | 1 | 65 | (104) |
| **Total** | $334 | $263 | $ (60) |

The components of income tax provision (benefit) were:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| Current: | | | |
| U.S. federal | $ (9) | $ 14 | $ 154 |
| U.S. state | 2 | 4 | 16 |
| Outside United States | 26 | 53 | 60 |
| **Total Current** | 19 | 71 | 230 |
| Deferred: | | | |
| U.S. federal | 158 | 74 | (68) |
| U.S. state | 10 | 7 | (7) |
| Outside United States | (28) | (39) | (90) |
| **Total Deferred** | 140 | 42 | (165) |
| **Total** | $159 | $113 | $ 65 |

Factors causing Monsanto's income taxes to differ from the U.S. federal statutory rate were:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| U.S. federal statutory rate | $117 | $ 92 | $ (21) |
| U.S. export earnings | (11) | (20) | (24) |
| U.S. R&D tax credit | (15) | (6) | (5) |
| Higher (lower) ex-U.S. rates | (3) | (8) | 8 |
| Nondeductible goodwill | 57 | 46 | 24 |
| Acquired in-process R&D | — | — | 71 |
| Equity loss | — | — | 9 |
| State income taxes | 8 | 7 | 6 |
| Other | 6 | 2 | (3) |
| **Income Taxes** | $159 | $113 | $ 65 |

Deferred income tax balances were related to:

| | 2000 | 1999 |
|---|---|---|
| Employee fringe benefits | $ 90 | $ 13 |
| Restructuring reserves | 19 | 10 |
| Bad debt reserve | 50 | 41 |
| Net operating loss and tax credit carryforwards | 147 | 305 |
| Intangibles | 74 | 157 |
| Other | 115 | 79 |
| Valuation allowance | (69) | (62) |
| **Total Deferred Tax Assets** | $426 | $543 |
| Property | $234 | $203 |
| Other | 47 | 12 |
| **Total Deferred Tax Liabilities** | $281 | $215 |
| **Net Deferred Tax Assets** | $145 | $328 |

As of Dec. 31, 2000, Monsanto had available approximately $381 million in net operating loss carryforwards outside the United States, the majority of which do not expire. Monsanto has recorded a valuation allowance totaling $69 million against the loss carryforwards, an increase of $7 million for 2000, based on Monsanto management's conclusion that it was more likely than not that the company would not be able to realize a portion of the deferred tax assets.

Income taxes and remittance taxes have not been recorded on the undistributed earnings of foreign operations of Monsanto, either because any taxes on dividends would be offset substantially by foreign tax credits, or because Monsanto intends to reinvest those earnings indefinitely. It is not practicable to estimate the income tax liability that might be incurred if such earnings were remitted to the United States.

Monsanto's current and deferred tax amounts have been presented as if it had been a separate company for the years 2000, 1999 and 1998. Monsanto did not make any cash payments for taxes for the periods through Aug. 31, 2000, since Monsanto's operating results were included in the Pharmacia consolidated federal and state income tax returns for those periods. Effective Sept. 1, 2000, Monsanto and Pharmacia entered into a tax sharing agreement. To the extent Monsanto's results are included in any Pharmacia income tax return, Monsanto, in general, is obligated to pay Pharmacia the amount of taxes that would be due as if Monsanto had filed its own tax returns. As of Dec. 31, 2000, Monsanto had an amount due to Pharmacia of $12 million related to income taxes payable.

## NOTE 9
## Debt and Other Credit Arrangements

The company has committed borrowing facilities amounting to $1.5 billion that were unused as of Dec. 31, 2000. Expiration periods occur as follows: $1.0 billion in 2001 and $500 million in 2005. The facilities exist largely to support commercial paper borrowings. Covenants under these credit facilities restrict maximum borrowings. While there are no related compensating balances, the facilities are subject to various fees. The company had aggregate short-term loan facilities of $183 million with unrelated parties, under which loans totaling $22 million were outstanding as of Dec. 31, 2000.

### Short-Term Debt

| | 2000 | 1999 |
|---|---|---|
| Commercial paper | $ 50 | $ — |
| Current maturities of long-term debt | 58 | 48 |
| Notes payable to banks | 22 | 21 |
| Bank overdrafts | 22 | 20 |
| Current maturities of ESOP guaranteed debt attributable to Monsanto | 6 | — |
| Subtotal | 158 | 89 |
| Related party short-term loans payable — Pharmacia Treasury Services AB | 635 | — |
| Total short-term debt | $793 | $ 89 |

### Long-Term Debt

| | 2000 | 1999 |
|---|---|---|
| Commercial paper | $500 | $ 605 |
| 5 ⅜ percent notes due 2001 | — | 500 |
| 5.95 percent junior subordinated deferrable debentures due 2003 | — | 700 |
| Variable-rate medium-term notes due 2003 | 424 | 480 |
| 5.75 percent notes due 2005 | — | 599 |
| 5 ⅞ percent notes due 2008 | — | 199 |
| 6.5 percent debentures due 2018 | — | 498 |
| 6.6 percent debentures due 2028 | — | 697 |
| Noncurrent maturities of ESOP guaranteed debt attributable to Monsanto | 38 | — |
| Total long-term debt | $962 | $4,278 |

Annual aggregate maturities of variable-rate medium-term notes are $56 million in 2002 and $368 million in 2003. The commercial paper balance of $500 million as of Dec. 31, 2000, was classified as long-term debt because Monsanto has the ability and intent to renew these obligations beyond 2001. As of Dec. 31, 2000, the company has included guaranteed ESOP-related notes attributable to Monsanto from Pharmacia, that it plans to guarantee beginning in 2001, for original principal amounts of $44 million (8.13 percent as of Dec. 31, 2000), which mature in 2006, of which $6 million is due in 2001. Annual aggregate maturities of guaranteed ESOP debt through expiration are $7 million in 2002, $7 million in 2003, and $8 million each in 2004, 2005 and 2006. The 1999 debt position represents the amounts of Pharmacia's debt that were specifically attributable to Monsanto, primarily for seed company acquisitions.

Information regarding interest expense and weighted-average interest rates below reflect Monsanto's interest expense or interest expense on debt specifically attributable to Monsanto in 2000, 1999 and 1998:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| Interest cost incurred | $251 | $292 | $130 |
| Less: Capitalized on construction | (37) | (23) | (9) |
| Interest expense | $214 | $269 | $121 |
| Weighted average interest rate on short-term borrowings at end of period | 7.7% | 12.8% | 8.3% |

## NOTE 10
## Financial Instruments Fair Values

The notional amounts, carrying amounts and estimated fair values of the company's financial instruments were as follows:

| | 2000 | | | 1999 | | |
|---|---|---|---|---|---|---|
| | NOTIONAL AMOUNT | CARRYING AMOUNT | FAIR VALUE | NOTIONAL AMOUNT | CARRYING AMOUNT | FAIR VALUE |
| Financial assets: | | | | | | |
| Forward currency exchange contracts: | | | | | | |
| Contracts purchased | $350 | $ 16 | $ 16 | $ — | $ — | $ — |
| Contracts sold | 449 | (13) | (13) | — | — | — |
| Commodity futures: | | | | | | |
| Futures purchased | 126 | 3 | 3 | 106 | (3) | (3) |
| Futures sold | 8 | — | — | 9 | — | — |
| Financial liabilities: | | | | | | |
| Short-term debt | — | 787 | 787 | — | 89 | 89 |
| Long-term debt | — | 924 | 924 | — | 4,278 | 3,951 |
| Guaranteed ESOP debt attributable to Monsanto | — | 44 | 45 | — | — | — |

These instruments generally have maturities of less than 12 months and require the company to exchange currencies at agreed-upon rates at maturity. Pharmacia Treasury Services AB, a wholly owned subsidiary of Pharmacia, is the counterparty for all foreign currency exchange contracts. The company does not expect any losses from credit exposure related to these instruments. Prior to Sept. 1, 2000, the date of Monsanto's separation from Pharmacia, our foreign currency risk was managed by Pharmacia jointly with foreign currency risks of other Pharmacia businesses, and it was not practicable to determine foreign currency amounts and risks specifically attributable to Monsanto.

**Foreign Currency Risk Management**
The company is exposed to currency exchange rate fluctuations related to certain intercompany and third-party transactions. The exposures and related hedging programs are managed centrally, using forward currency exchange contracts to hedge a portion of both recorded commercial currency transaction exposures on the balance sheet and anticipated currency transactions. Financial instruments are neither held nor issued by the company for trading purposes.

The company's program to hedge recorded commercial currency transaction exposures is designed to protect cash flows from potentially adverse effects of exchange rate fluctuations. As of Dec. 31, 2000, the notional amounts of the company's outstanding forward currency exchange contracts purchased and forward currency exchange contracts sold used to hedge net transaction exposure were $350 million and $449 million, respectively. Foreign currencies in which Monsanto has significant hedged exposures are the euro and Polish zlotys. The aggregate net transaction losses, net of related hedging gains and losses, included in net earnings for the year ended Dec. 31, 2000, were $22 million.

**Commodity Risk Management**
Commodity futures and options contracts are used to hedge the price volatility of certain commodities, primarily soybeans and corn. This hedging activity is intended to manage the price paid to production growers for corn and soybean seeds. As of Dec. 31, 2000, the company had futures contracts with notional amounts of $95 million, $31 million and $(8) million for soybeans, corn and lean hogs, respectively. As of Dec. 31, 1999, the company had futures contracts with notional amounts of $78 million, $28 million and $(9) million for soybeans, corn and lean hogs, respectively.

**Credit Risk Management**
The company invests excess cash in deposits with major banks throughout the world and in high-quality short-term debt instruments. Such investments are made only in instruments issued or enhanced by high-quality institutions. As of Dec. 31, 2000, the company had no financial instruments that represented a significant concentration of credit risk. The amounts invested in any single institution are limited to minimize risk. The company has not incurred credit risk losses related to those investments.

The company sells a broad range of agricultural products to a diverse group of customers operating throughout the world. Largely in the United States, the company makes substantial sales to relatively few large wholesale customers. The company's agricultural products business is highly seasonal and is subject to weather conditions that affect commodity prices and seed yields. Credit limits, ongoing credit evaluation, and account monitoring procedures are utilized to minimize the risk of loss. Collateral is secured when deemed appropriate by the company.

## NOTE 11
## Postretirement Benefits — Pensions

Most Monsanto employees are covered by noncontributory pension plans either through Monsanto-sponsored plans or through Pharmacia-sponsored plans in which Monsanto employees participate. Pursuant to the Separation Agreement between Monsanto and Pharmacia, on Sept. 1, 2000, certain Pharmacia-sponsored pension plans transferred plan benefit obligations to Monsanto-sponsored plans for the benefit of Monsanto employees; Monsanto assumed sponsorship of certain plans in which a limited number of Pharmacia employees participate; and certain Pharmacia-sponsored plans in which Monsanto employees participate continued. Prior to Sept. 1, 2000, most Monsanto employees participated in Pharmacia-sponsored noncontributory pension plans.

No detailed information regarding the funded status of the plans and components of net periodic pension cost, as it relates solely to Monsanto, is available for dates and periods prior to Sept. 1, 2000. Accordingly, the corresponding net pension asset or liability has not been included in Monsanto's Statement of Consolidated Financial Position as of Dec. 31, 1999. Monsanto's Statement of Consolidated Financial Position as of Dec. 31, 2000, includes a net pension liability related to the Monsanto-sponsored plans of $70 million.

Total pension cost related to Monsanto employees in 2000, 1999 and 1998 and included in the Statement of Consolidated Income (Loss) was $24 million, $49 million and $48 million, respectively. For the period subsequent to Sept. 1, 2000, the expense related to Monsanto-sponsored plans for Monsanto employees only comprised service costs for benefits, interest cost on benefit obligation, assumed return on plan assets, and amortization of unrecognized net loss of $2 million, $3 million, $1 million and $1 million, respectively. The information that follows relates to all of the Monsanto- and Pharmacia-sponsored pension plans in which Monsanto employees participated. The components of pension cost for these plans were:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| Service cost for benefits earned during the year | $ 60 | $ 65 | $ 58 |
| Interest cost on benefit obligation | 163 | 171 | 170 |
| Assumed return on plan assets | (168) | (200) | (156) |
| Amortization of unrecognized net (gain)/loss | (5) | 49 | 22 |
| **Total** | $ 50 | $ 85 | $ 94 |

Pension benefits are based on an employee's years of service and/or compensation level. Pension plans were funded in accordance with Monsanto and Pharmacia's long-range projections of the plans' financial conditions. These projections took into account benefits earned and expected to be earned, anticipated returns on pension plan assets, and income tax and other regulations.

Pension costs were determined through the use of the preceding year-end rate assumptions. The following assumptions, calculated on a weighted average basis, were used as of Dec. 31 for the principal plans in which Monsanto employees participated:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| Discount rate | 7.50% | 7.75% | 6.75% |
| Assumed long-term rate of return on plan assets | 9.50% | 9.50% | 9.50% |
| Annual rates of salary increase (for plans that base benefits on final compensation level) | 4.50% | 4.50% | 4.00% |

The funded status of the pension plans in which Monsanto employees participate as of Dec. 31, 2000 and 1999 was:

| | 2000 | | | 1999 |
|---|---|---|---|---|
| **PLAN SPONSOR** | **MONSANTO** | **MONSANTO** | **PHARMACIA** | **PHARMACIA** |
| **PLAN PARTICIPANTS** | **MONSANTO ONLY** | **MONSANTO & PHARMACIA** | **MONSANTO & PHARMACIA** | **MONSANTO & PHARMACIA** |
| **Change in benefit obligation** | | | | |
| Benefit obligation at beginning of year | $ — | $ — | $2,522 | $2,655 |
| Service cost | 2 | 1 | 57 | 65 |
| Interest cost | 3 | 1 | 159 | 171 |
| Plan participants' contributions | — | — | 2 | 1 |
| Amendments | — | — | — | 6 |
| Actuarial (gain)/loss | 3 | 2 | 16 | (143) |
| Acquisitions/divestitures | — | — | 42 | — |
| Settlements | — | — | — | 15 |
| Benefits paid | (4) | (2) | (237) | (248) |
| Benefit obligation transferred to Monsanto plans | 126 | 73 | (199) | — |
| Benefit obligation transferred to Pharmacia only plans | — | — | (637) | — |
| Benefit obligation at year end | $130 | $ 75 | $1,725 | $2,522 |
| **Change in plan assets** | | | | |
| Fair value of plan assets at beginning of year | $ — | $ — | $2,332 | $2,146 |
| Actual return on plan assets | (1) | (3) | 6 | 411 |
| Employer contribution | 3 | — | 19 | 24 |
| Plan participants' contributions | — | — | 2 | 3 |
| Acquisitions/divestitures | 1 | — | 42 | — |
| Settlements | — | — | — | (4) |
| Fair value of benefits paid | (4) | (2) | (237) | (248) |
| Fair value of plan assets transferred to Monsanto plans | 26 | 111 | (137) | — |
| Fair value of plan assets transferred to Pharmacia plan | — | — | (433) | — |
| Plan assets at end of year | $ 25 | $106 | $1,594 | $2,332 |
| Unfunded status | $105 | $ (31) | $ 131 | $ 190 |
| Unrecognized initial net gain | 3 | 1 | 1 | 9 |
| Unrecognized prior service cost | (7) | (2) | (44) | (82) |
| Unrecognized subsequent gain/(loss) | (19) | 20 | 151 | 371 |
| Accrued net pension liability/(asset) | $ 82 | $ (12) | $ 239 | $ 488 |

The projected benefit obligation, the accumulated benefit obligation (ABO) and fair value of plan assets for pension plans with ABOs in excess of plan assets for Monsanto-sponsored plans were $99 million, $98 million and zero, respectively, as of Dec. 31, 2000. The projected benefit obligation, the ABO and fair value of plan assets for pension plans with ABOs in excess of plan assets for Pharmacia-sponsored plans in which Monsanto employees participate were $319 million, $315 million and zero, respectively, as of Dec. 31, 1999; plan assets consist principally of common stocks and U.S. government and corporate obligations.

In 2000, amounts recognized in the Statement of Consolidated Financial Position for accrued pension liability, additional minimum liability, accumulated other comprehensive loss, prepaid benefit cost and intangible assets are $77 million, $24 million, $(24) million, $(5) million and $(2) million, respectively. As Monsanto employees participated in third-party plans in previous years, prior year data was not available.

## NOTE 12
## Postretirement Benefits — Health Care and Other

Pursuant to the separation agreement between Monsanto and Pharmacia, on Sept. 1, 2000, Monsanto created and assumed the sponsorship of all medical, life, disability, and other welfare benefit plans in which its employees participate. Prior to Sept. 1, 2000, most Monsanto employees participated in certain Pharmacia-sponsored benefit plans which provided health care and life insurance benefits for retired employees. No detailed information is available about the components of the total cost and obligations, as it relates solely to Monsanto for periods prior to Sept. 1, 2000. Accordingly, the corresponding postretirement benefit liability has not been included in Monsanto's Statement of Consolidated Financial Position as of Dec. 31, 1999. Monsanto's Statement of Consolidated Financial Position as of Dec. 31, 2000, includes a postretirement benefit liability related to the Monsanto-sponsored plans of $280 million.

Total postretirement benefit costs related to Monsanto employees and included in Monsanto's Statement of consolidated Income (Loss) in 2000, 1999 and 1998 were $18 million, $23 million and $22 million, respectively.

Substantially all regular, full-time U.S. employees and certain employees in other countries may become eligible for these benefits if they reach retirement age while employed by Monsanto. These postretirement benefits are unfunded and generally are based on the employees' years of service and/or compensation levels. The costs of postretirement benefits are accrued by the date the employees become eligible for the benefits.

The information that follows relates to all of the Monsanto- and Pharmacia-sponsored postretirement benefit plans in which Monsanto employees participate, principally health care and life insurance. The components of costs for these plans were:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| Service cost for benefits earned during the year | $13 | $16 | $13 |
| Interest cost on benefit obligation | 25 | 27 | 27 |
| Amortization of unrecognized net (gain)/loss | (8) | 15 | (1) |
| Total | $30 | $58 | $39 |

Postretirement costs were determined using the preceding year-end rate assumptions. The following assumptions, calculated on a weighted average basis, were used as of Dec. 31 for the principal plans:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| Discount rate | 7.50% | 7.75% | 6.75% |
| Initial trend rate for health care costs | 5.00% | 5.25% | 5.75% |
| Ultimate trend rate for health care costs | 5.00% | 5.25% | 4.75% |

A one percent increase/decrease in the assumed trend rate for health care costs would have had no effect on Monsanto's cost of 2000 postretirement health care benefits for these plans and would have increased/decreased the accumulated postretirement benefit obligation by $5 million as of Dec. 31, 2000.

As of Dec. 31, 2000, the status of the postretirement health care, life insurance and employee disability benefit plans in which Monsanto employees participated was:

| | 2000 | 1999 |
|---|---|---|
| **Change in benefit obligation** | | |
| Pharmacia sponsored: | | |
| Benefit obligation at beginning of year | $ 420 | $403 |
| Service cost | 10 | 16 |
| Interest cost | 19 | 27 |
| Acquisitions/divestitures | 17 | — |
| Actuarial (gain)/loss | 7 | (10) |
| Plan participant contributions | 1 | — |
| Benefits paid | (20) | (16) |
| Benefit obligation transferred to Pharmacia plans | (178) | — |
| Monsanto sponsored: | | |
| Benefit obligation at separation date, Sept. 1 | $ 276 | — |
| Service cost | 3 | — |
| Interest cost | 6 | — |
| Plan amendments | 1 | — |
| Actuarial (gain) | (7) | — |
| Benefits paid | (7) | — |
| Benefit obligation at end of year | $ 272 | $420 |
| Unfunded status | $ 272 | $420 |
| Unrecognized prior service cost | 4 | 6 |
| Unrecognized subsequent gain (loss) | 4 | (3) |
| Accrued postretirement liability | $ 280 | $423 |

In 2000, amounts recognized in the Statement of Consolidated Financial Position for miscellaneous accruals and postretirement liabilities are $14 million and $266 million, respectively.

## NOTE 13
## Employee Savings Plans

For some company employee savings plans, employee contributions are matched in part by the company. Monsanto employees participate in an Employee Stock Ownership Plan (ESOP) which held 14.7 million shares of Pharmacia common stock as of Dec. 31, 2000. At its inception, the ESOP acquired shares by using proceeds from the issuance of long-term notes and debentures guaranteed by Pharmacia and a loan from Pharmacia. A portion of the ESOP shares is allocated each year to employee savings accounts as matching contributions. In 2000, 848,119 shares were allocated to all participants under the plan. An additional 409,553 shares were released in 2000 awaiting allocation to all participants, leaving 6 million unallocated shares as of Dec. 31, 2000. Compensation expense is equal to the cost of the shares allocated to participants, less cash dividends paid on the shares held by the ESOP. Dividends on the common stock owned by the ESOP are used to repay the ESOP borrowings, which were $83 million as of Dec. 31, 2000. Compensation expense related to Monsanto employees and included in the Statement of Consolidated Income (Loss) in 2000, 1999 and 1998 was $6 million, $11 million and $5 million, respectively. The following information relates to the Pharmacia ESOP plan in which the Monsanto employees participated for the years ended Dec. 31:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| Total ESOP expense | $18 | $31 | $21 |
| Interest portion of total ESOP expense | 8 | 9 | 10 |
| Cash contribution | 21 | 37 | 14 |
| Dividends paid on ESOP shares held | 4 | 2 | 2 |

## NOTE 14
## Stock-based Compensation Plans

Monsanto established three fixed stock option plans for employees in 2000. Under the Monsanto 2000 Management Incentive Plan (the 2000 Plan) and the Monsanto Non-Employee Director Equity Incentive Compensation Plan (the Director Plan), the company may grant key officers, directors and employees of Monsanto or Pharmacia stock-based awards, including stock options, of up to 22.6 million shares of common stock. Other employees were granted options under the Monsanto Broad-Based Stock Option Plan (the Broad-Based Plan) which permits the granting of a maximum of 2.7 million shares of common stock to employees other than officers subject to special reporting requirements. Under the plans, the exercise price of any option must be no less than the fair market value of the company's common stock on the grant date. The plans provide that the term of any option granted may not exceed 10 years and that each option may be exercised for such period as may be specified by the Board of Directors' People Committee which administers the plans.

The Director Plan was established for directors who are not company employees or employees of our affiliates. Half of the annual retainer for each non-employee director will automatically be paid in the form of deferred stock, which are shares of common stock delivered at a specified time in the future. The remaining half of the director's annual retainer may be received in the form of non-qualified stock options, restricted common stock, deferred common stock or cash. The exercise price of any stock option will be the fair market value of the company's common stock on the grant date. The term of any options granted under the Director Plan is 10 years and the options vest in installments over the life of the director's term. The Director Plan is administered by a committee of company executives. Compensation expense recognized for the Director Plan was $359 thousand in 2000.

The 2000 Plan also authorizes the grant of restricted or unrestricted shares. In 2000, 10,000 restricted shares were granted and vest in increments of 33 percent in 2001 and 67 percent in 2002. Compensation expense is measured based on the market price of Monsanto's common stock at the grant date and is recognized over the vesting period. Compensation expense recognized for these restricted shares was $20 thousand in 2000.

In addition, in 2000, four executives signed Phantom Share Agreements which provide each executive with a number of phantom shares of common stock equal to the cash severance and value of benefits continuation they would have received under a prior change-of-control agreement, divided by the IPO offering price. The phantom shares provide the holders the opportunity to earn a cash award equal to the fair value of the company's common stock upon the attainment of certain performance goals and vest on Oct. 1, 2002. As of Dec. 31, 2000, the company had 801,950 phantom shares outstanding and recognized $3 million in compensation expense related to the phantom shares. Compensation expense is measured based on the market price of Monsanto's common stock and recognized over the 24-month vesting period.

In connection with the IPO on Oct. 23, 2000, Monsanto issued a one-time founder's grant of stock options to all of its employees under the 2000 Plan and the Broad-Based Plan. Approximately 22.3 million options were granted on that date, each of which has an exercise price of $20 per share. Founder's options vest to employees in increments of 50 percent in 2002 and 50 percent in 2003 with a maximum term of 10 years.

Prior to the IPO, Monsanto employees participated in Pharmacia incentive plans. Any related outstanding options held by Monsanto employees will be exercised, canceled or forfeited under the provisions of the Pharmacia plans. A summary of the status of the Monsanto plans for the period Oct. 23, 2000, through Dec. 31, 2000, follows:

| | OUTSTANDING | |
|---|---|---|
| | SHARES | WEIGHTED-AVERAGE EXERCISE PRICE |
| Balance outstanding Oct. 23, 2000 | — | $ — |
| Granted | 22,607,420 | 20.07 |
| Exercised | — | — |
| Forfeited | (40,600) | 20.00 |
| Balance outstanding Dec. 31, 2000 | 22,566,820 | $20.07 |

Monsanto stock options outstanding at year-end are summarized as follows:

| RANGE OF EXERCISE PRICES | SHARES | WEIGHTED-AVERAGE REMAINING CONTRACTUAL LIFE (YEARS) | WEIGHTED-AVERAGE EXERCISE PRICE PER SHARE |
|---|---|---|---|
| $20.00 | 22,224,470 | 9.8 | $20.00 |
| $20.01-$25.29 | 342,350 | 9.9 | $24.83 |

As of Dec. 31, 2000, none of the Monsanto options were exercisable.

As permitted by SFAS No. 123, *Accounting for Stock-Based Compensation*, the company has elected to follow the guidance of Accounting Principles Board Opinion No. 25, *Accounting for Stock Issued to Employees*, for measuring and recognizing stock-based transactions with employees. Accordingly, no compensation expense has been recognized in relation to any of the Monsanto or Pharmacia option plans in which Monsanto employees participate. Had a determination of compensation expense for these plans been based on fair value at the grant dates for awards under these plans, consistent with the method of SFAS No. 123, Monsanto's net income (loss) would have been reduced by approximately $113 million or $0.44 per pro forma common share for 2000 ($37 million or $0.14 per pro forma common share is specifically attributable to Monsanto Plans), $37 million or $0.14 per pro forma common share for 1999 and $39 million or $0.15 per pro forma common share for 1998. Pro forma compensation expense may not be representative of compensation expense that will be incurred on a pro forma basis in future years.

In computing the pro forma compensation expense, the fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. The weighted-average fair values of options granted to employees of Monsanto during 2000 were $7.24 for Monsanto stock options and $15.73 for Pharmacia stock options, and during 1999 and 1998 were $13.99, and $16.94, respectively, related to Pharmacia stock options. The following weighted-average assumptions were used for grants:

| | 2000 | | 1999 | 1998 |
|---|---|---|---|---|
| | MONSANTO PLANS | PHARMACIA PLANS | PHARMACIA PLANS | PHARMACIA PLANS |
| Expected dividend yield | 1.96% | 1.00% | 0.34% | 0.25% |
| Expected volatility | 43.7% | 26.0% | 39.5% | 30.0% |
| Risk-free interest rates | 5.7% | 6.75% | 4.4% | 5.6% |
| Expected option lives (years) | 3.5 | 5.0 | 4.1 | 4.0 |

Certain Monsanto employees were issued stock appreciation rights as part of Pharmacia's stock compensation plan. These rights entitle the employees to receive a cash amount determined by appreciation in the fair market value of the company's common stock between the date of the award and the date of exercise. Upon the closing of the merger of Pharmacia & Upjohn, Inc. with the former Monsanto Company on March 31, 2000, the rights vested. The company recognized compensation expense of $13 million associated with these rights in 2000. There was no compensation expense in 1999 and 1998.

## NOTE 15
## Earnings Per Pro Forma Share

On Oct. 23, 2000, Monsanto sold 38,033,000 shares of its common stock at $20 per share in an IPO, including 3,033,000 shares of common stock with respect to which the underwriters exercised their overallotment option on Oct. 20, 2000. Subsequent to the offering, Pharmacia owned and continues to own 220,000,000 shares of common stock, representing 85.3 percent ownership of Monsanto. The company issued 10,000 restricted shares at the time of the IPO.

Basic earnings per pro forma share for all periods were computed using the weighted average number of common shares outstanding (258,043,000) after the IPO. Diluted earnings per pro forma share in 2000 were calculated using the common shares outstanding plus the dilutive effect of common share equivalents totaling 0.5 million shares, based on outstanding stock options. The options expire in 2010.

## NOTE 16
## Commitments and Contingencies

Commitments, principally in connection with uncompleted additions to property, were approximately $60 million, and commitments to purchase seed inventories were approximately $52 million, as of Dec. 31, 2000. Monsanto was contingently liable as a guarantor for bank loans and for miscellaneous receivables directly attributable to Monsanto totaling approximately $33 million as of Dec. 31, 2000. Future minimum payments under noncancelable operating leases, unconditional inventory purchases, and R&D alliances are $60 million for 2001, $53 million for 2002, $42 million for 2003, $31 million for 2004, $28 million for 2005, $26 million for 2006 and $9 million thereafter. Rent expense was $116 million, $72 million and $54 million for the years ended Dec. 31, 2000, 1999 and 1998, respectively.

The more significant concentrations in Monsanto's trade receivables at year-end were from: U.S. agricultural product distributors for $784 million in 2000 and $709 million in 1999; customers in Argentina for $628 million in 2000 and $424 million in 1999; customers in Brazil for $495 million in 2000 and $383 million in 1999; European agricultural product distributors for $310 million in 2000 and $328 million in 1999; customers in Canada for $61 million in 2000 and $86 million in 1999; customers in the former Soviet Union for $17 million in 2000 and $74 million in 1999; and customers in Southeast Asia for $49 million in 2000 and $56 million in 1999. Management of Monsanto does not anticipate losses on its trade receivables in excess of established allowances.

The patent protecting glyphosate, the active ingredient in *Roundup*, expired in the United States on Sept. 20, 2000. Excluding *Roundup* lawn and garden products, *Roundup* represents approximately 48 percent of total company sales in 2000. The United States is the largest market for *Roundup*.

Monsanto's Statement of Consolidated Financial Position includes accrued liabilities of $10 million as of Dec. 31, 2000, and $7 million as of Dec. 31, 1999, for the remediation of existing and former manufacturing facilities and certain off-site disposal and formulation facilities. Monsanto's future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to Monsanto at the sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties. Monsanto does not expect the resolution of such uncertainties to have a material adverse effect on its financial position, profitability or liquidity.

Pharmacia is a party to a number of lawsuits and claims relating to Monsanto, for which Monsanto assumed responsibility upon its separation from Pharmacia and which Monsanto is vigorously defending. Monsanto is also a party to litigation in its own name. Such matters relate to a variety of issues. Certain of the lawsuits and claims seek damages in very large amounts, or seek to restrict the company's business activities. Although the results of litigation cannot be predicted with certainty, it is management's belief that the final outcome of such litigation will not have a material adverse effect on Monsanto's financial position, profitability or liquidity.

In April 1999, a jury verdict was returned against DEKALB Genetics (which is now a wholly owned subsidiary of Monsanto), in a lawsuit filed in U.S. District Court in North Carolina. The lawsuit was brought by Aventis CropScience S.A. (formerly Rhone Poulenc Agrochimie S.A.) (Aventis), claiming that a 1994 license agreement was induced by fraud stemming from DEKALB Genetic's nondisclosure of relevant information and that DEKALB Genetics did not have the right to license, make or sell products using Aventis' technology for glyphosate resistance under this agreement. The jury awarded Aventis $15 million in actual damages for unjust enrichment and $50 million in punitive damages. DEKALB Genetics has appealed this verdict, believes it has meritorious grounds to overturn the verdict and intends to vigorously pursue all available means to have the verdict overturned. An arbitration has been filed on behalf of Calgene LLC, a wholly owned subsidiary of Monsanto's, claiming that as a former partner of Aventis, Calgene is entitled to at least half of any damages, royalties or other amounts recovered by Aventis from Monsanto or DEKALB Genetics pursuant to these proceedings. No provision has been made in Monsanto's consolidated financial statements with respect to the award for punitive damages.

On March 20, 1998, a jury verdict was returned against Pharmacia in a lawsuit filed in the California Superior Court. The lawsuit was brought by Mycogen Corporation (Mycogen), Agrigenetics, Inc. and Mycogen Plant Science, Inc. claiming that Pharmacia delayed providing access to certain gene technology under a 1989 agreement with Lubrizol Genetics Inc., a company which Mycogen subsequently purchased. The jury awarded $174.9 million in future damages. This jury award was overturned on appeal by the California Court of Appeals. The California Supreme Court has granted Mycogen's petition requesting further review. We will continue to vigorously pursue our position on appeal. No provision has been made in Monsanto's consolidated financial statements with respect to this verdict.

## NOTE 17
## Segment and Geographic Data

Monsanto manages its business in two segments: Agricultural Productivity, and Seeds and Genomics. The Agricultural Productivity segment consists of the crop protection products, animal agriculture and environmental technologies businesses. The Seeds and Genomics segment consists of global seeds and related traits businesses and genetic technology platforms. Sales between segments were not significant.

| | AGRICULTURAL PRODUCTIVITY | SEEDS AND GENOMICS | TOTAL |
|---|---|---|---|
| Net sales | | | |
| 2000 | $3,885 | $1,608 | $5,493 |
| 1999 | 3,586 | 1,662 | 5,248 |
| 1998 | 3,500 | 948 | 4,448 |
| Earnings (loss) before interest and taxes | | | |
| 2000 | 1,099 | (581) | 518 |
| 1999 | 897 | (391) | 506 |
| 1998 | 869 | (835) | 34 |
| Depreciation and amortization expense | | | |
| 2000 | 209 | 337 | 546 |
| 1999 | 185 | 362 | 547 |
| 1998 | 175 | 193 | 368 |
| Restructuring and other special items | | | |
| 2000 | 22 | 239 | 261 |
| 1999 | 27 | 74 | 101 |
| 1998 | 45 | 559 | 604 |
| Equity affiliate expense | | | |
| 2000 | (3) | (31) | (34) |
| 1999 | (9) | (9) | (18) |
| 1998 | (10) | (21) | (31) |
| Total assets | | | |
| 2000 | 6,104 | 5,622 | 11,726 |
| 1999 | 5,340 | 5,761 | 11,101 |
| Capital expenditures | | | |
| 2000 | 439 | 143 | 582 |
| 1999 | 448 | 184 | 632 |
| Investment in equity affiliates | | | |
| 2000 | 17 | 66 | 83 |
| 1999 | 51 | 75 | 126 |

A reconciliation of earnings before interest and taxes to net income (loss) before cumulative effect of accounting change for each year follows:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| Earnings before interest and taxes | $ 518 | $ 506 | $ 34 |
| Interest expense — net | (184) | (243) | (94) |
| Income tax provision | (159) | (113) | (65) |
| Net income (loss) before cumulative effect of accounting change | $ 175 | $ 150 | $ (125) |

Although inflation is relatively low in most of Monsanto's major markets, it continues to affect operating results. To mitigate the effect of inflation, Monsanto has implemented measures to control costs, to improve productivity, to manage new fixed and working capital, and to raise selling prices when government regulations and competitive conditions permit. In addition, the current costs of replacing certain assets are estimated to be greater than the historical costs presented in the financial statements. Accordingly, the depreciation expense reported in the Statement of Consolidated Income (Loss) would be greater if it were stated on a current-cost basis.

Net sales and long-lived assets are attributed to geographic areas based upon the location of each of Monsanto's legal entities. For example, a sale from the United States to a customer in Latin America is reported as a U.S. export sale.

| | NET SALES TO UNAFFILIATED CUSTOMERS EXCLUDING INTER-AREA SALES | | | LONG-LIVED ASSETS | |
|---|---|---|---|---|---|
| | 2000 | 1999 | 1998 | 2000 | 1999 |
| United States | $3,089 | $2,895 | $2,515 | $5,127 | $5,062 |
| Latin America | 1,103 | 932 | 682 | 801 | 695 |
| Europe-Africa | 635 | 685 | 657 | 656 | 742 |
| Asia-Pacific | 449 | 460 | 349 | 131 | 142 |
| Canada | 217 | 276 | 245 | 14 | 14 |
| Total | $5,493 | $5,248 | $4,448 | $6,729 | $6,655 |

## NOTE 18
## Other (Expense) Income — Net

The significant components of Other (Expense) Income — net were:

| | 2000 | 1999 | 1998 |
|---|---|---|---|
| Equity affiliate expense | $(34) | $ (18) | $(31) |
| Gain (loss) on sale of businesses and assets | (2) | 37 | (1) |
| Failed merger costs | — | (85) | — |
| Foreign currency losses | (22) | (25) | (15) |
| Royalty income | 2 | 7 | 7 |
| Other miscellaneous income (expense) | 7 | (20) | 19 |
| Other expense — net | $(49) | $(104) | $(21) |

Equity affiliate expense includes investments in a number of affiliates that are accounted for using the equity method. Equity expense from Renessen LLC, a 50/50 joint venture between Monsanto and Cargill, was $31 million in 2000 and $15 million in 1999 and represented the most significant losses. Equity affiliate expense in 1998 included $20 million related to the cancellation of DEKALB Genetics stock options associated with the acquisition of the remaining 60 percent interest in DEKALB Genetics that Monsanto did not previously own.

## NOTE 19
## Quarterly Data (Unaudited)

Monsanto adopted SAB 101 in the fourth quarter of 2000 and, as a result, the first three quarters of 2000 have been restated to reflect the adoption of that standard. See Note 3 — New Accounting Standards — to the consolidated financial statements for further details. The fourth quarter of 1999 was also restated as if Monsanto retroactively applied SAB 101 recognition guidelines to provide comparability with the fourth quarter of 2000.

| 2000 | | NET SALES | GROSS PROFIT | INCOME BEFORE CUMULATIVE EFFECT OF ACCOUNTING CHANGE | CUMULATIVE EFFECT OF ACCOUNTING CHANGE NET (NOTE 3) | NET INCOME |
|---|---|---|---|---|---|---|
| 1st Quarter | — as previously reported | $1,441 | $ 752 | $ 117 | $ — | $ 117 |
| | as restated | 1,321 | 633 | 43 | (26) | 17 |
| 2nd Quarter | — as previously reported | 1,849 | 1,052 | 152 | — | 152 |
| | as restated | 2,007 | 1,206 | 248 | — | 248 |
| 3rd Quarter | — as previously reported | 1,003 | 454 | (66) | — | (66) |
| | as restated | 1,006 | 457 | (64) | — | (64) |
| 4th Quarter | — as reported | 1,159 | 427 | (52) | — | (52) |
| Total | — as restated | 5,493 | 2,723 | 175 | (26) | 149 |
| **1999** | | | | | | |
| 1st Quarter | — as previously reported | $1,483 | $ 784 | $ 126 | $ — | $ 126 |
| 2nd Quarter | — as previously reported | 1,653 | 969 | 243 | — | 243 |
| 3rd Quarter | — as previously reported | 983 | 426 | (127) | — | (127) |
| 4th Quarter | — as previously reported | 1,129 | 513 | (92) | — | (92) |
| | as restated | 1,087 | 471 | (118) | — | (118) |
| Total | — as previously reported | 5,248 | 2,692 | 150 | — | 150 |
| | as restated | 5,206 | 2,650 | 124 | — | 124 |

| (AMOUNTS PER PRO FORMA COMMON SHARE) | | BASIC AND DILUTED EARNINGS (LOSS) PER SHARE | | |
|---|---|---|---|---|
| 2000 | | INCOME BEFORE CUMULATIVE EFFECT OF ACCOUNTING CHANGE | CUMULATIVE EFFECT OF ACCOUNTING CHANGE NET (NOTE 3) | NET INCOME |
| 1st Quarter | — as previously reported | $ 0.45 | $ — | $ 0.45 |
| | as restated | 0.17 | (0.10) | 0.07 |
| 2nd Quarter | — as previously reported | 0.59 | — | 0.59 |
| | as restated | 0.96 | — | 0.96 |
| 3rd Quarter | — as previously reported | (0.26) | — | (0.26) |
| | as restated | (0.25) | — | (0.25) |
| 4th Quarter | — as reported | (0.20) | — | (0.20) |
| Total | — as restated | 0.68 | (0.10) | 0.58 |
| **1999** | | | | |
| 1st Quarter | — as previously reported | $ 0.49 | $ — | $ 0.49 |
| 2nd Quarter | — as previously reported | 0.94 | — | 0.94 |
| 3rd Quarter | — as previously reported | (0.49) | — | (0.49) |
| 4th Quarter | — as previously reported | (0.36) | — | (0.36) |
| | as restated | (0.46) | — | (0.46) |
| Total | — as previously reported | 0.58 | — | 0.58 |
| | as restated | 0.48 | — | 0.48 |



Historically, Monsanto has generated the majority of its sales during the first half of the year, primarily because of the timing of the planting and growing season. As a result, in each of the last two years all of its operating income was generated in the first half of the year and it incurred operating losses in the second half of the year.

Net income for the first quarter of 2000 included a net after tax credit of $3 million primarily related to the reversal of restructuring reserves established in 1998 as a result of lower actual severance cost than originally estimated. The second quarter of 2000 included an after tax charge of $126 million to operations, primarily associated with our plan to more stringently focus on key programs within research and development. Net income for the third quarter of 2000 included a net after tax charge of $21 million primarily related to the elimination of certain nutrition research and development programs, as part of our ongoing plan to focus on key projects. The fourth quarter of 2000 included a net after tax charge of $53 million primarily related to facility closures and operation consolidations, as part of our ongoing plan to focus on key programs.

Net income for the third quarter of 1999 included a net after tax charge of $44 million primarily related to the accelerated integration of agricultural and seed operations. The fourth quarter of 1999 includes an after tax charge of $53 million for a termination fee and other expenses

associated with the failed merger with Delta and Pine Land. Also included in the fourth quarter of 1999 was an after tax gain of $7 million principally resulting from the reversal of restructuring liabilities established in 1998. These restructuring liability reversals were required as a result of lower actual severance and facility shutdown costs incurred than were originally estimated. In addition, the fourth quarter included an after tax gain of $9 million for the sale of the Stoneville Pedigreed Seed Company.

## NOTE 20
### Advertising Costs

Costs incurred for producing and communicating advertising for the various brands and products were charged to selling, general and administrative expenses as incurred or expensed ratably during the year in relation to revenues or certain other performance measures. Advertising costs were $103 million, $96 million, and $71 million in 2000, 1999, and 1998, respectively.

## NOTE 21
### Related Party Transactions

On Sept. 1, 2000, the company entered into a Transition Services Agreement with Pharmacia, the company's majority shareowner. Under the agreement, Monsanto provides certain administrative support services for Pharmacia while Pharmacia primarily provides information technology support for Monsanto. In addition, the two companies pay various payroll charges, taxes, and travel costs that are associated with the business activities of the other. Monsanto and Pharmacia also rent research and office space from each other. Since Sept. 1, 2000, each party has charged the other entity rent based on a percentage of occupancy times the cost to operate the facilities. Monsanto recognized expenses of $25 million during the last four months of 2000 and recorded a reimbursement of $24 million for costs incurred on behalf of Pharmacia. As of Dec. 31, 2000, the company had a net receivable balance of $99 million with Pharmacia (excluding dividends payable), largely associated with transactions related to the separation agreement.

Since the IPO closing date of Oct. 23, 2000, Pharmacia Treasury Services AB (PTS), a wholly owned subsidiary of Pharmacia, manages the loans and deposits of Monsanto's ex-U.S. subsidiaries. Interest rates and fees are comparable to the Commercial Paper (CP) rate and fees that Monsanto would have incurred with an independent CP dealer. As of Dec. 31, 2000, Monsanto was in a net borrowing position of $430 million with PTS. On Dec. 7, 2000, Monsanto declared a prorated quarterly dividend of $0.09 per share and recorded a related dividend payable to Pharmacia of $20 million.

## NOTE 22
### Capital Stock

The company is authorized to issue 1.5 billion shares of common stock, $0.01 par value, and 20 million shares of undesignated preferred stock, $0.01 par value. The board of directors has the authority, without action by the shareowners, to designate and issue preferred stock in one or more series and to designate the rights, preferences, and privileges of each series, which may be greater than the rights of the company's common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock upon the rights of holders of common stock until the board of directors determines the specific rights of the holders of preferred stock.

The authorization of undesignated preferred stock makes it possible for Monsanto's board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of the company. These and other provisions may have the effect of deferring hostile takeovers or delaying changes of control of management.

There were no shares of preferred stock outstanding as of Dec. 31, 2000. As of that date, 258 million shares of common stock were outstanding and 25.3 million shares of common stock were reserved for employee and director stock options. Dividends on common stock of $23 million were payable as of Dec. 31, 2000.

## NOTE 23
### Accounts Receivable

The following table displays a roll-forward of allowances for doubtful trade accounts receivable for the year ended Dec. 31, 2000:

| | |
|---|---|
| Balance Jan. 1, 1998 | $ 38 |
| Additions — charged to expense | 29 |
| — acquisitions and adjustments | 16 |
| Deductions | — |
| Balance Dec. 31, 1998 | 83 |
| Additions — charged to expense | 70 |
| — acquisitions and adjustments | 9 |
| Deductions | (11) |
| Balance Dec. 31, 1999 | 151 |
| Additions — charged to expense | 58 |
| Deductions | (38) |
| Balance Dec. 31, 2000 | $171 |

Monsanto Company's management is responsible for the fair representation and consistency, in accordance with generally accepted accounting principles, of all the financial information included in this annual report. Where necessary, the information reflects management's best estimates and judgments.

Management is also responsible for maintaining a system of accounting controls with the objective of providing reasonable assurance that Monsanto's assets are safeguarded against material loss from unauthorized use or disposition and that authorized transactions are properly recorded to permit the preparation of accurate financial information. An important consideration in this regard is the cost of control vs. the risk of loss. The effectiveness of internal control is maintained by personnel selection and training, division of responsibilities, establishment and communication of policies, and ongoing internal review programs and audits.

Management believes that Monsanto's system of internal control as of Dec. 31, 2000, was effective and adequate to accomplish the objectives described above.

Hendrik A. Verfaillie
President and Chief Executive Officer

Terrell K. Crews
Executive Vice President and Chief Financial Officer

Feb. 21, 2001

To the Shareowners of Monsanto Company:

We have audited the accompanying statement of consolidated financial position of Monsanto Company and subsidiaries as of Dec. 31, 2000 and 1999, and the related statements of consolidated income (loss), cash flows, shareowners' equity and comprehensive income (loss) for each of the three years in the period ended Dec. 31, 2000. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Monsanto Company and subsidiaries as of Dec. 31, 2000 and 1999, and the results of their operations and their cash flows for each of the three years in the period ended Dec. 31, 2000, in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 3 to the consolidated financial statements, in 2000 Monsanto Company changed its method of recognizing revenue to conform to the Securities and Exchange Commission's Staff Accounting Bulletin No. 101, *Revenue Recognition in Financial Statements.*



St. Louis, Missouri
Feb. 12, 2001

LEFT TO RIGHT:
GWENDOLYN S. KING, HENDRIK A. VERFAILLIE, FRANK V. ATLEE III,
WILLIAM U. PARFET, JOHN S. REED, C. STEVEN MCMILLAN,
CHRISTOPHER J. COUGHLIN, HÅKAN ÅSTRÖM, AND MICHAEL (MICKEY) KANTOR.



**Frank V. AtLee III**, 60, of Scottsdale, Arizona, is chairman of the board of Monsanto. He is a retired president of the former American Cyanamid Company and chairman of the former Cyanamid International — companies involved in the discovery, development, manufacturing and marketing of medical and agricultural products. He has served Monsanto's board as a director and chairman since June 2000. Mr. AtLee chairs the board's executive committee.

**Hendrik A. Verfaillie**, 55, of St. Louis, is president and chief executive officer of Monsanto. He joined the former Monsanto Company (now Pharmacia Corporation) in 1976 and has served it in a variety of management positions. Mr. Verfaillie also served as a director of the former company from June 1999 to March 2000, and as a director on the Monsanto board since February 2000. He is a member of the board's executive committee.

**Håkan Åström**, 53, of Chatham, New Jersey, is senior vice president, strategy and corporate affairs, of Pharmacia Corporation, a leading global pharmaceutical company. He has held a variety of sales, marketing and management positions in his more than 28 years in the pharmaceutical industry. Mr. Åström has served as a director on the Monsanto board since June 2000. He is a member of the board's public policy committee.

**Christopher J. Coughlin**, 48, of Morristown, New Jersey, is executive vice president and chief financial officer of Pharmacia Corporation, a leading global pharmaceutical company. Prior to joining Pharmacia & Upjohn Inc. in 1998, he was president of Nabisco International, a manufacturer of biscuits, snacks and other premium food products. Mr. Coughlin joined the Monsanto board in March 2000. He is a member of the board's executive, and science and technology committees.

**Michael (Mickey) Kantor**, 61, of Washington, D.C., is a former U.S. secretary of commerce and a former U.S. trade representative. He is currently a partner in the international law firm of Mayer, Brown and Platt. Mr. Kantor was first elected to the board of the former Monsanto Company (now Pharmacia Corporation) in 1997, and he continues to serve on the Pharmacia board. He has served as a director on the Monsanto board since June 2000. Mr. Kantor chairs the board's public policy committee, and is a member of the science and technology committee.

**Gwendolyn S. King**, 60, of Washington, D.C., is president of Podium Prose, a speakers bureau founded in 2000. Prior to joining Podium Prose, she had retired as senior vice president, corporate and public affairs, for PECO Energy Company (formerly Philadelphia Electric Company), a diversified utility company. She also served as the 11th commissioner of Social Security in the administration of former President George Bush. Mrs. King was first elected to the board of the former Monsanto Company (now Pharmacia Corporation) in 1993, and she continues to serve on the Pharmacia board. She has served as a director on the Monsanto board since February 2001, and is a member of the board's people and public policy committees.

**C. Steven McMillan**, 55, of Chicago, is president and chief executive officer of Sara Lee Corporation, a global consumer packaged goods company whose brands include Sara Lee, Douwe Egberts, Hillshire Farm, Hanes, and Playtex. He has served as a director on the Monsanto board since June 2000. Mr. McMillan chairs the board's people committee, and he is a member of the audit and finance committee. He has served on the board of Pharmacia Corporation since March 2000, and on the board of Pharmacia & Upjohn Inc. since 1998.

**William U. Parfet**, 54, of Hickory Corners, Michigan, is chairman and chief executive officer of MPI Research Inc., a preclinical toxicology research laboratory. He has served as a director on the Monsanto board since June 2000 and is a member of the board's people, and audit and finance committees. Mr. Parfet has served on the board of Pharmacia Corporation since March 2000, and on the board of Pharmacia & Upjohn Inc. since 1985.

**John S. Reed**, 62, of New York, is the retired chairman of Citigroup Inc., a global financial services company. He was first elected to the board of the former Monsanto Company (now Pharmacia Corporation) in 1985 and served on its board until February 2001. Mr. Reed has served as a director on the Monsanto board since June 2000. He chairs the board's audit and finance, and science and technology committees.

Ages as of March 1, 2001.

Chairman of the Board
**Frank V. AtLee III***

President and Chief Executive Officer
**Hendrik A. Verfaillie***

Executive Vice President and
Chief Operating Officer
**Hugh Grant***

Executive Vice President and
Chief Technology Officer
**Robert T. Fraley, Ph.D.***

Executive Vice President and
Chief Financial Officer
**Terrell K. Crews***

Senior Vice President,
General Counsel and Secretary
**R. William Ide III***

Senior Vice President,
Government Affairs
**Steven L. Engelberg***

Senior Vice President,
Human Resources
**John M. Murabito***

Senior Vice President,
Public Affairs
**Sarah Hull***

Vice President, North America
**Carl M. Casale***

Chief Information Officer
**Janet M. Holloway***

Vice President, Manufacturing
**Mark J. Leidy***

President, Animal Agricultural Group
**Cheryl P. Morley***

Vice President and Controller
**C.T. Tomlin**

*Executive officers as defined by the U.S. Securities and Exchange Commission. Current as of March 1, 2001.

#### Dividend Policy

The declaration and payment of quarterly dividends is made at the discretion of Monsanto's board of directors. The dividend is reviewed by the board quarterly.

#### Duplicate Mailings

If you receive duplicate mailings of Monsanto's annual report and would like to eliminate the extra copies, please send us your written permission. Duplicate mailings can occur if shares are held in multiple accounts, are registered under different names, or are registered with slight differences in names and addresses. Please send the labels from the copies you *don't* want to Monsanto's agent, Mellon Investor Services. If you have account numbers, those would also be helpful.

#### Transfer Agent and Registrar

**To request or send information contact:**
Mellon Investor Services
P.O. Box 3315
South Hackensack, New Jersey 07606-1915
U.S.A.

**Telephone:**
(888) 725-9529
toll free within the United States and Canada

(201) 329-8660
outside the United States and Canada

(201) 231-5469
for the hearing impaired

**On the Internet:**
You can also access your Monsanto account on line with Mellon Investor Services by going to:
https://vault.mellon-investor.com/isd

#### Additional Shareowner Information

Shareowner, financial and other information about Monsanto is available to you free of charge from several sources throughout the year. These materials include quarterly earnings statements, significant news releases and Forms S-1, 10-K and 10-Q, which are filed with the U.S. Securities and Exchange Commission.

**On the Internet:** You can access financial and other information, such as significant news releases, Forms 10-K and 10-Q, and the text of this annual report, on the Internet at http://www.monsanto.com.

**By writing:** You can also request these materials by writing:

Monsanto Company – D2000
800 North Lindbergh Boulevard
St. Louis, Missouri 63167
U.S.A.

#### Additional Information about Monsanto

**Monsanto's Sustainable Development Report**
You can read Monsanto's sustainable development report on the Internet at http://www.monsanto.com.

#### Annual Meeting

The next annual meeting of the shareowners of Monsanto will be held at 1:30 p.m. on Wednesday, April 18, 2001, in K Building at the company's offices at 800 North Lindbergh Boulevard, St. Louis, Missouri. A formal notice of the meeting and a proxy statement are being mailed to each shareowner.

MON
LISTED
NYSE®

Monsanto's stock is traded principally on the New York Stock Exchange. Our symbol is MON.

Footnotes to page 1

(1) In 2000, Monsanto adopted Staff Accounting Bulletin No. 101, *Revenue Recognition in Financial Statements* (SAB 101), the Securities and Exchange Commission's interpretation of accounting guidelines on revenue recognition. The adoption of SAB 101 primarily affected the company's recognition of license revenues from biotechnology traits sold through competitor seed companies. Monsanto now recognizes this revenue when a grower purchases seed as compared with the previous practice of recognizing the license revenue when the third-party seed company sold the seed into the distribution system. As a result, no license revenues from biotechnology traits sold by third-party seed companies were recognized in the fourth quarter of 2000 whereas the fourth quarter of 1999 included $42 million of such license revenues.

SAB 101 requires companies to report any change in revenue recognition related to adopting its provisions as an accounting change in accordance with Accounting Principles Board Opinion No. 20, *Accounting Changes.* Monsanto recognized the cumulative effect of a change in accounting principle, effective Jan. 1, 2000. The effect on 2000 earnings was an after-tax charge of $26 million, net of taxes of $16 million. If Monsanto had retroactively applied SAB 101 and recorded the seed licensee fees when the royalty period began, 1999 net income would have been $124 million or $0.48 per pro forma common share, compared with $175 million or $0.68 per pro forma common share in 2000.

(2) The pro forma earnings per share (EPS) and net income have been prepared in order to illustrate the estimated effects of the separation of the Monsanto Company from the businesses of Pharmacia Corporation (Pharmacia), the initial public offering (IPO), and related transactions, as if they had occurred as of the beginning of each period presented, as well as the adoption of SAB 101 (see Note 1). The pro forma adjustments are based on currently available information and upon estimates and assumptions that Monsanto's management believes are reasonable. The pro forma financial information should be read in conjunction with Monsanto's Form 10-K for the period ended Dec. 31, 2000, and the historical combined financial statements of the Monsanto Company Agricultural Business and notes to those statements, included in Monsanto's Registration Statement on Form S-1, as amended.

The pro forma adjustments reflect the following adjustments to the historical Statement of Consolidated Income. Interest expense on a pro forma basis was reduced by $112 million and $183 million for 2000 and 1999, respectively. Interest expense decreased because debt was reduced by $2.2 billion as a result of the Separation Agreement between Monsanto and Pharmacia dated as of Sept. 1, 2000, and by $723 million as a result of the use of the proceeds from our IPO to repay debt. In addition and related to the lower interest expense, pro forma income tax expense increased by $44 million and $70 million for the full year 2000 and 1999, respectively. Pro forma diluted earnings per diluted pro forma common share information was prepared using pro forma common shares outstanding (see Note 3).

The pro forma financial information provided on page 1 is presented for illustrative purposes only. The pro forma financial information is not necessarily indicative of the results of operations that Monsanto would have attained had the separation of the agricultural business from Pharmacia, the IPO and the related transactions been completed as of the beginning of each period presented, nor is it necessarily indicative of future operating results.

(3) Monsanto Company and subsidiaries, and its predecessor (Monsanto Company Agricultural Business), which was previously a division of Pharmacia, is comprised of the operations, assets and liabilities of the Monsanto Company Agricultural Business that were transferred to Monsanto from Pharmacia on Sept. 1, 2000. The financial information presented has been prepared on a carve-out basis, which reflects the historical operating results of these business operations. The costs of certain services provided by Pharmacia included in the Statement of Consolidated Income (Loss) have been allocated to Monsanto based on methodologies that management believes to be reasonable, but which do not necessarily reflect what the results of operations or financial position would have been had Monsanto been a separate, stand-alone public entity during all periods presented. Earnings per share information on a carve-out basis were prepared using pro forma common shares outstanding after the IPO.

On Oct. 23, 2000, Monsanto sold 38,033,000 shares of its common stock at $20 per share in an IPO, including 3,033,000 shares of common stock with respect to which the underwriters exercised their over-allotment option. The total net proceeds to Monsanto were $723 million. Subsequent to the offering, Pharmacia continues to own 220,000,000 shares of common stock, representing approximately 85 percent ownership of Monsanto.

(4) Free cash flow represents cash flows from operations less cash required for investing activities.

(5) EBIT (earnings before interest expense and taxes) is income (loss) before taxes and interest expense. EBITDA (excluding special items) is EBIT excluding depreciation and amortization expense, and excludes the effects of restructuring and special items. The presentation of EBIT, EBIT (excluding special items) and EBITDA (excluding special items) is not intended to replace net income, cash flows, financial position or comprehensive income, and it is not a measure of financial performance as determined in accordance with accounting principles generally accepted in the United States.

(6) Special items for the year ended Dec. 31, 2000, included pretax charges of $261 million ($197 million after tax) associated with our plan to focus on certain projects, resulting in the termination of certain research-and-development programs, offset by the reversal of restructuring reserves. Special items for the year ended Dec. 31, 1999, included pretax charges of $101 million ($81 million after tax) associated with a failed merger and costs related to accelerated business integration of our agricultural chemical and seed operations, offset by reversals of restructuring and integration reserves.



This report is printed on recycled paper that contains postconsumer waste.

Trademarks and service marks owned or licensed by Monsanto and its subsidiaries are indicated by special type throughout this publication.

©2001 Monsanto Company

**Monsanto is a new company completely devoted to agriculture. Our new pledge embodies our commitment to the growers and processors who are our customers, to the consumers who are their customers, and to everyone who cares about agriculture around the world.**

## The New MONSANTO PLEDGE

### DIALOGUE

We will work with all parties, including customers, to understand their concerns about agricultural biotechnology.

### TRANSPARENCY

We will make published scientific data and data summaries on product safety and benefits publicly available and accessible. We will work within rigorous, science-based regulations as required by appropriate government agencies around the world.

### RESPECT

We will respect the religious, cultural and ethical concerns of people throughout the world by not using genes from animals or humans in products intended for food or feed. We will never commercialize a product in which a known allergen has been introduced. We affirm our commitment not to pursue technologies that result in sterile seeds. We will use alternatives to antibiotic-resistance genes to select for new traits as soon as the technology allows us to do so. We will commercialize commodity grain products only after they have earned approval for consumption by both humans and animals.

### SHARING

We will bring the knowledge and advantages of all forms of agriculture to resource-poor farmers in the developing world to help improve food security and protect the environment.

### BENEFITS

We will work for farmers commercially as well as environmentally, delivering benefits through technologies that contribute directly to a vision of abundant food and a healthy environment.

For more information on the New Monsanto Pledge, visit www.monsanto.com.

MONSANTO™

800 North Lindbergh Boulevard | St. Louis, Missouri 63167 | U.S.A. | www.monsanto.com